The e-Psychonauts’ ‘Spiced’ World; Assessment of the Synthetic Cannabinoids’ Information Available Online

Journal: Current Neuropharmacology

Manuscript Type: Original Paper

Date Submitted by the Author: 13-Dec-2019

Complete List of Authors: Zangani, Caroline; University of Milan, Department of Health Sciences
Schifano, Fabrizio; University of Hertfordshire, Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences
Napoletano, Flavia; East London NHS Foundation Trust, Homerton University Hospital
Arilloita, Davide; University of Catania, Department of Clinical and Experimental Medicine
Gilgar, Liam; Cardiff and Vale University Health Board, Gabalfa Clinic
Guirguis, Amira; Swansea University Medical School, Institute of Life Sciences
Corkery, John; University of Hertfordshire, Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit
Gambini, Orsola; University of Milan, Department of Health Sciences
Vento, Alessandro; Guglielmo Marconi University, School of educational Science; Addictions Observatory, (ODDPSS); ASL Roma 2, Department of Mental Health

Abstract: BACKGROUND. A wide range of novel psychoactive substances (NPS) is regularly searched and discussed online by web-based drug enthusiasts (i.e. the e-psychonauts). Among NPS, the range of synthetic cannabinoids (SC; ‘Spice’) currently represents a challenge for governments and clinicians.

METHODS. Using a web crawler (i.e. the NPS.Finder®) the present study aimed at assessing psychonauts’ fora/platforms to better understand the online mentions of SC.

RESULTS. The open-web crawling/navigating software identified here some 1,103 synthetic cannabinoids. Of these, 863 molecules were not listed in either the international or the European NPS databases.

CONCLUSIONS. A web crawling approach helped here in identifying a large range of unknown SC likely to possess a misuse potential. Most of these novel/emerging molecules are still relatively unknown. This is a reason for concern; each of these analogues potentially presents with different toxicodynamic profiles and there is a lack of docking, preclinical, and clinical observations. Strengthening multidisciplinary collaboration between clinicians and bioinformatics may prove useful in better assessing SC-associated public health risks.

Keywords: psychonauts; NPS; new psychoactive substances; synthetic cannabinoids; web crawling.

1. INTRODUCTION

1.1 Background

The web may play a pivotal role in the ‘life cycle’ of NPS. [1] After being synthesized in illegal chemical laboratories, NPS are then made available through e-commerce to interested customers. These customers include the e-psychonauts, [2] whose primary aim is discovering and experiencing with the effects of new chemical compounds. [3] [4] e-Psychonauts share their experiences on a range of multilingual, specialized, dedicated web fora/blogs, [5] [6] hence facilitating information spreading to other consumers of the index new psychoactive molecule. [2] [3]

Within this scenario, synthetic cannabinoids (SC), known also as synthetic cannabimimetics or synthetic cannabinoid receptor agonists (SCRAs), constitute one of the main class of new/novel psychoactive substances (NPS). Despite the term ‘novel’, the first products were synthesized by pharmaceutical industries between the ’70s and ’80s, after noticing the potential analgesic, antiemetic and narcotic effects of the endocannabinoid system. [7]

Since the first SC identification in the drug market in 2008, numbers of cannabinoids available have grown steadily. According to both the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and the United Nations Office on Drugs and Crime (UNODC), SC are the most
typically seized NPS reported in Europe and elsewhere. [8] [9] [10] [11] [12]

Whilst being labelled as ‘not for human consumption’ or as ‘labouratory products’, [13] [14] [15] SC are usually made available in colourful packages with different names (e.g. ‘Spice’, ‘K2’, ‘Kronic’, ‘Voodoo’). SC use has been associated with vulnerable subjects, including inmates and homeless people. [16]

Because of their activity on CB1 receptors, over the last decade SC have at times been interpreted as the ‘legal substitutes’ of cannabis. [8] Indeed, they show higher CB1 binding affinity levels than (–)-trans-Δ9-tetrahydrocannabinol (THC), [8] though multiple interactions with remaining classes of receptors have also been commented. [14] Hence, SC present with a range of unpredictable clinical effects, which have included severe ill-health events [17] and fatalities. [9] [10] [18]

Clinicians and health professionals typically perceive their NPS-, including SC-, related knowledge levels as inadequate. [19] Indeed, the pace at which scientific evidence is updated cannot withstand the constant and rapid entry into the market of further NPS molecules.

1.2 Aims

The aim of the current research was to: (a) identify and categorize the number of SC molecules collected by a dedicated web crawler (i.e. the NPS.Finder®) from a range of psychonaut, NPS-related, online sources; (b) compare the NPS.Finder® SC list with related findings from the UNODC and the EMCDDA.

2. METHODS

2.1 Search strategy

To facilitate the process of early recognition of emerging psychoactive molecules, a crawling/navigating software (i.e. the ‘NPS.Finder®’) was designed to automatically scan the open/surface web for new/novel/emerging NPS (for a thorough description of both web crawling and data cleaning activities please refer to recently published studies [5] [6]). This software was designed to map on a 24/7 basis the large variety of psychoactive molecules mentioned within a range of popular online psychonaut websites/fora (Appendix 1).

First, a number of proper piloting searches were performed using a range of key words, including: NPS; novel psychoactive substances; new psychoactive substances; emerging psychoactive substances; drugs online; buy new substances; psychonauts, drug forums; psychoactive products; synthetic cannabinoids; synthetic cathinones; psychedelic phenethylamines; novel stimulants; synthetic opioids; tryptamine derivatives; phenethylamine-like dissociatives; piperazines; GABA-A/B receptor agonists; prescribed medications; psychoactive plants; psychoactive herbs; and image- and performance-enhancing drugs. Any new website of interest was added to the list. Afterwards, a range of specific automatic web crawler activities were carried out from 14 November 2017 to 31 May 2019. Although the language most typically used in these websites was English, further languages analyzed by the NPS.Finder® included: Dutch, French, Turkish, Swedish, Spanish, German, Russian, and Italian.

Resulting data were collected using Python-language web crawlers, one for each site listed, through daily scanning activities. Emerging findings were first stored in a temporary virtual storage area and then in an MYSQL database which presented with an SSL security protocol. All data were encrypted with asymmetric cryptographic procedures.

2.2 Data collection

NPS.Finder® extracted a range of NPS-related information, including chemical and street names; chemical formula; three-dimensional images; and anecdotally reported clinical/psychoactive effects. These data were automatically stored in an online, restricted access/password-controlled database located within firewall protected, highly secure, and consistently performing servers.

2.3 Data screening and duplication check

With the help of an ‘ad hoc’ check control panel, all data were manually and carefully analyzed by 4 medically/psychiatrically trained professionals (i.e. FN; DA; CZ; and LG). In the case of data interpretation issues, these were resolved by consultation with FS, AG, JC and AV.

The web crawler-identified SC molecules’ denominations were first searched in Medline/PubMed [20] and in Google®/Google® Scholar. [21] [22] A further screening was carried out with the help of Pubchem; [23] ChemSpider®; [24] and ChEMBL®. [25] [26] [27] To avoid duplications, the International Union of Pure and Applied Chemistry (IUPAC) denomination was used for each molecule. In this way, a full assessment and editing of each NPS.Finder® data entry was carried out and the range of unique SC molecules here commented was identified (please note that the complete and regularly updated list of NPS identified by the web-crawler activities is freely available at https://npsfinder.com/home.php).

3. RESULTS

With the help of the web crawler activities, some 5922 substances were here identified. After proper data screening and duplication check completion, some 4204 unique NPS molecules were included in the database and 1718/5922 (29.01%) remaining molecules were found to be false positives or duplicates. Of these, 1103 SC were collected, representing 26.2% (CI 95%: 25.9-27.6%) of the total number of molecules, and the second largest group after psychedelic phenethylamines (30.1%; CI 95%: 28.7-31.5%).

Conversely, by 13th June 2019 the UNODC listed some 286 SC and, by 1st April 2019, the EMCDDA database included 193 different SC. Some 863 SC (78.2%; CI 95%: 75.1-80.6%) were identified only by the NPS.Finder®, and 182 SC (16.5%; CI 95%: 14.4-18.8%) were common to all
three databases. Finally, some 52 molecules were mentioned in either the EMCDDA or the UNODC lists but had not been identified by the NPS.Finder® web crawler (Table 1). Hence, the three databases identified an overall number of 1155 synthetic cannabinoids (Appendix 2).

These 1155 SC were here further categorized with a hierarchical approach (i.e. categories 1; 2a; 2b; 3), as follows: 1) SC listed by the EMCDDA and/or by the UNODC: 292 (25.3%, CI 95%: 22.8-27.8%) molecules were included; 2a) SC which were not listed by either the EMCDDA or the UNODC, but which are scheduled, and/or for which evidence levels of abuse have already been reported in peer-reviewed papers; 94 molecules (8.1%, CI 95%: 6.6-9.7%); 2b) SC commented on the psychonaut websites/forums; 767 (66.4%, CI 95%: 63.7-69.1%); 3) SC used as laboratory research products/analytical references and/or studied in preclinical or animal research; 2 molecules (0.1%, CI 95%: 0.0-0.4%) (Figure 1).

4. DISCUSSION

The present paper provides unique and unprecedented figures in terms of overall numbers of synthetic cannabinoids, collected using an innovative and automatic search strategy. Consistent with previous observations from our group, [5] the NPS.Finder® database identified here a quantitative level of SC which is about 5-fold higher than that identified by both the UNODC and the EMCDDA. Although present results, highlighting a strong interest by psychonauts towards SC, do not necessarily confirm in any possible way these molecules’ levels of use, they can help in explaining levels of concern relating to the current NPS scenario, which well includes SC. [28] [29]

Indeed, out of the 1155 SC overall number identified by the 3 databases, NPS.Finder® captured 1103/1155 (95.5%) of them, a better performance than both the UNODC (286/1155; 24.8%) and the EMCDDA (193/1155; 16.7%). There might be different reasons behind these inconsistencies in data reporting. First, both the UN and EU agencies collect in their databases only those molecules which are detected/seized and properly analyzed. The EMCDDA reports on 28 EU countries only, whilst both the UNODC database and the psychonauts’ entries may better reflect the global situation. Furthermore, NPS.Finder® carried out here a range of open web crawling identification activities focusing on a large range of psychonaut-based, specialized, multilingual, sources with a specific focus on NPS. Although one could argue that discussing a molecule on the web is not, per se, an indication that the index molecule is being/will be ingested by interested individuals, the current SC list was generated whilst crawling only on the open web. In other words, this may well reflect the level of SC-related information which may be accessible to anyone, including vulnerable children and adolescents, without the need of using sophisticated search techniques or downloading deep web/darknet ad hoc browsers. [30]

Notably, roughly 1 out of 4 of the current 1155 SC is currently under surveillance by either EMCDDA or UNODC. Those SC under surveillance are likely to present with more convincing evidence of misuse compared with remaining molecules, resulting in high levels of concern by clinicians and policymakers. [12] Nonetheless, there are further 94 SC which have been mentioned in the literature [31] [32] [33] [34] but which are currently not listed by EMCDDA nor UNODC. With the introduction of new control laws, some of these compounds have recently been scheduled, [15] with their purchase now being arguably more problematic. [35] Finally, roughly 2/3 of the 1155 SC were here mentioned only by the psychonauts’ fora. Some of these SC might currently be at their ‘life cycle’ early stages and it is possible that some of them will become more popular in the future. [1] [9] [36] Indeed, reports on new drugs are likely to emerge considerably later than their first appearance in e- psychonauts’ discussions. [36] [37]

4.1 Pharmacological and clinical pharmacological considerations

Although the evidence base for most SC molecules here mentioned is lacking, they are likely to act as partial/full agonists, and with different affinity levels, at the CB1 receptors. Nonetheless, SC may act as well on both 5-HT2A and NMDA receptors. [38] hence the vast range of ill-health consequences associated with these molecules. [5] Moreover, there are difficulties in identifying them with analytical chemistry techniques. [39] A clear understanding of the clinical toxicity of each compound is at present problematic. Although the in vitro pKi values/binding affinities for some SC molecules are already available, [40] consistent with what it has been suggested for novel synthetic opioids this may not provide enough information about the relative in vivo potency. [41] In fact, there might be variable effects on receptors, which could potentially give rise to a great diversity of intracellular consequences following the administration of different analogues with apparently similar pharmacodynamics. [42] Furthermore, as highlighted using a molecular docking model, some substances are too structurally similar for the scoring function to distinguish between different similar molecules. [43] [44]

4.2 Use of the ‘big data’ analysis in understanding changes in drug scenarios

Since the recreational drug business has moved from face-to-face to an anonymous, web-based, marketplace [30] the best approach to understand the current drug scenario is to analyze the information/data made available by the consumers/e-psychonauts themselves. [37] However, the analysis of this data requires the management of ‘high-volume, high-velocity, and high-variety’ [45] range of modifications in the NPS market, which makes it a convincing example of ‘big data’. Over the past few years, the use of big data analytics has been successfully used in a range of health-related areas, including the early identification of influenza epidemics. [46] [47] [48] There are however methodological limitations with this approach, [45] [49] and these are related to the reliability of web-based collected data. [49] Conversely, when the amount of information overtakes the capacity of traditional research methods, the use of big data analytics can help to provide a nearly real-time update. [50]
The use of automatic software such as the NPSfinder® has allowed here both scanning and identification activities of a constant flow of drug-related data. To improve accuracy and provide a thorough evaluation of SC use, however, further research should focus on an integrative model in which web-based analyses will be combined with more traditional identification methods. [49] Understanding the pharmacological characteristics/potency of those SC molecules which are of appeal for potential consumers will hopefully help in both predicting SC diffusion and reducing the existing gap in knowledge between the web-based consumers and clinicians, hence facilitating the planning of ad hoc prevention strategies.

4.3 Limitations

During the current phase of its development, the NPS.Finder® has crawled on the open web only. Future studies by our group will be expanding drug searches on less accessible areas of the web, such as the deep web and the darknet. [30] A qualitative/nnetographic approach [51] [52] will be needed as well, to better assess the possible psychonauts’ preference between SC analogues and their motivation for use. Since previous studies have highlighted their importance in NPS-based studies, [53] next NPS.Finder®-based research will need to focus as well on further languages, e.g Chinese, Japanese and Arabic. Finally, some SC commented online may have been missed by our search software. Nonetheless, to the best of our knowledge, the most comprehensive literature dataset of SC has been provided here.

CONCLUSIONS

The web crawler activities may well possess the potential to identify a wide range of novel/previously undescribed NPS, including SC. The literature base regarding these molecules is limited in terms of acute and long-term effects, adverse effects, abuse potential, and manufacturing/distribution in both the virtual and real markets. Indeed, future in silico, in vitro, and in vivo studies could provide important findings. Furthermore, it is deemed here essential to monitor the real-life scenarios through drug checking in interdiction, drug outpatient clinics and in critical care settings. Better levels of misusing drugs’ clinical pharmacological-related knowledge are needed so that properly tailored management/treatment strategies and guidelines can be drawn up and made available. Finally, strengthening multidisciplinary collaboration between clinicians and bioinformatics may prove useful in better assessing the SC-associated public health risks.

SUPPLEMENTARY MATERIAL

The list of the open psychonauts’ websites scanned by NPS.Finder® is provided in Appendix 1.

The list of all synthetic cannabinoids collected in our database is provided in Appendix 2.

REFERENCES

[1] Corkery, J.M.; Orsolini, L.; Papanti, D.; Schifano, F. From concept(ion) to life after death/the grave: The ‘natural’ history and life cycle(s) of novel psychoactive substances (NPS). Human Psychopharmacology, 2017,32(3). doi:10.1002/hup.2566.

[2] Guirguis, A. New psychoactive substances: a public health issue. International Journal of Pharmacy Practice, 2017,25: 323–325. doi:10.1111/ijpp.12313.

[3] Orsolini, L.; Papanti, G.D.; Francesconi, G.; Schifano, F. Mind Navigators of Chemicals’ Experimenters? A Web-Based Description of E-Psychoauts. Cyberpsychology, behavior, and social networking, 2015,18(5): 296-300. doi:10.1089/cyber.2014.0486.

[4] Soussan, C.; Andersson, M.; Kjellgren, A. The diverse reasons for using Novel Psychoactive Substances - A qualitative study of the users’ own perspectives. International Journal of Drug Policy, 2018, 52: 71-78.

[5] Schifano, F.; Napoletano, F.; Chiappini, S.; Guirguis, A.; Corkery J.M.; Bonaccorso, S.; Ricciardi, A.; Scherbaum, N.; Vento, A. New/emerging psychoactive substances and associated psychopathological consequences. Psychological Medicine, 2019, 12: 1. doi:10.1017/s003329179900254x.

[6] Schifano, F.; Napoletano, F.; Arilotta, D.; Zangani, C.; Gilgar L.; Guirguis, A.; Corkery, J.M.; Vento, A. The clinical challenges of synthetic cathinones. British Journal of Clinical Pharmacology, 2019. doi: 10.1111/bcp.14132. [Epub ahead of print]

[7] Shevyrin, V.A.; Morzherin, Y.Y. Cannabinoids: structures, effects, and classification. Russian Chemical Bulletin, 2015, 64(6): 1249-1266.

[8] European Monitoring Centre for Drug and Drug Addiction (EMCDDA), 2017. Synthetic cannabinoids in Europe (Perspectives on drugs). Available at: http://www.emcdda.europa.eu/publications/pods/synthetic-cannabinoids (Accessed November 5, 2019).

[9] European Monitoring Centre for Drug and Drug Addiction (EMCDDA), 2019. European Drug Report 2019: Trends and Developments. Available at: http://www.emcdda.europa.eu/publications/edr/trends-developments/2019_en (Accessed November 5, 2019).

[10] European Monitoring Centre for Drug and Drug Addiction (EMCDDA), 2019. Synthetic cannabinoids. Available at: http://www.emcdda.europa.eu/topics/pods/synthetic-cannabinoids (Accessed November 5, 2019).

[11] United Nations Office on Drugs and Crime (UNODC), 2019. Synthetic cannabinoids. Available at: https://www.unodc.org/SSS/SubstanceGroup/Details/ae45e06-6d33-4f5f-916a-e873f07bde02 (Accessed July 25, 2019).

[12] Ifeagwu, S.C.; Ratibellhuber, M.; Crean. C.; Gerostamoulos, D.; Chung, H.; Tettey, J.N. Toxicology in international drug control-Prioritizing the most harmful, persistent and prevalent substances. Forensic Science International, 2017,274: 2-6. doi:10.1016/j.forsciint.2016.11.022.

[13] Martinotti, G.; Santacroce, R.; Papanti, G.D.; Elgharably, Y.; Prilutskaya, M.; Corazza, O. Synthetic Cannabinoids: Psychopharmacology, Clinical Aspects, Psychotic Onset. CNS & Neurological Disorders-Drug Targets, 2017,16(5): 567-575. doi:10.2174/1871527316666170413101839.

[14] Schifano, F.; Orsolini, L.; Papanti, G.D.; Corkery, J.M. Novel psychoactive substances of interest for psychiatry. World Psychiatry, 2015, 14: 15-26.

[15] Treeki, J.; Gerona, R.R.; Schwartz, M.D. Synthetic cannabinoid-related illnesses and deaths. New England Journal of Medicine, 2015, 373(2): 103-107.

[16] European Monitoring Centre for Drug and Drug Addiction (EMCDDA), 2018. European Drug Report 2018: Trends and Developments. Available at:
Short Running Title of the Article

http://www.emcdda.europa.eu/system/files/publications/8585/20181816_TD_AT18001ENN_PDF.pdf (Accessed November 5, 2019).

[17] Tai, S.; Fantegrossi, W.E. Pharmacological and Toxicological Effects of Synthetic Cannabinoids and Their Metabolites. In: Baumann MH, Glennon RA, Wiley JL (eds). Neuropharmacology of New Psychoactive Substances (NPS): The Science Behind the Headlines. Switzerland: Springer, 2017.

[18] Langford, A.M.; Bolton, J.R. Synthetic cannabinoids: Variety is definitely not the spice of life. Journal of Forensic and Legal Medicine, 2018, 59: 36-38.

[19] Simonato, P.; Corazza, O.; Santonastaso, P.; Corkery, J.; Deluca, P.; Davey, Z.; Blaszko, U.; Schifano, F. Novel psychoactive substances as a novel challenge for health professionals: results from an Italian survey Human Psychopharmacology, 2013, (28): 324-331. doi:10.1002/hup.2300.

[20] PubMed. Available at: https://www.ncbi.nlm.nih.gov/pubmed/ (Accessed November 5, 2019).

[21] Google Available at: https://www.google.com/ (Accessed November 5, 2019).

[22] Google Scholar Available at: https://scholar.google.com/ (accessed November 5, 2019).

[23] PubChem. Available at: https://pubchem.ncbi.nlm.nih.gov/ (Accessed November 5, 2019).

[24] ChemSpider. Available at: http://www.chemspider.com/?gclid=EAIaIQobChMIpYnOiLhtS5QVhLhtCh2uVwPETAAAYASAEgKX_fD_BwE (Accessed November 5, 2019).

[25] CHEMBL Database Release 25. Available at: https://doi.org/10.6019/CEMBLdatabase.25. (Accessed November 5, 2019).

[26] Gaulton, A.; Hersey, A.; Nowotka, M.; Bento, A.P.; Chambers, J.; Mendez, D.; Mutowoo, P.; Atkinson, F.; Bello, L.J.; Cibrían-Uhalte, E.; Davies, M.; Dedman, N.; Karlsson, A.; Magaritis, M.P.; Overington, J.P.; Papadatos, G.; Smit, I.; Leach, A.R. The ChEMBL Database in 2017. Nucleic Acids Research, 2017, 45(D1): D945–D954. doi: 10.1093/nar/gkw1074.

[27] Davies, M.; Nowotka, M.; Papadatos, G.; Dedman, N.; Gaulton, A.; Atkinson, F.; Bello, L.; Overington, J.P. Overington.ChEMBL Web Services: StreamingAccess to Drug Discovery Data and Utilities. Nucleic Acids Research, 2015, 43(W1): W612–W620. doi:10.1093/nar/gkv352.

[28] Bonaccorso, S.; Metastasio, A.; Ricciardi, A.; Stuart, N.; Jamal, L.; Rujully, N.U.; Theleritis, C.; Ferracuti, S.; Ducci, G.; Schifano, F. Synthetic cannabinoid use in a case series of patients with psychosis presenting to acute psychiatric settings: clinical presentation and management issues. Brain Sciences, 2005, 87(7): E133. doi:10.3390/brainsci8070133.

[29] Fattore, L.; Weinstein, A.M. Editorial: Novel Psychoactive Drugs. Frontiers in Psychiatry, 2019, 10: 119. doi:10.3389/fspsy.2019.00119.

[30] Orsolini, L.; Pacchetti, D.; Corkery, J.; Schifano, F. An insight into the deep web; why it matters for addiction psychiatry? Human Psychopharmacology, 2017, 32(3). doi:10.1002/hup.2573.

[31] Ho, R.; Gerona, R.R.; Olson, K. Clinical course of 4-bromo-2, 5-dimethoxyphenylamine (2C-B) intoxication with laboratory confirmation. Clinical Toxicology, 2013, 51(7): 666-667.

[32] Thornton, S.L.; Lo, J.; Clark, R.F.; Wu, A.H.B.; Gerona, R.R. Simultaneous detection of multiple designer drugs in serum, urine, and CSF in a patient with prolonged psychosis. Clinical Toxicology, 2012, 50(10): 1165-1168. doi:10.3109/15563650.2012.744096.

[33] Qian, Z.; Hua, Z.; Liu, C.; Jia, W. Four types of cannabimimetic indazole and indole derivatives, ADB-BINACA, AB-FUBICA, ADB-FUBICA, and AB-BICA, identified as new psychoactive substances. Forensic Toxicology, 2016, 34: 133-143. doi:10.1007/s11419-015-0297-2.

[34] Westphal, F.; Sönnichsen, F.D.; Knecht, S.; Auwärter, V.; Huppertz, L. Two thiaziolyldiones and a benzimidazole: novel compounds on the designer drug market with potential cannabinoid receptor activity. Forensic Science International, 2015, 249: 133-147.

[35] Madras, B.K. The Growing Problem of New Psychoactive Substances (NPS). In: Baumann MH, Glennon RA, Wiley JL (eds) Neuropharmacology of New Psychoactive Substances (NPS): The Science Behind the Headlines. Switzerland: Springer, 2016. doi:10.1007/7854_2016_34.

[36] Schifano, F.; Deluca, P.; Baldacchino, A.; Scherbaum, N.; Torrens, M.; Farre, M.; Flores, I.; Rossi, M.; Eastwood, D.; Guionnet, C.; Rawf, S.; Agosti, L.; Di Furia, L.; Brigada, R.; Majava, A.; Siemann, H.; Leoni, M.; Tomasin, A.; Rovetto, F.; Ghodsie, H. Drugs on the web: The Psychoyouth 2002 EU project. Progress in Neuropsychopharmacology and Biological Psychiatry, 2006, 30(4): 640-646.

[37] Davey, Z.; Schifano, F.; Corazza, O.; Deluca, P.; Psychonaut Web Mapping Group. Psychonaut Web Mapping Group. e-Psychonauts: conducting research in online drug forum communities. Journal of Mental Health, 2012, 21(4): 386-94.

[38] Papanit, G.D.; Orsolini, L.; Francesconi, G.; Schifano, F. ‘Noids’ in a nutshell: Everything you (don’t) want to know about synthetic cannabimimetics. Advances in Dual Diagnosis, 2014, 7(3): 137-148. doi:10.1108-ADD-02-2014-0006.

[39] Franz, F.; Angerer, V.; Jechle, H.; Pegoro, M.; Ertl, H.; Weinifurtner, G.; Janele, D.; Schögl, C.; Friedl, M.; Gerl, S.; Mielke, R.; Zehnle, R.; Wagner, M.; Moosmann, B.; Auwärter, V. Immunnoassay screening in urine for synthetic cannabinoids - an evaluation of the diagnostic efficiency. Clinical Chemistry and Laboratory Medicine, 2017, 55(9): 1375-1384.

[40] Cannacert, D.; Storme, J.; Franz, F.; Auwärter, V.; Stove, C.P. Detection and Activity Profiling of Synthetic Cannabinoids and Their Metabolites with a Newly Developed Bioassay. Analytical Chemistry, 2016, 88(23): 11476-11485.

[41] Baumann, M.H.; Majumdar, S.; Le Rouzic, V.; Hankele, A.; Uprety, R.; Huang, X.P.; Xu, J.; Roth, B.L.; Pan, Y.X.; Pasternak, G.W. Pharmacological characterization of novel synthetic opioids (NSO) found in the recreational drug marketplace. Neuropharmacology, 2018, 134: 101-7. doi:10.1016/j.neuropharm.2017.08.016.

[42] Smith, J.S.; Leftkowitz, R.J.; Rajagopal, S. Biased signalling: from simple switches to allosteric microprocessors. Nature Reviews Drug Discovery, 2018, 17: 243-60. doi:10.1038/nrd.2017.229.

[43] Ellis, C.R.; Kruhlak, N.L.; Kim, M.T.; Hawkins, E.G.; Stavitskaya, L. Predicting opioid receptor binding affinity of pharmacologically unclassified designer substances using molecular docking. PLoS ONE, 2018, 13(3): e0197734. doi:10.1371/journal.pone.0197734.

[44] Ellis, C.R.; Raz, R.; Kruhlak, N.L.; Kim, M.T.; Hawkins, E.G.; Strauss, D.G.; Stavitskaya, L. Assessing the Structural and Pharmacological Similarity of Newly Identified Drugs of Abuse to Controlled Substances Using Public Health Assessment via Structural Evaluation. Clinical Pharmacological Therapy, 2019, 106: 116-22. doi:10.1002/cpt.1418.

[45] Gandomi, A.; Haider, M. Beyond the hype: Big data concepts, methods, and analytics. International Journal of Information Management, 2015, 35: 137-144.

[46] Clemente, L.; Lu, F.; Santillana, M. Improved Real-Time Influenza Surveillance: Using Internet Search Data in Eight Latin American Countries. JMIR Public Health and Surveillance, 2019, 5(2): e12214. doi:10.2196/12214.

[47] Ljubic, B.; Gligorijevic, D.; Gligorijevic, J.; Pavlovski, M.; Obradovic, Z. Social network analysis for better understanding of influenza.
Journal of Biomedical Informatics, 2019, 93: 103161. doi:10.1016/j.jbi.2019.103161.

[48] Spreco, A.; Eriksson, O.; Dahlström, Ö.; Cowling, B.J.; Timpka, T. Integrated Detection and Prediction of Influenza Activity for Real-Time Surveillance: Algorithm Design. Journal of Medical Internet Research, 2017, 19(6): e211.

[49] Lazer, D.; Kennedy, R.; King, G.; Vespignani, A. The parable of Google Flu: traps in big data analysis. Science, 2014, 343: 1203-1205.

[50] Raghupathi, W.; Raghupathi, V. Big data analytics in healthcare: promise and potential. Health Information Science and Systems, 2014, 2: 3.

[51] Wang, Y.S. Exploring the "like" in the psychological interaction of users on fan community: A netnography analysis. Journal of Community Psychology, 2019, 47(6): 1380-1398. doi:10.1002/jcop.22192.

[52] Loi, B.; Zloh, M.; De Luca, M.A.; Pintori, N.; Corkery, J.; Schifano, F. 4,4’-Dimethylaminorex (“4,4’-DMAR”: “Serotoni”) misuse: A Web-based study. Human Psychopharmacology Clinical and Experimental, 2017, 32: e2575. doi:10.1002/hup.2575

[53] Deluca, P.; Davey, Z.; Corazza, O.; Di Furia, L.; Farre, M.; Flesland, L.H.; Mannonen, M.; Majava, A.; Peltoniemi, T.; Pasinetti, M.; Pezzolesi, C.; Scherbaum, N.; Siemann, H.; Skutle, A.; Torrens, M.; van der Kreeft, P.; Iversen, E.; Schifano, F. Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 2012, 39(2):221-6. doi:10.1016/j.pnpbp.2012.07.011
Table 1 Number of SCRAs in the NPS.Finder®, UNODC, and EMCDDA databases. The number of SCRAs shared between the three databases is also presented, as follows: I= total number of molecules included in the NPS.Finder database; II= total number of molecules included in the UNODC list; III= total number of molecules included in the EMCDDA list; IV= number of molecules included in all three lists; V= number of molecules included in both NPS.Finder and UNODC lists, but not in the EMCDDA one; VI= number of molecules included in the NPS.Finder and EMCDDA lists, but not in UNODC one; VII= number of molecules included in both UNODC and EMCDDA lists, but not in the NPS.Finder one; VIII = number of molecules included only in the NPS.Finder list; IX = number of molecules included only in the UNODC list; X = number of molecules included only in the EMCDDA list; XI: total number of unique SC molecules identified.

| DATABASE | Number of SCRs |
|----------|----------------|
| I        | NPS.Finder® total | 1103 |
| II       | UNODC total       | 286  |
| III      | EMCDDA total      | 193  |
| IV       | NPS.Finder® and UNODC and EMCDDA | 182 |
| V        | NPS.Finder® and UNODC | 54  |
| VI       | NPS.Finder® and EMCDDA | 4   |
| VII      | UNODC and EMCDDA  | 5    |
| VIII     | NPS.Finder® alone  | 863  |
| IX       | UNODC alone       | 45   |
| X        | EMCDDA alone      | 2    |
| XI       | Total number of unique molecules | 1155 |
Figure 1 categorization of 1,155 SC: category 1) SC listed by the EMCDDA and/or by the UNODC: 292 molecules; 2a) SC which are already scheduled, and/or for which evidence levels of abuse have already been reported in peer-reviewed papers, but which are not listed by either the EMCDDA or the UNODC: 94 molecules; 2b) SC commented on the psychonauts’ websites; 3) SC used as laboratory research products/analytical references and/or studied in preclinical or animal research: 2 molecules.
| N | website name                                                                 |
|---|------------------------------------------------------------------------------|
| 1 | Avalonmagicplants.com                                                        |
| 2 | Azarius.net                                                                  |
| 3 | Bluelight.org                                                                |
| 4 | Bluemorphotours.com                                                          |
| 5 | Cannabis.net                                                                 |
| 6 | Chemeurope.com                                                               |
| 7 | Committedpsychonaut.tumblr.com                                               |
| 8 | Daath.hu/psychonauts                                                         |
| 9 | Dancesafe.org                                                                |
|10 | Deviantart.com/psychonaut-a                                                  |
|11 | Druglibrary.org                                                              |
|12 | Drugs.tripsit.me                                                             |
|13 | Drugs-forum.com                                                              |
|14 | Drugs-plaza.com                                                              |
|15 | Dutch-headshop.eu                                                            |
|16 | Ecstasydata.org                                                              |
|17 | Elephantos.com                                                               |
|18 | Energycontrol.org                                                            |
|19 | Entheogen-network.com/forums                                                 |
|20 | Erowid.org                                                                  |
|21 | Eusynth.org                                                                  |
|22 | Everything2.com/title/Psychonaut                                             |
|23 | Fungifun.org                                                                 |
|24 | Hedweb.com                                                                  |
|25 | Hipforums.com/forum                                                          |
|26 | Isomerdesign.com                                                             |
|27 | Knehnav.home.xs4all.nl                                                       |
|28 | Kratomshop.com                                                               |
|29 | Legal-high-inhaltsstoffe.de                                                  |
|30 | Mindstates.org                                                               |
|31 | Mycotopia.net                                                                |
|32 | Natmedtalk.com                                                               |
|33 | Peyote.com/peyolink.html                                                     |
|34 | Psychedelic-library.org                                                      |
|35 | Psychonaut.ca                                                                |
|36 | Psychonaut.fr                                                                |
|37 | Psychonautdocs.com                                                           |
|38 | Psychonautwiki.org                                                           |
|39 | Psyconauts.tripod.com                                                        |
|40 | Reddit.com and drug-related subreddits (e.g. Reddit.com/r/Psychonaut/; Reddit.com/r/shroomers/) |
|41 | Shayanashop.com                                                              |
|42 | Sjamaan.com                                                                  |
|43 | Tripzine.com                                                                 |
|   | Website                |
|---|-----------------------|
| 44 | Tryptamin.com         |
| 45 | Urban75.net           |
| 46 | Zamnesia.com          |

Appendix 1: List of websites monitored by the NPS.Finder® web crawler during the time frame November 2017-May 2019; surface web only.
### Appendix 2

List of SC mentioned by the psychoauts and identified either through the web crawler activities or presented in the EMCDDA and/or UNODC lists, for a total of 1,155 unique molecules. The table reports names of all SC; their alternative and IUPAC denominations; if they are present (Y) in the UNODC, EMCDDA and NPSfinder® lists and their categorization (i.e. Categories: 1) SC listed by the EMCDDA and/or by the UNODC: 292 molecules; 2a) SC which are already scheduled, and/or for which evidence levels of abuse have already been reported in peer-reviewed papers, but which are not listed by either the EMCDDA or the UNODC: 94 molecules; 2b) SC commented on the psychoauts’ websites/fora: 767 molecules; 3) SC used as laboratory research products/analytical references and/or studied in preclinical or animal research: 2 molecules.

| NAME | OTHER NAMES | IUPAC denomination | UNODC | EMCDDA | NPSFinder |
|------|-------------|---------------------|-------|--------|-----------|
| 1    | (1,1'-BIPHENYL)-2-YL[1-PENTYL-1H-INDOL-3-YL]METHANONE | N/A | C26H25NO; (1,1'-Biphenyl)-2-yl[1-pentyl-1H-indol-3-yl]methanone | . | . | Y |
| 2    | (1,1'-BIPHENYL)-3-YL[1-PENTYL-1H-INDOL-3-YL]METHANONE | N/A | C26H25NO; (1,1'-Biphenyl)-3-yl[1-pentyl-1H-indol-3-yl]methanone | . | . | Y |
| 3    | [1-BENZOFURAN-7-YL]-[1-(2-MORPHOLIN-4-YL)ETHYL]-1H-INDOL-3-YL]METHANONE | N/A | C23H22N2O3; (1-Benzofuran-7-yl)[1-[2-(morpholin-4-yl)ethyl]-1H-indol-3-yl]methanone | Y | . | . |
| 4    | (1-PENTYL-1H-INDAZOL-3-YL)[2,2,3,3-TETRAMETHYLCYCLOPROPYL]METHANONE | N/A | C20H28N2O; [1-pentyl-1H-indazol-3-yl][2,2,3,3-tetramethylcyclopropyl]methanone | Y | . | . |
| 5    | (1-PENTYL-1H-INDAZOL-3-YL)[PIPERAZIN-1-YL]METHANONE | N/A | C17H24N4O; [1-pentyl-1H-indazol-3-yl][piperazin-1-yl]methanone | Y | . | . |
| 6    | (1-PENTYL-1H-INDOL-3-YL)[PYRIDIN-3-YL]METHANONE | N/A | C19H20NO2; [1-pentyl-1H-indol-3-yl][pyridin-3-yl]methanone | Y | . | . |
| 8    | [1'5,2'S)-5-[HYDROXYMETHYL]-4-[2-METHYL-6-[MORPHOLIN-4-YL]-HEXAN-2-YL]-2'-[(PROP-1-EN-2-YL)-1'2', 3', 4'-TETRAHYDRO[1,1'-BIPHENYL]-2,6-DIOL | N/A | C27H41N4O; [1',5,2'S)-5-[Hydroxymethyl]-4-[2-methyl-6-[morpholin-4-y]hexan-2-yl]-2'-[(prop-1-en-2-yl)-1',2',3',4'-tetrahydro[1,1'-biphenyl]-2,6-diol | . | Y |
| 9    | (1E)-1-[(6AR,10AR)-1-HYDROXY-6,6,9-TRIMETHYL-6A,7,10,10A-TETRAHYDRO-6H-DIBENZO[B,D]PYRAN-3-YL]OCT-1-EN-3-ONE | N/A | C24H23O3; (1E)-1-[(6aR,10aR)-1-Hydroxy-6,6,9-trimethyl-6a,7,10,10a-tetrahydro-6h-dibenzo[b,d]pyran-3-yl]oct-1-en-3-one | Y | . | . |
| 10   | (2-ADAMANTYL) 5CL-APINACA | N/A | C23H20CIN3O; N-(Adamantan-2-yl)-1-(3-chloropentyl)-1H-indazole-3-carboxamide | . | . | Y |
| 11   | (2-FLUOROPHENYL)[(3R)-5-METHYL-3-[MORPHOLIN-4-YL]ETHYL]-2,3-DIHYDRO[1,4]OXAZINO[2,3,4-H]INDOL-6-YL]METHANONE | N/A | C23H23FN2O3; (2-Fluorophenyl)[(3R)-5-methyl-3-[morpholin-4-yl]ethyl]-2,3-dihydro[1,4]oxazino[2,3,4-h]indol-6-yl]methanone | Y | . | . |
| 12   | (2-PENTYL) JW-018 | N/A | C24H24NO; [Naphthalen-1-yl]-[1-pentan-2-yl]-1H-indol-3-yl]methanone | Y | . | . |
| 13   | (2H-INDAZOLE) APINACA | N/A | C23H31N3O; N-(Adamantan-1-yl)-2-pentyl-2H-indazole-3-carboxamide | Y | . | . |
| 14   | (2MB) JW-018 | N/A | C24H24NO; [1-(2-Methylbutyl)-1H-indol-3-yl]methanone | Y | . | . |
| 15   | (2R,5S)-5-METHYL-9-PENTYL-2-(PROPAN-2-YL)-3,4,5,6-TETRAHYDRO-2H-2,6-METHANO-1-BENZOXOCIN-7-OL | N/A | C23H23O2; (2R,5S)-5-Methyl-9-pentyl-2-(propan-2-yl)-3,4,5,6-tetrahydro-2H-2,6-methano-1-benzoxocin-7-ol | Y | . | . |
| 16   | (3-PENTYL) JW-018 | N/A | C24H23NO; [Naphthalen-1-yl]-[1-pentan-3-yl]-1H-indol-3-yl]methanone | Y | . | . |
| 17   | (3R)-N-(ADAMANTAN-1-YL)-3-ETHYL-7-OXO-2,3-DIHYDRO-7H-[1,4]OXAZINO[2,3,4-U]QUINOLINE-6-CARBOXYLATE | N/A | C24H23O2NO3; (3R)-N-(Adamantan-1-yl)-3-ethyl-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-u]quinoline-6-carboxylate | Y | . | . |
| 18   | (32)-5-CHLORO-1-[2-(MORPHOLIN-4-YL)ETHYL]-3-[NAPHTHALEN-1-YL]IMINO]-1,3-DIHYDRO-2H-INDOL-2-ONE | N/A | C24H22CIN3O2; (32)-5-Chloro-1-[2-(morpholin-4-yl)ethyl]-3-[naphthalen-1-yl]imino]-1,3-dihydro-2H-indol-2-one | Y | . | . |
| No. | Chemical Structure | Name | PubChem CID | CAS Number |
|-----|--------------------|------|-------------|------------|
| 19  | ![Chemical Structure](image) | (4-Bromonaphthalen-1-yl)[1-[(1-Methylpiperidin-2-yl)Methyl]-1H-indol-3-yl]Methanone | N/A | C26H25BrN2O; (4-Bromonaphthalen-1-yl)[1-[(1-methylpiperidin-2-yl)methyl]-1H-indol-3-yl]methanone |
| 20  | ![Chemical Structure](image) | (4-Fluoronaphthalen-1-yl)[1-[(1-Methylpiperidin-2-yl)Methyl]-1H-indol-3-yl]Methanone | N/A | C26H25FN2O; (4-Fluoronaphthalen-1-yl)[1-[(1-methylpiperidin-2-yl)methyl]-1H-indol-3-yl]methanone |
| 21  | ![Chemical Structure](image) | (4-Hydroxynaphthalen-1-yl)[1-[(1-Methylpiperidin-2-yl)Methyl]-1H-indol-3-yl]Methanone | N/A | C26H26NO2; (4-Hydroxynaphthalen-1-yl)[1-[(1-methylpiperidin-2-yl)methyl]-1H-indol-3-yl]methanone |
| 22  | ![Chemical Structure](image) | (4-Methoxynaphthalen-1-yl)[1-[(1-Methylpiperidin-2-yl)Methyl]-1H-indol-3-yl]Methanone | N/A | C27H28N2O2; (4-Methoxynaphthalen-1-yl)[1-[(1-methylpiperidin-2-yl)methyl]-1H-indol-3-yl]methanone |
| 23  | ![Chemical Structure](image) | (4-Methoxyphenyl)[(3R)-5-Methyl-3-[(Morpholin-4-yl)Methyl]-2,3-dihydro[1,4]oxazino[2,3,4-hi]indol-6-yl]Methanone | N/A | C24H26N2O4; (4-Methoxyphenyl)[(3R)-5-methyl-3-[(morpholin-4-yl)methyl]-2,3-dihydro[1,4]oxazino[2,3,4-hi]indol-6-yl]methanone |
| 24  | ![Chemical Structure](image) | (4-Methoxyphenyl)[3-[(Morpholin-4-yl)Methyl]-2,3-dihydro-1H-pyrrolo[1,2-a]indol-9-yl]Methanone | N/A | C24H26N2O3; (4-Methoxyphenyl)[3-[(morpholin-4-yl)methyl]-2,3-dihydro-1H-pyrrolo[1,2-a]indol-9-yl]methanone |
| 25  | ![Chemical Structure](image) | (4AR,10BR)-1,2,5,5-Tetramethyl-8-Pentyl-1,3,4,4a,5,10b-Hexahydro-2H-[1]benzopyrano[4,3-b]pyridin-10-ol | N/A | C21H33NO2; (4AR,10BR)-1,2,5,5-Tetramethyl-8-pentyl-1,3,4,4a,5,10b-hexahydro-2H-[1]benzopyrano[4,3-b]pyridin-10-ol |
| 26  | ![Chemical Structure](image) | (5-Methyl-6-(2-Morpholin-6-yl)thieno[2,3-b]pyrrol-4-yl)(1-propyl-1H-indol-2-yl)methanone | US 2013/0178453 #11 | C25H23N3O2S; (5-Methyl-6-(2-(morpholin-4-yl)ethyl)-6H-thieno[2,3-b]pyrrol-4-yl)(1-propyl-1H-indol-2-yl)methanone |
| 27  | ![Chemical Structure](image) | (5-Methyl-6-propylthieno[2,3-b]pyrrrol-4-yl)(6-propylthieno[2,3-b]pyrrrol-5-yl)methanone | US 2013/0178453 #83 | C20H22N2O3S; (5-Methyl-6-propyl-6H-thieno[2,3-b]pyrrol-4-yl)(6-propyl-6H-thieno[2,3-b]pyrrol-5-yl)methanone |
| 28  | ![Chemical Structure](image) | (5AR,9AR)-7,7-Dimethyl-3-(2-Methyloctan-2-yl)-5a,6,7,8,9,9a-hexahydrodibenzo[b,d]furanc-1-ol | N/A | C23H36O2; (5AR,9AR)-7,7-Dimethyl-3-(2-methyloctan-2-yl)-5a,6,7,8,9,9a-hexahydrodibenzo[b,d]furanc-1-ol |
| 29  | ![Chemical Structure](image) | (6-Ethylthieno[2,3-b]pyrrrol-5-yl)-(1-propylpyrrrolo[2,3-b]pyrridin-3-yl)methanone | US 2013/0178453 #34 | C19H19N3OS; (6-Ethyl-6H-thieno[2,3-b]pyrrol-5-yl)(1-propyl-1H-pyrrlo[2,3-b]pyrindin-3-yl)methanone |
| 30  | ![Chemical Structure](image) | (6-Ethylthieno[2,3-b]pyrrrol-5-yl)-(1-oxan-4-ylmethyl)-3-yl)methanone | US 2013/0178453 #16 | C23H24N2O3S; (6-Ethyl-6H-thieno[2,3-b]pyrrol-5-yl)(1-oxan-4-ylmethyl)-1H-indol-3-yl)methanone |
| 31  | ![Chemical Structure](image) | (6-Hydroxynaphthalen-1-yl)[1-[(1-Methylpiperidin-2-yl)Methyl]-1H-indol-3-yl]Methanone | N/A | C26H26N2O2; (6-Hydroxynaphthalen-1-yl)[1-[(1-methylpiperidin-2-yl)methyl]-1H-indol-3-yl]methanone |
| 32  | ![Chemical Structure](image) | (6AR,10AR)-3-(2-Cyclohexylpropan-2-yl)-6,6,9-Trimethyl-6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-1-ol | N/A | C25H36O2; (6AR,10AR)-3-(2-Cyclohexylypropan-2-yl)-6,6,9-trimethyl-6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-1-ol |
| 33  | ![Chemical Structure](image) | (6AR,10AR)-6,6,9-Trimethyl-3-(2-Methyloctan-2-yl)-6a,7,8,10a-Tetrahydro-6H-dibenzo[b,d]pyran-1-amine | N/A | C25H35NO; (6AR,10AR)-6,6,9-Trimethyl-3-(2-methyloctan-2-yl)-6a,7,8,10a-tetrahydro-6H-dibenzo[b,d]pyran-1-amine |
| 34  | ![Chemical Structure](image) | (6AR,10AR)-6,6,9-Trimethyl-3-(2-Methyloctan-2-yl)-6a,7,8,10a-Tetrahydro-6H-dibenzo[b,d]pyran-1-carbonitrile | N/A | C26H37NO; (6AR,10AR)-6,6,9-Trimethyl-3-(2-methyloctan-2-yl)-6a,7,8,10a-tetrahydro-6H-dibenzo[b,d]pyran-1-carbonitrile |
| 35  | ![Chemical Structure](image) | (6AR,10AR)-6,6,9-Trimethyl-3-[(2-Phenyl-1,3-dithiolan-2-yl)Methanol]-1H-indol-3-yl]Methanone | N/A | C25H28O2S; (6AR,10AR)-6,6,9-Trimethyl-3-[(2-phenyl-1,3-dithiolan-2-yl)Methanol]-1H-indol-3-yl]Methanone |
| 36  | ![Chemical Structure](image) | (6AR,10AR)-6,6,9-Trimethyl-3-pentyl-6a,7,8,10a-Tetrahydro-6H-dibenzo[b,d]pyran-1-amine | N/A | C21H31NO; (6AR,10AR)-6,6,9-Trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-dibenzo[b,d]pyran-1-amine |
| 37  | ![Chemical Structure](image) | (Allyl)JWH-018 | N/A | C22H17NO; (Naphthalen-1-yl)[1-prop-2-(en-1-yl)-1H-indol-3-yl]methanone |
| 38  | ![Chemical Structure](image) | (Azepane) AB-005 | N/A | C23H32N2O; [1-(1-methylazepan-3-yl)-1H-indol-3-yl][2,2,3,3-tetramethylcyclopentyl]methanone |
| 39  | ![Chemical Structure](image) | (Azepane) AM-1220 | N/A | C26H26N2O; [1-(1-Methylazepan-3-yl)-1H-indol-3-yl][naphthalen-1-yl]methanone |
| 40  | ![Chemical Structure](image) | (Benzy1)JWH-018 | N/A | C26H19NO; (1-Benzyl-1H-indol-3-yl)[naphthalen-1-yl]methanone |
| 41  | ![Chemical Structure](image) | (Benzy1)PB-22 | N/A | C25H18N2O2; Quinolin-8-yl-1-benzyl-1H-indole-3-carboxylate |
| 42  | ![Chemical Structure](image) | (C11)-CP-47,497 | N/A | C25H42O2; 2-[1S(3R,3)-3-Hydroxyecyclohexyl]-5-(2-methyldecane-2-yl)phenol |
43  (C4) JWH-210  N/A  C25H25NO; [1-Butyl-1H-indol-3-yl][4-ethynaphthalen-1-yl]methanone
44  (C4) ORTHO-RCS-4  RCS-2-C4;  C20H21NO2; [1-Butyl-1H-indol-3-yl][2-methoxyphenyl]methanone
45  (C4) UR-144  N/A  C20H27NO; [1-Propyl-1H-indol-3-yl][2,2,3,3-tetramethylcyclopropyl]methanone
46  (C6)-CP 47,497  CP 47,497-C6-homolog  C20H32O2; 2-[(1S,3R)-3-Hydroxyoctyl]5-(2-methylheptan-2-yl)phenol
47  (C9)-CP 47,497  CP 47,497-C9-homolog  C23H38O2; 2-[(1S,3R)-3-Hydroxyhexyl]5-(2-methyleneoctan-2-yl)phenol
48  (CARBOXY) JWH-072  N/A  C22H17N3O3; 3-[3-(Naphthalene-1-carboxyl]-1H-indol-1-yl)propanoic acid
49  (CHM) JWH-210  N/A  C28H29NO; [1-(Cyclohexylmethyl)-1H-indol-3-yl][4-ethynaphthalen-1-yl]methanone
50  (CHM) JWH-412  N/A  C26H24FNO; [1-(Cyclohexylmethyl)-1H-indol-3-yl][4-fluoronaphthalen-1-yl]methanone
51  (CHM) UR-144  N/A  C23H31NO; [1-(Cyclohexylmethyl)-1H-indol-3-yl][2,2,3,3-tetramethylcyclopropyl]methanone
52  (CP) JWH-018  N/A  C22H19NO; [1-Cyclopentyl-1H-indol-3-yl][4a,8a-dihydronaphthalen-1-yl]methanone
53  (CPE) JWH-018  N/A  C24H21NO; [1-Cyclopentyl-1H-indol-3-yl][naphthalen-1-yl]methanone
54  (CPM) JWH-018  N/A  C23H19NO; [1-Cyclopentyl-1H-indol-3-yl][naphthalen-1-yl]methanone
55  (CYCLOHEXYL) JWH-018  N/A  C20H27NO; Cyclohexyl[1-pentyl-1H-indol-3-yl]methanone
56  (DECALIN) JWH-018  N/A  C24H33NO; [Decahydroquinaphthalen-1-yl][1-pentyl-1H-indol-3-yl]methanone
57  (DECYL) JWH-018  N/A  C29H33NO; [1-Decyl-1H-indol-3-yl][naphthalen-1-yl]methanone
58  (DEGRADANT) A-796,260  N/A  C22H30N2O2; (2E)-3,4,4-Trimethyl-1-[1-[2-(morpholin-4-yl)ethyl]-1H-indol-3-yl]pent-2-ene-1-on
59  (HEXAHYDRO-2,5-METHANOPENTALEN-3A(1H)-YL)1-[(OXANY-4-YL)METHYL]1H-INDOL-3-YLMETHANONE  N/A  C24H25N2O; [Hexahydro-2,5-methanopentalen-3a(1H)-yl][1-[(oxany-4-y1)methyl]-1H-indol-3-yl]methanone
60  (INDAZOLE) PB-22, INPB-22  N/A  C22H21N3O2; Quinolin-8-yl 1-pentyl-1H-indazole-3-carboxylate
61  (NAPHTHALEN-1-YL)[1-PENTYL-1H-PYRROLO[2,3-B]PYRIDIN-3-YLMETHANONE  N/A  C23H22N2O; (Naphthalen-1-yl)[1-pentyl-1H-pyrrolo[2,3-b]pyridin-3-yl]methanone
62  (NAPHTHALEN-1-YL)[1-PENTYL-1H-PYRROLO[2,3-C]PYRIDIN-3-YLMETHANONE  N/A  C23H22N2O; (Naphthalen-1-yl)[1-pentyl-1H-pyrrolo[2,3-c]pyridin-3-yl]methanone
63  (NAPHTHALEN-1-YL)[1-PENTYL-1H-PYRROLO[3,2-C]PYRIDIN-3-YLMETHANONE  N/A  C23H22N2O; (Naphthalen-1-yl)[1-pentyl-1H-pyrrolo[3,2-c]pyridin-3-yl]methanone
64  (NONYL) JWH-018  N/A  C28H31NO; [Naphthalen-1-yl][1-nonyl-1H-indol-3-yl]methanone
65  (OCTAHYDROISOQUINOLIN-2(1H)-YL)[4-(PROPAN-2-YL)-3-PYRROLIDINE-1-SULFONYL]PHENYL]METHANONE  N/A  C23H34NO2S; [Octahydroisouquinolin-2(1H)-yl][4-(propan-2-yl)-3-pyrrolidine-1-sulfonyl]phenyl]methanone
66  (OCTYL) JWH-018  N/A  C27H29NO; (Naphthalen-1-yl)[1-octyl-1H-indol-3-yl]methanone
67  (ORIGINAL) SDB-005  n-phenyl SDB-006  C20H22N2O; 1-Pentyl-N-phenyl-1H-indole-3-carboxamide
68  (PENTENYL) AM-694  N/A  C20H18N2O; [2-Iodophenyl][1-[(pent-4-en-1-yl)-1H-indol-3-yl]methanone
69  (PENTENYL) JWH-149  N/A  C26H25NO; [1-(Methyl)naphthalen-1-yl][2-methyl-1-[(pent-4-en-1-yl)-1H-indol-3-yl]methanone
| Page | Entry | N/A | Chemical Structure | Description |
|------|-------|-----|--------------------|-------------|
| 70   | (PIPET) AM-1220 | N/A | C26H26N2O; [Naphthalen-1-yl][1-[2-(piperidin-1-yl)ethyl]-1H-indol-3-yl]methanone | . . Y |
| 71   | (R,R)-EPI-CP 47,497 | N/A | C21H3402; Z-[1R,3R]-3-Hydroxycyclohexyl]-5-[2-methyloctan-2-yl]phenol | . . Y |
| 72   | (S,S)-EPI-(C8)-CP 47,497 | N/A | C21H3602; 2-[1S,3S]-3-Hydroxycyclohexyl]-5-(2-methylnonan-2-yl)phenol | . . Y |
| 73   | (S,S)-EPI-CP 47,497 | N/A | C21H3402; 2-[1S,3S]-3-Hydroxycyclohexyl]-5-(2-methyloctan-2-yl)phenol | . . Y |
| 74   | [TPM] JWH-018 | N/A | C25H23N02; [Naphthalen-1-yl][1-[(oxan-4-yl)methyl]-1H-indol-3-yl]methanone | . . Y |
| 75   | [1-(2-METHOXYETHYL)-1H-INDOL-3-YL][2,2,3,3-TETRAMETHYLICYCLOPROPYL]METHANONE | N/A | C19H25N02; [1-(2-Methoxyethyl]-1H-indol-3-yl][2,2,3,3-tetramethylcyclopropyl]methanone | . . Y |
| 76   | [1-(5-FLUOROPENTYL)-6-NITRO-1H-INDOL-3-YL][2-IODOPHENYL]METHANONE | N/A | HONGFENG DENG PHD #7.15 | C20H18F5N2O3; [1-(5-Fluoropentyl)-6-nitro-1H-indol-3-yl][2-iiodophenyl]methanone | . . Y |
| 77   | [1-(CYCLOHEXYLMETHYL)-7-METHOXY-1H-INDOL-3-YL][4-ETHYL-3,3-DIMETHYLPIPERAZIN-1-YL]METHANONE | N/A | C25H37N3O2; [1-(Cyclohexylmethyl)-7-methoxy-1H-indol-3-yl][4-ethyl-3,3-dimethylpiperazin-1-yl]methanone | . . Y |
| 78   | [4-(2-HYDROXYETHYL)NAPHTHALEN-1-YL][1-(1-METHYLPIPERIDIN-2-YL)METHYL]-1H-INDOL-3-YLMETHANONE | N/A | C28H30N2O2; [4-(2-Hydroxyethyl)naphthalen-1-yl][1-(1-methylpiperidin-2-yl)methyl]-1H-indol-3-ylmethanone | . . Y |
| 79   | [1(2R)-1-[3-(7-CHLORO-1-[(OXAN-4-YL]METHYL]-1H-INDOL-3-YL)-1,2,4-THIADIAZOL-5-YL]METHYL]PYRROLIDIN-2-YLMETHANOL | N/A | C22H27ClN4O2S; [1(2R)-1-[3-(7-Chloro-1-[(oxan-4-yl)methyl]-1H-indol-3-yl)-1,2,4-thiadiazol-5-yl]methyl]pyrrolidin-2-ylmethanol | . . Y |
| 80   | [3R]-5-METHYL-3-[MORPHOLIN-4-YL]METHYL]-2,3-DIHYDRO[1,4]OXAZINO[2,3,4-HI]INDOL-6-YL]QUINOLIN-7-YLMETHANONE | N/A | C26H26N3O3; [(3R)-5-Methyl-3-[morpholin-4-yl]methyl]-2,3-dihydro[1,4]oxazino[2,3,4-hi]indol-6-yl]quinolin-7-ylmethanone | . . Y |
| 81   | [1-(1-METHYLPIPERIDIN-2-YL)METHYL]-1H-INDAZOL-3-YL]NAPHTHALEN-1-YLMETHANONE | N/A | C25H25N3O; [1-(1-Methylpiperidin-2-yl)methyl]-1H-indazol-3-yl]naphtalen-1-ylmethanone | . . Y |
| 82   | [1-(1-METHYLPIPERIDIN-2-YL)METHYL]-OCTAHYDROQUINOLIN-1(2H)-YLMETHANONE | N/A | C25H35N3O; [1-(1-Methylpiperidin-2-yl)methyl]-1H-indol-3-yl]octahydroquinolin-1(2H)-ylmethanone | . . Y |
| 83   | [1-(OXAN-4-YL)METHYL]-1H-INDOL-3-YL][SPIRO[2.5]OCTAN-1-YLMETHANONE | N/A | C23H29N02; [1-(Oxan-4-yl)methyl]-1H-indol-3-yl][spiro[2.5]octan-1-ylmethanone | . . Y |
| 84   | [1-(PYRIDIN-4-YL]METHYL]-1H-INDOL-3-YL][2,2,3,3-TETRAMETHYLCYCLOPROPYL]METHANONE | N/A | C22H24N02; [1-(Pyridin-4-yl)methyl]-1H-indol-3-yl][2,2,3,3-tetramethylcyclopropyl]methanone | . . Y |
| 85   | [1-(4-METHYLSULFANYL]BUTYL]-1H-INDOL-3-YL][2,2,3,3-TETRAMETHYLCYCLOPROPYL]METHANONE | N/A | C21H29NOS; [1-(4-Methylsulfonyl]butyl]-1H-indol-3-yl][2,2,3,3-tetramethylcyclopropyl]methanone | . . Y |
| 86   | [2-CHLORO-1-[2-(MORPHOLIN-4-YL)ETHYL]-1H-INDOL-3-YL]NAPHTHALEN-1-YLMETHANONE | N/A | C25H23ClN02; [2-Chloro-1-[2-(morpholin-4-yl)ethyl]-1H-indol-3-yl]naphtalen-1-ylmethanone | . . Y |
| 87   | [2-METHYL-1-[2-(MORPHOLIN-4-YL)ETHYL]-1H-INDOL-3-YL]QUINOLIN-7-YLMETHANONE | N/A | C25H25N3O; [2-Methyl-1-[2-(morpholin-4-yl)ethyl]-1H-indol-3-yl]quinolin-7-ylmethanone | . . Y |
| 88   | [2-METHYL-1-[2-(PIPERIDIN-1-YL)ETHYL]-1H-INDOL-3-YL]NAPHTHALEN-1-YLMETHANONE | N/A | C27H26N02; [2-Methyl-1-[2-(piperidin-1-yl)ethyl]-1H-indol-3-yl]naphtalen-1-ylmethanone | . . Y |
| 89   | [4,5,6,7-TETRAFLUORO-1-[OXAN-4-YL]METHYL]-1H-INDOL-3-YL][2,2,3,3-TETRAMETHYLICYCLOPROPYL]METHANONE | N/A | C22H24F4N02; [4,5,6,7-Tetrafluoro-1-[oxan-4-yl]methyl]-1H-indol-3-yl][2,2,3,3-tetramethylcyclopropyl]methanone | . . Y |
| 90   | [5-(OXAN-4-YL)METHYL]-2H,5H-[1,3]DIOXOLO[4,5-F][INDOL-7-YL][2,2,3,3-TETRAMETHYLICYCLOPROPYL]METHANONE | N/A | C23H29N04; [5-(Oxan-4-yl)methyl]-2H,5H-[1,3]dioxolo[4,5-f]indol-7-yl][2,2,3,3-tetramethylcyclopropyl]methanone | . . Y |
| 91   | [6-(BENZYL]OXY)-1-[OXAN-4-YL]METHYL]-1H-INDOL-3-YL][2,2,3,3-TETRAMETHYLICYCLOPROPYL]METHANONE | N/A | C29H35N03; [6-(Benzyl]oxy)-1-[oxan-4-yl]methyl]-1H-indol-3-yl][2,2,3,3-tetramethylcyclopropyl]methanone | . . Y |
| 92   | [6-BROMO-1-[OXAN-4-YL]METHYL]-1H-INDOL-3-YL][2,2,3,3-TETRAMETHYLICYCLOPROPYL]METHANONE | N/A | C22H28BrN02; [6-Bromo-1-[oxan-4-yl]methyl]-1H-indol-3-yl][2,2,3,3-tetramethylcyclopropyl]methanone | . . Y |
| 93   | [6-CHLORO-1-[OXAN-4-YL]METHYL]-1H-INDOL-3-YL][2,2,3,3-TETRAMETHYLICYCLOPROPYL]METHANONE | N/A | C22H28ClN02; [6-Chloro-1-[oxan-4-yl]methyl]-1H-indol-3-yl][2,2,3,3-tetramethylcyclopropyl]methanone | . . Y |
| #  | Name                                                                 | CAS Number                                      | Molar Mass       | Yields | Reference |
|----|----------------------------------------------------------------------|-------------------------------------------------|------------------|--------|-----------|
| 94 | (6-METHOXY-1-[(OXAN-4-YL)METHYL]-1H-INDOL-3-YL][2,2,3,3- TETRAMETHYLCYCLOPROPYLMETHANONE] | N/A                                             | C23H31NO3; [6-Methoxy-1-[(oxan-4-yl)methyl]-1H-indol-3-yl][2,2,3,3-tetramethylcyclopropyl]methanone | .     | Y         |
| 95 | (6-METHYL-1-[(OXAN-4-YL)METHYL]-1H-INDOL-3-YL][2,2,3,3- TETRAMETHYLCYCLOPROPYLMETHANONE] | N/A                                             | C23H31N02; [6-Methyl-1-[(oxan-4-yl)methyl]-1H-indol-3-yl][2,2,3,3-tetramethylcyclopropyl]methanone | .     | Y         |
| 96 | (7-METHOXY-1-[(OXAN-4-YL)METHYL]-1H-INDOL-3-YL][2,2,3,3- TETRAMETHYLCYCLOPROPYLMETHANONE] | N/A                                             | C23H31N03; [7-Methoxy-1-[(oxan-4-yl)methyl]-1H-indol-3-yl][2,2,3,3-tetramethylcyclopropyl]methanone | .     | Y         |
| 97 | 1-[(1-NAPHTHYLMETHYLENE)INDENE]                                       | N/A                                             | C2OH14; 1-[(E)-1-Inden-1-yldenemethyl]naphthalene | .     | Y         |
| 98 | 1-[(2-NAPHTHYLMETHYLENE)INDENE]                                       | N/A                                             | 1-[(2-Naphthylmethylene)indene]                | .     | Y         |
| 99 | 1-[(2-NAPHTHYLMETHYLENE)INDENE]                                       | N/A                                             | 1-[(2-Naphthylmethylene)indene]               | .     | Y         |
| 100| 1-[(5-FLUOROPENTYL)-3-[(2-ETHYLBENZOYL)INDOLE]                       | AM-694 ethyl substituted for iodine             | C2H24FNO; 1-[(5-fluoropentyl)-1H-indol-3-yl][2-ethylphenyl]methanone; [2-(Ethylphenyl)]1-[(5-fluoropentyl)-1H-indol-3-yl]methanone | Y     | Y         |
| 101| 1-[(2-FLUOROPHENYL)METHYL]-7-METHYL-N-(4- METHYLICYCLOHEXYL)-4-OXO-1,4-DIHYDRO-1,8-NAPHTHYRIDINE-3-CARBOXYLAMIDE | N/A                                             | C2H26FNO3O2; 1-[(2-fluorophenyl)methyl]-7-methyl-N-(4-methylcyclohexyl)-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide | .     | Y         |
| 102| 1-[(OXAN-4-YL)METHYL]-3-[(2,2,3,3- TETRAMETHYLCYCLOPROPANE-1-CARBONYL]-1H-INDOLE-6-CARBONITRILE | N/A                                             | C2H28N02O3; 1-[(OXAN-4-YL)METHYL]-3-[(2,2,3,3-tetramethylcyclopropyl)carbonyl]-1H-indole-6-carbonitrile | .     | Y         |
| 103| 1-BENZYL-N-(QUINOLIN-8-YL)-1H-INDAOLE-3-CARBOXYLAMIDE                | N/A                                             | C2H18N04; 1-Benzyl-N-(quinolin-8-yl)-1H-indazole-3-carboxamide | Y     | .         |
| 104| 1-BENZYL-N-(QUINOLIN-8-YL)-1H-INDOL-3-CARBOXYLAMIDE                  | N/A                                             | C2H19N03; 1-benzyl-N-(quinolin-8-yl)-1H-indole-3-carboxamide | Y     | .         |
| 105| 1-BENZYL-N-CYCLOHEXYL-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLAMIDE     | N/A                                             | C2H26N02O2; 1-Benzyl-N-cyclohexyl-4-oxo-1,4-dihydroquinoline-3-carboxamide | .     | Y         |
| 106| 1-BENZYL-N-CYCLOHEXYL-7-METHOXY-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLAMIDE | N/A                                             | C2H26N03O2; 1-Benzyl-N-cyclohexyl-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxamide | .     | Y         |
| 107| 1-CYCLOHEXYLTHYL-3-(2-METHOXYPHENYLACETYL)INDOLE                     | RCS-8                                           | C2H29N02O2; 1-[(1-[(2-cyclohexylethyl)methyl]-3-yl)-2-[2-methoxyphenyl]methane | Y     | .         |
| 108| 1-HYDROXY-6,6-DIMETHYL-3-(2-METHOXYACETAN-2-YL)-6H- DIBENZ(2,5)PYRAN-9-CARBOXYLIC ACID | N/A                                             | C2H32O4; 1-Hydroxy-6,6-dimethyl-3-(2-methoxyacetan-2-yl)-6H-dibenzo[2,5]pyran-9-carboxylic acid | .     | Y         |
| 109| 1-PENTYL 3-(3-TOLYL) INDOLE                                         | N/A                                             | C2H12N03; 1-Methoxyphenyl][1-pentyl-1H-indol-3-yl]methanone | .     | Y         |
| 110| 1-PENTYL 3-BENZOYL INDOLE                                           | N/A                                             | C2H21N02; 1-Pentyl-1H-indol-3-yl][phenyl]methanone | .     | .         |
| 111| 1-PENTYL-N-(QUINOLIN-8-YL)-1H-INDOLE-3-CARBOXYLAMIDE                | N/A                                             | C2H23N03O2; 1-pentyl-N-(quinolin-8-yl)-1H-indole-3-carboxamide | Y     | .         |
| 112| 1H-INDOL-3-YL-(1-NAPHTHYLMETHANE)                                   | 3-[(1-NAPHTHYLMETHANE)INDOLE                    | C19H15N; 1H-Indol-3-yl-(1-naphthyl)methane     | .     | Y         |
| 113| 1H-INDOL-3-YL-(2-NAPHTHYLMETHANE)                                   | 3-[(2-NAPHTHYLMETHANE)INDOLE                    | 1H-Indol-3-yl-(2-naphthyl)methane              | .     | Y         |
| 114| 2-[(1R,2R,5R)-5-HYDROXY-2-[HYDROXYMETHYL]CYCLOHEXYL]- 5-(2-METHOXYACETAN-2-YL)PHENOL | US 4371720 #1-1                                  | C2H32O3; 2-[(1R,2R,5R)-5-Hydroxy-2-[hydroxymethyl]cyclohexyl]-5-(2-methoxyacetan-2-yl)phenol | .     | Y         |
| 115| 2-[(1R,2S,5S)-5-HYDROXY-2-[HYDROXYETHYL]CYCLOHEXYL]- 5-(2-METHOXYACETAN-2-YL)PHENOL | US 4371720 #1-2                                  | C2H32O3; 2-[(1R,2S,5S)-5-Hydroxy-2-[hydroxyethyl]cyclohexyl]-5-(2-methoxyacetan-2-yl)phenol | .     | Y         |
| 116| 2-[[HYDROXY-2-(3-HYDROXYPROPYL)PHENYL]-5-(2-METHOXYACETAN-2-YL)BENZEN-1,3-DIOL] | US 2004/0087590 #25                             | C2H34O4; 6-[[3-Hydroxypropyl]-4-[2-methoxyacetan-2-yl]1,1′-biphenyl]-2,3,6-triol | .     | Y         |
| 117| 2-[[3-(7-CHLORO-1-[(OXAN-4-YL)METHYL]-1H-INDOL-3-YL]- 1,2,4-OXADIAZOL-5-YLMETHYL][METHYLAMINO]ACETAMIDE | N/A                                             | C2H24ClN03O; 2-[[3-(7-Chloro-1-[(oxan-4-yl)methyl]-1H-indol-3-yl)-1,2,4-oxadiazol-5-yl)methyl][methylamino]acetamide | .     | Y         |
| 118| 2-AGE                                                                | Noladin ether                                   | C2H34NO3; 2-[[5,8,11,14Z]-icos-5,8,11,14-tetraen-1-yl]oxo)propane-1,3-diol | .     | Y         |
|   | Compound                                                                 | CAS Number | 1H-Indole-3-carboxamide | 1H-Indole-3-carboxamide | Notes       |
|---|--------------------------------------------------------------------------|------------|--------------------------|--------------------------|-------------|
| 118| 2-BROMOPHENYL 4-METHYL-3-(PIPERIDINE-1-SULFONYL)BENZOATE                | N/A        |                          |                          |             |
| 119| 2-DESMETHYL WIN 55212-2                                                 | N/A        |                          |                          |             |
| 120| 2-ETHOXY-N-[5-METHYL-3-(OXAN-4-YL METHYL)-1,3-THIAZOL-2-YLDENE]BENZAMIDE| US 2008/058335 #203 |                          |                          |             |
| 121| 2-METHYL-4,4-DIMETHYL-7-(2-METHYLOCTAN-2-YL)-2,4-DIHYDRO[1]BENZOPYRANO[4,3-C]PYRAZOL-9-OL | N/A        |                          |                          |             |
| 122| 2-FLUORO-ADB                                                             | methyl 2-(1-(2-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate; 2F-ADB; 2F-MDMB-PINACA | C20H28FN3O3; methyl 2-(1-(2-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate | Y | . |
| 123| 2-FUB-007                                                                | N/A        |                          |                          |             |
| 124| 2-FUB-SDB-005                                                            | N/A        |                          |                          |             |
| 125| 2-ME-5F-PB-22                                                            | N/A        |                          |                          |             |
| 126| 2-ME-MAM-2201                                                            | N/A        |                          |                          |             |
| 127| 2-Fluoropentyl-1H-indazole-3-carboxamido; 2F-ADB; 2F-MDMB-PINACA         | C20H28FN3O3; methyl 2-(1-(2-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate | Y | . |
| 128| 2-METHYL-5-(OCTAHYDROISOQUINOLINE-2(1H)-CARBONYL)-N-(PROPAN-2-YL)BENZEN-1-SULFONAMIDE | N/A        |                          |                          |             |
| 129| 2-METHYL-UR-12                                                            | N/A        |                          |                          |             |
| 130| 2,5,5-TRIMETHYL-8-(3-METHYLOCTAN-2-YL)-1,3,4,5-TETRAHYDRO-2H-[1]BENZOPYRANO[4,3-C]PYRIDIN-10-OL | N/A        |                          |                          |             |
| 131| 2'-BD-JWH-369                                                            | JWH-307 BROMINATED ANALOGUE; JWH-307 (bromo); [5-(2-Bromophenyl)-1-penty1-1H-pyrro1-3-yl][naphthalen-1-yl]methanone | C26H24BNO; [5-(2-Bromophenyl)-1-pentyl-1H-pyrro1-3-yl][naphthalen-1-yl]methanone | Y | Y |
| 132| 2'-CL-AM-694                                                             | N/A        |                          |                          |             |
| 133| 2'-ME-AM-694                                                             | 1-(5-fluoropentyl)-3-(2-methylbenzoyl)indole, (1-(5-fluoropentyl)-1H-indol-3-yl)-(o-tolyl) methanone; AM-694 methyl substituted for iodine | C21H22FNO; [1-(5-fluoropentyl)-1H-indol-3-yl][2-methylphenyl]methanone | Y | Y | Y |
| 134| 2'-MEO-AM-694                                                            | N/A        |                          |                          |             |
| 135| 2'-METHOXY-4-(2-METHYLOCTAN-2-YL)[1,1'-BIPHENYL]-2-OL                    | N/A        |                          |                          |             |
| 136| 2'-METHYL-4-(2-METHYLOCTAN-2-YL)[1,1'-BIPHENYL]-2-OL                      | N/A        |                          |                          |             |
| 137| 2',5'-DIMETHYL-4-(2-METHYLOCTAN-2-YL)[1,1'-BIPHENYL]-2-OL                | N/A        |                          |                          |             |
| 138| 2',6'-DIMETHYL-4-(2-METHYLOCTAN-2-YL)[1,1'-BIPHENYL]-2-OL                | N/A        |                          |                          |             |
| 139| 2F-AB-PINACA                                                             | AB-PINACA N-(2-fluoropentyl) | C18H25FNAO2; N-(25)-1-Amino-3-methyl-1-oxobutan-2-yl-1-(2-fluoropentyl)-1H-indazole-3-carboxamide | Y | Y |
| 140| 2F-NNEI                                                                  | N/A        |                          |                          |             |
| Compound                                                                 | Formula          | Description                                                                 | 2-fluoro-QMPSB | N/A   | JWH-018 isoform | N/A   | N/A   | N/A   |
|--------------------------------------------------------------------------|------------------|----------------------------------------------------------------------------|----------------|-------|----------------|-------|-------|-------|
| 3-[4-[[METHANESULFINYL]METHYL]NAPTHALENE-1-CARBONYLAMINO]-6-METHOXY-N-[[OXAN-4-YL]METHYL]PYRIDINE-2-CARBOXAMIDE | N/A              | C26H29N3OSS; 3-[[4-[[Methanesulfanyl]methyl]naphthalene-1-carbonyl]amino]-6-methoxy-N-[[oxan-4-yl]methyl]pyridine-2-carboxamid | N/A            | N/A   | 3-(1-Adamantoyl)indo | N/A   | N/A   | N/A   |
| 3-[(1-ADAMANTOYL)INDOLE]                                                | N/A              | 3-(1-Adamantoyl)indo                                                          | N/A            | N/A   | 3-[(1-Naphthoyl)indo] | N/A   | N/A   | N/A   |
| 3-[(1-NAPHTHOYL)INDOLE]                                                 | N/A              | 3-[(1-Naphthoyl)indo]                                                        | N/A            | N/A   | 3-[(1-Naphthoyl)pyrrole] | N/A   | N/A   | N/A   |
| 3-[(2-ADAMANTOYL)INDOLE]                                                | N/A              | 3-[(2-Adamantoyl)indo]                                                       | N/A            | N/A   | N/A             | N/A   | N/A   | N/A   |
| 3-[(2-NAPHTHOYL)INDOLE]                                                | N/A              | 3-[(2-Naphthoyl)pyrrole]                                                     | N/A            | N/A   | 3-[(2-Naphthoyl)pyrrole] | N/A   | N/A   | N/A   |
| 3-[(2,2,3,3-TETRAMETHYLCYCLOPROPYL)CARBONYL]INDOLE                     | N/A              | 3-[(2,2,3,3-Tetramethylcyclopropylcarbonyl)indo]                              | N/A            | N/A   | 3-[(2,2,3,3-Tetramethylcyclopropylcarbonyl)indo] | N/A   | N/A   | N/A   |
| 3-[(4-HYDROXYMETHYLBENZOYL)-1-PENTYL]INDOLE                            | Tai High         | C21H23NO2; 4-[[hydroxymethyl]phenyl]-[1-pencylindol-3-yl]methanone            | N/A            | N/A   | C21H23NO2; 4-[[hydroxymethyl]phenyl]-[1-pencylindol-3-yl]methanone | Y     | Y     | Y     |
| 3-[(5-BENZYL-1,3,4-OXADIAZOL-2-YL)-1-[(2-MORPHOLIN-4-YL)ETHYL]]-1H]INDOLE | N/A              | C23H24N4O2; 4-[[2-[[5-benzyl-1,3,4-oxadiazol-2-y1]]-1H-1-indol-1-yl]ethy]morpoline | N/A            | N/A   | C23H24N4O2; 4-[[2-[[5-benzyl-1,3,4-oxadiazol-2-yl]]-1H-indol-3-yl]ethyl]morpoline | Y     | .     | .     |
| 3-[(5-BENZYL-1,3,4-OXADIAZOL-2-YL)-1-[(2-PYRROLIDIN-1-YL)ETHYL]]-1H]INDOLE | N/A              | C23H24N4O; 2-benzyl-5-[[2-(pyrrolidin-1-yl)]ethyl]-1H-oxidol-3-yl-1,3,4-oxadiazole | N/A            | N/A   | C23H24N4O; 2-benzyl-5-[[2-(pyrrolidin-1-yl)]ethyl]-1H-oxidol-3-yl-1,3,4-oxadiazole | Y     | .     | .     |
| 3-[(P-METHOXYBENZOYL)-N-METHYLN]INDOLE                                 | 4-methoxyphenyl][1-methyl-1H-indol-3-yl]methanone; 3-(p-methoxybenzoyl)-N-methylindole; AC1MI471; LS-91297 | C17H15N2O; 4-methoxyphenyl]-[1-methylindol-3-yl]methanone                  | Y              | Y     | Y              | Y     | Y     | Y     |
| 3-CAF                                                                    | N/A              | C24H15FN2O2; Naphthalen-2-yl 1-[(2-fluorophenyl)-1H-indazole-3-carboxylate]    | N/A            | N/A   | 3-[(5-Benzyloctyl)-3-(1-naphthoyl)]-indole; | N/A   | N/A   | N/A   |
| 3-CARBOXAMIDEINDAZOLE                                                   | N/A              | 3-Carboxamideindazole                                                        | N/A            | N/A   | 3-Carboxamideindazole | N/A   | N/A   | N/A   |
| 3-CARBOXAMIDEINDOLE                                                     | N/A              | 3-Carboxamideindazole                                                        | N/A            | N/A   | 3-Carboxamideindazole | N/A   | N/A   | N/A   |
| 3-CL-PEA                                                                | N/A              | C8H10CIN; 2-[[3-Chlorophenyl]ethan-1-amine]                                  | N/A            | N/A   | C8H10CIN; 2-[[3-Chlorophenyl]ethan-1-amine] | N/A   | N/A   | N/A   |
| 3-FLUORO-ADB                                                            | methyl 2-[(1-3-fluoropentyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate (3F-ADB, 3F-MDMB-PINACA) | C20H28FN3O3; methyl 2-[(1-3-fluoropentyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate | Y              | .     | .              | .     | .     |
| 3-PHENYLACETYLINDOLE                                                    | N/A              | C16H13NO; 1-(1H-Indol-3-yl)-2-phenylethanol                                  | N/A            | N/A   | C16H13NO; 1-(1H-Indol-3-yl)-2-phenylethanol | Y     | .     | .     |
| 3,5-AB-CHMFUPPYCA                                                        | AB-CHFUPPYCA; AB-CHMFUPPYCA                                                 | C22H29FN4O2; N-[[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-(cyclohexyl)methyl]-3-(4-[[fluorophenyl]-1H-pyrazole-5-carboxamidin] | Y              | Y     | Y              | Y     | Y     | Y     |
| 3′-METHYL-4-[(3-METHYLOCTAN-2-YL)-6′-[(PROPAN-2-YL)-2′,3′,4′,5′-TETRAHYDRO[1,1′-BIPHENYL]-2,6-DIOL] | 1.1′-BIPHENYL] | C25H40O2; 3′-Methyl-4-[(3-methyloclan-2-yl)-6′-[(propan-2-yl)-2′,3′,4′,5′-tetrahydro[1,1′-biphenyl]-2,6-diol | N/A            | N/A   | C25H40O2; 3′-Methyl-4-[(3-methyloctan-2-yl)-6′-[(propan-2-yl)-2′,3′,4′,5′-tetrahydro[1,1′-biphenyl]-2,6-diol | Y     | .     | .     |
| 3′,5′-DICHLORO-4-[(2-METHYL-2-OCTANYL)-2,6-BIPHENYLDIOL]                | US 2004/0087590 #1 | C21H26Cl2O2; 3′,5′-Dichloro-4-[(2-methyloclan-2-yl)]-[1,1′-biphenyl]-2,6-diol | US 2004/0087590 #1 | N/A   | C21H26Cl2O2; 3′,5′-Dichloro-4-[(2-methyloclan-2-yl)]-[1,1′-biphenyl]-2,6-diol | Y     | .     | .     |
| 3′,5′-DIMETHYL-4-[(2-METHYLOCTAN-2-YL)[1,1′-BIPHENYL]-2,6-DIOL]         | N/A              | C23H32O; 3′,5′-Dimethyl-4-[(2-methyloclan-2-yl)]-[1,1′-biphenyl]-2,6-diol     | N/A            | N/A   | C23H32O; 3′,5′-Dimethyl-4-[(2-methyloclan-2-yl)]-[1,1′-biphenyl]-2,6-diol | Y     | .     | .     |
| 3′,5′-DIMETHYL-4-[(2-METHYLOCTAN-2-YL)[1,1′-BIPHENYL]-2,6-DIOL]         | N/A              | C24H23NO; N-[3-(Methylbutyl)-1H-indol-3-yl][(naphthalen-1-yl)methanone]       | Y              | Y     | Y              | Y     | Y     | Y     |
| 3′-ME-JWH-073                                                           | JWH-018 isoform; N-[3-Methylbutyl]-3-(1-naphthoyl)ido; JWH-018 N-[3-methylbutyl] iso | C24H23NO; N-[3-(Methylbutyl)-1H-indol-3-yl][(naphthalen-1-yl)methanone]       | Y              | Y     | Y              | Y     | Y     | Y     |
| **166** | 31-HEXYL-13,15-DIMETHYL-31,32,33,34,35,36-HEXAHYDRO[11,21,24,31-TERPHENYL]-22-OL | N/A | C26H36O; 31-Hexyl-13,15-dimethyl-31,32,33,34,35,36- hexahydro[11,21,24,31-terphenyl]-22-ol | . | . | Y |
| **167** | 3F-AMB | N/A | C19H26FN3O3; Methyl [(2S)-2-[[1-(3-fluoropentyl)-1H-indazole-3-carbonyl]amino]-3-methylbutanoate | Y | . | Y |
| **168** | 3F-MN-24 | 1-(3-fluoropentyl)-N-(naphthalen-1-yl)-1H-indole-3-carboxamide; 3F-NNEI; 3F-NNEI | C24H23FN2O; 1-(3-fluoropentyl)-N-(naphthalen-1-yl)-1H-indole-3-carboxamide | Y | . | . |
| **169** | 4-[1-HEXYLCYCLOPENTYL]-3’,5’-DIMETHYL[1,1’-BIPHENYL]-2-OL | N/A | C25H34O; 4-(1-Hexylcyclopentyl)-3’,5’-dimethyl[1,1’-biphenyl]-2-ol | . | . | Y |
| **170** | 4-[1-HEXYLCYCLOPROPYL]-3’,5’-DIMETHYL[1,1’-BIPHENYL]-2-OL | N/A | C23H30O; 4-(1-Hexylcyclopropyl)-3’,5’-dimethyl[1,1’-biphenyl]-2-ol | . | . | Y |
| **171** | 4-[1-[(1-METHYLPIPERIDIN-2-YL)METHYL]-1H-INDOLE-3-CARBONYL]NAPHTHALENE-1-CARBONITRILE | N/A | C27H25N3O; 4-[1-[[1-Methylpiperidin-2-yl]methyl]-1H-indole-3-carbonyl]napthalene-1-carbonitrile | . | . | Y |
| **172** | 4-Br-3-MA | 4-Bromo-3-methoxyamphetamine | C10H14BrNO; 1-[4-Bromo-3-methoxyphenyl]propan-2-amine | . | . | Y |
| **173** | 4-CHLORO-N-CYCLOHEXYL-3-(PYRROLIDINE-1-SULFONYL)BENZAMIDE | N/A | C17H23ClN2O3; 4-Chloro-N-cyclohexyl-3-(pyrrolidine-1-sulfonnyl)benzamide | . | . | Y |
| **174** | 4-HO-UR-144 | UR-144 N(4-HYDROXYPENTYL) | C21H29NO2; 1-(4-Hydroxypentyl)-1H-indol-3-yl[2,2,3,3-tetramethylcyclopropyl]methanone | . | . | Y |
| **175** | 4-HTMPIPO | N/A | C21H31NO2; 4-hydroxy-3,3,4-trimethyl-1-[1-pentyl-1H-indol-3-yl]-1-pentanone | Y | Y | Y |
| **176** | 4-METHYL-3-(PIPERIDINE-1-SULFONYL)-N-(QUINOLIN-8-YL)BENZAMIDE | N/A | C22H28N3O3S; 4-Methyl-3-[piperidine-1-sulfonfonyl]-N-(quinolin-8-yl)benzamide | . | . | Y |
| **177** | 4-METHYL-N-{[(2-(MORPHOLIN-4-YL)ETHYL)-1H-INDOL-3-YLMETHYL]ANILINE | N/A | C22H27N3O; 4-Methyl-N-{[2-(morpholin-4-yl)ethyl]-1H-indol-3-yl}methyl]aniline | . | . | Y |
| **178** | 4-OH-ADB-CHMINACA | N/A | C21H30N4O3; N-[2S]-1-Amino-3,3-dimethyl-1-oxobutan-2-yl-1-[4-hydroxycyclohexyl]methyl]1H-indazole-3-carboxamide | . | . | Y |
| **179** | 4-OH-DET-LEUCINE-ADB-CHMINACA | N/A | C21H29N3O4; (2S)-2-[[1-[[4-Hydroxycyclohexyl]methyl]-1H-indazole-3-carbonyl]amino]-3,3-dimethylbutanoic acid; N-[1-[(4-Hydroxycyclohexyl)methyl]-1H-indazole-3-carbonyl]-3-methyl-L-valine | . | . | Y |
| **180** | 4-OXO-1-PENTYL-7-(PHENYLSULFANYL)-N-[[15,25,4R]-1,3,3-TRIMETHYLBICYCLO[2.2.1]HEPTAN-2-YL]-1,4-DIHYDROQUINOLINE-3-CARBOXAMIDE | N/A | C31H38N8O2S; 4-Oxo-1-pentyl-7-(phenylsulfanyl)-N-[[15,25,4R]-1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl]-1,4-dihydroquinoline-3-carboxamide | . | . | Y |
| **181** | 4-OXO-1-PENTYL-N-[[15]-1,2,3,4-TETRAHYDROANTHACEN-1-YL]-1,4-DIHYDROQUINOLINE-3-CARBOXAMIDE | N/A | C25H28N2O2; 4-Oxo-1-pentyl-N-[[15]-1,2,3,4-tetrahydroanthacen-1-yl]-1,4-dihydroquinoline-3-carboxamide | . | . | Y |
| **182** | 4,4-DIFLUORO-1-[[3-(4-[2-FLUORO-5-METHOXYPHENYL]-1H-IMIDAZOL-2-YL)PHENYL]METHYL]PIPERIDINE | N/A | C22H22F3N3O4; 4,4-Difluoro-1-[[3-(4-[2-fluoro-5-methoxyphenyl]-1H-imidazol-2-yl)phenyl]methyl]piperidine | . | . | Y |
| **183** | 4'-ET-JWH-200 | N/A | C27H28N2O2; (4-Ethylanthracen-1-yl)[1-[(2-morpholin-4-yl)ethyl]-1H-indol-3-yl]methanone | . | . | Y |
| **184** | 4CN-ADB | N/A | C20H26N4O3; Methyl (2S)-2-[[1-(4-cyanobutyl)-1H-indazole-3-carbonyl]amino]-3,3-dimethylbutan-2-yl)-1-[(4-fluoropentyl)-1H-indazole-3-carboxamide | . | . | Y |
| **185** | 4F-AB-PINACA | N/A | C18H25FN4O2; N-[1-amino-3-methyl-1-oxobutan-2-yl]-1-(4-fluoropentyl)-1H-indazole-3-carboxamide | Y | . | Y |
| **186** | 4F-ADB | 4F-MDMB-BINACA | C19H26FN3O3; Methyl (25)-2-[[1-(4-fluorobutyl)-1H-indazole-3-carbonyl]amino]-3,3-dimethylbutan-2-yl | Y | Y | Y |
| **187** | 4F-AKB48 | N/A | C22H28FN3O; N-(adamantan-1-yl)-1-(4-fluorobutyl)-1H-indazole-3-carboxamide | . | . | Y |
| **188** | 4F-AMB | N/A | C19H26FN3O3; methyl [1-(4-fluoropentyl)-1H-indazole-3-carbonyl]-L-valinate | Y | . | . |
| Entry | Short Running Title of the Article | Journal Name, 2014, Vol. 0, No. 0 | 19 |
|-------|-----------------------------------|-----------------------------------|----|
| 189   | 4F-NNEI                          | 4F-MN-24                          | C24H23FN2O; 1-(4-Fluoropentyl)-N-(naphthalen-1-yl)-1H-indole-3-carboxamide | Y . Y |
| 190   | 4F-PB-22                         | N/A                               | C22H19FN2O2; Quinolin-8-yl 1-(4-fluorobutyl)-1H-indole-3-carboxylate | . . Y |
| 191   | 4FJ3-JWH-073                     | TFB-073                           | C23H18F3NO; [Naphthalen-1-yl][1-(4,4,4-trifluorobutyl)-1H-indol-3-yl]methanone | . . Y |
| 192   | 4HO-AM-2201                      | AM2201 N-(4-hydroxypentyl) metabolite | C24H22FNO; [1-(5-Fluoro-4-hydroxypentyl)-1H-indol-3-yl][naphthalen-1-yl]methanone | . . Y |
| 193   | 4Q3C                             | 4-Quinolone-3-Carboxamide         | C26H34N2O3; N-(Adamantan-1-yl)-8-methoxy-4-oxo-1-pentyl-1,4-dihydroquinoline-3-carboxamide | . . Y |
| 194   | 5-(ADAMANTAN-1-YL)-2-[(1R,2R,5R)-5-(HYDROXYMETHYL)-2-(PROP-1-EN-2-YL)CYCLOHEXYL]BENZENE-1,3-DIOL | N/A                               | C26H36O3; 5-(Adamantan-1-yl)-2-[(1R,2R,5R)-5-(hydroxymethyl)2-(prop-1-en-2-y1)cyclohexyl]benzene-1,3-diol | . . Y |
| 195   | 5-BR-Thj-018                     | 5-bromopentyl JWH 018 indazole analog | C23H21BN2O2; 1-[5-(Bromopentyl)-1H-indazol-3-yl][naphthalen-1-yl]methanone | . . Y |
| 196   | 5-FLUORO-7-METHOXY-2-METHYL-1-[(2-[MORPHOLIN-4-YL]ETHYL)-N-[[15,25,4R]-1,3,3-TRIMETHYLCYCLO[2.2.1]HEPTAN-2-YL]-1H-INDOLE-3-CARBOXAMIDE | N/A                               | C27H38F3NO3; 5-Fluoro-7-methoxy-2-methyl-1-[2-[morpholin-4-yl]ethyl]N-[[15,25,4R]-1,3,3-trimethylcyclo[2.2.1]heptan-2-yl]-1H-indole-3-carboxamide | . . Y |
| 197   | 5-FLUOROPENTYL-3-PYRIDINYLINDOLE | N/A                               | C19H19FN2O; [2-(5-Fluoropentyl)-1H-indol-3-yl]pyridin-2-ylmethanone | Y Y Y |
| 198   | 5,3-AB-CHFUPYCA                  | AB-CHFUPYCA; AB-CHMFUPPYCA        | C22H29FN4O2; (5)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-5-(4-fluorophenyl)-1H-pyrazole-3-carboxamide | . . Y |
| 199   | 5,5-DIMETHYL-8-(3-METHYLOCTAN-2-YL)-1,2,3,5-TETRAHYDRO-1,4-ETHANO[1]BENZOPYRANO[3,4-B]PYRIDIN-10-OL | N/A                               | C25H37NO2; 5,5-Dimethyl-8-(3-methyloctan-2-yl)-1,2,3,5-tetrahydro-1,4-ethano[1]benzopyrano[3,4-b]pyridin-10-ol | . . Y |
| 200   | 5BR-AKB48                        | 5-bromo AKB48, N-(adamantan-1-yl)-1-(5-bromopentyl)-1H-indole-3-carboxamide | C19H19FN2O; [1-(5-Fluoropentyl)-1H-indol-3-yl][pyridin-3-yl]methanone | Y . . |
| 201   | 5BR-JHW-018                      | N/A                               | C24H22BrNO; [1-(5-Bromopentyl)-1H-indol-3-yl][naphthalen-1-yl]methanone | Y Y Y |
| 202   | 5BR-JHW-122                      | N/A                               | C25H24BrNO; [1-(5-Bromopentyl)-1H-indol-3-yl][4-methylnaphthalen-1-yl]methanone | . . Y |
| 203   | 5BR-UR-144                       | 5-Bromopentyl UR-144; UR-144 N-(5-bromopentyl) | C21H28BrNO; [1-(5-Bromopentyl)-1H-indol-3-yl][2,2,3,3-tetramethylcyclopenty]methanone | Y . Y |
| 204   | 5C-74K84                         | 5CI-74K84; 5CI-APINACA            | C23H30ClN3O; N-(Adamantan-1-yl)-1-[5-chloropentyl]-1H-indazole-3-carboxamide | Y Y Y |
| 205   | 5CL-AB-PINACA                    | N/A                               | C18H25ClN4O2; N-[[25]-1-Amino-3-methyl-1-oxobutan-2-yl]-1-(5-chloropentyl)-1H-indazole-3-carboxamide | Y Y Y |
| 206   | 5CL-AM-694                       | N/A                               | C20H19ClNO; [1-(5-Chloropentyl)-1H-indol-3-yl][2-iodophenyl]methanone | Y Y Y |
| 207   | 5CL-CUMYL-PEGACLONE              | N/A                               | C25H27ClN2O; 5-[5-(Chloropentyl)-2-[2-phenylpropan-2-yl]-2,5-dihydro-1H-pyrido[4,3-b]indol-1-one | Y . . |
| 208   | 5CL-JHW-018                      | N/A                               | C24H22ClNO; [1-(5-Chloropentyl)-1H-indol-3-yl][naphthalen-1-yl]methanone | Y Y Y |
| 209   | 5CL-JHW-122                      | N/A                               | C25H24ClNO; [1-(5-Chloropentyl)-1H-indol-3-yl][4-methylnaphthalen-1-yl]methanone | Y Y Y |
| 210   | 5CL-MDMB-PINACA                  | 5CI-ADMB                          | C20H28ClN3O3; Methyl (25)-2-[1-(5-chloropentyl)-1H-indazole-3-carbonyl]amino)-3,3-dimethylbutanoate | Y Y |
| 211   | 5CL-NNEI                         | 5CI-NNEI                          | C24H23ClN2O; 1-(5-Chloropentyl)-N-(naphthalen-1-yl)-1H-indole-3-carboxamide | Y . Y |
| Code     | Name                        | Structure                                  | Formula                  | Y  | Y  | Y  |
|----------|-----------------------------|--------------------------------------------|--------------------------|----|----|----|
| 212      | SCL-THI-018                 | 5-chloropentyl JWH 018 indazole analogue   | C23H21CIN2O; [1-(5-Chloropentyl)-1H-indazol-3-yl][naphthalen-1-yl]methaneone | Y  | Y  | Y  |
| 213      | SCL-UR-144                 | UR-144 N-(5-chloropentyl) derivative       | C21H28CINO; [1-(5-Chloropentyl)-1H-indol-3-yl][2,2,3,3-tetramethylcyclopentyl]methaneone | Y  | Y  | Y  |
| 214      | SCN-UR-144                 | N/A                                        | C21H26N2O; [5-(2,2,3,3-Tetramethylcyclopropane-1-carbonyl)-1H-indol-1-yl]pentanenitrile | .  | .  | Y  |
| 215      | SF-3,5-AB-PFUPPYCA         | N/A                                        | C20H26F2N4O2; N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluorophenyl)-3-(4-fluorophenyl)-1H-pyrazole-5-carboxamide | Y  | Y  | Y  |
| 216      | SF-3,5-ADB-PFUPPYCA        | N/A                                        | C21H28F2N4O2; N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluorophenyl)-3-(4-fluorophenyl)-1H-pyrazole-5-carboxamide | .  | .  | Y  |
| 217      | SF-AB-2PINACA              | N/A                                        | C18H25F4N4O2; N-[(2S)-3,3-bis[1H-pyrazole-1-carboxamido]fluoropentyl]methyl]pentanenitrile       | Y  | Y  | Y  |
| 218      | SF-AB-FUPPYCA              | AZ-037                                     | C20H26F2N4O2; N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-(5-fluorophenyl)-5-(4-fluorophenyl)-1H-pyrazole-3-carboxamide | Y  | Y  | Y  |
| 219      | SF-AB-P7AICA               | N/A                                        | C18H25F4N4O2; N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-(5-fluorophenyl)-1H-pyrrol[2,3-b]pyridine-3-carboxamide | .  | Y  | .  |
| 220      | SF-AB-PICA                | SF-ABICA; SF-AMBICA                        | C19H26F3N4O2; N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-(5-fluorophenyl)-1H-indole-3-carboxamide | Y  | Y  | Y  |
| 221      | SF-AB-PINACA              | N/A                                        | C18H25F5N4O2; N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-(5-fluorophenyl)indazole-3-carboxamide | Y  | Y  | Y  |
| 222      | SF-AB-PINACA              | SF-ADBICA                                  | C20H28F3N3O2; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-(5-fluorophenyl)-1H-indole-3-carboxamide | Y  | Y  | Y  |
| 223      | SF-ADPINACA               | N/A                                        | C19H27F4N4O2; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-(5-fluorophenyl)-1H-indazole-3-carboxamide | Y  | Y  | Y  |
| 224      | SF-AEB                    | N/A                                        | C20H28F8N3O3; Ethyl (2S)-2-[[1-(5-fluorophenyl)-1H-indazole-3-carbonylamino]-3-methylbutanoate | Y  | .  | Y  |
| 225      | SF-AKB-4B-7N              | SF-7-APAICA; SF-A-P7AICA                   | C23H30F3N3O; N-[Adamantan-1-yl]-1-(5-fluorophenyl)-1H-pyrrol[2,3-b]pyridine-3-carboxamide | .  | Y  | Y  |
| 226      | SF-AKB-7                 | N/A                                        | C21H29F9N2O2; Adamantan-1-yl 1-(5-fluorophenyl)-1H-indazole-3-carboxylate | Y  | Y  | Y  |
| 227      | SF-AKB48                  | SF-AKB48; SF-AKB48; SF-APINACA: AKB-48F   | C23H30F3N3O; N-[Adamantan-1-yl]-1-(5-fluorophenyl)-1H-indazole-3-carboxylate | Y  | Y  | Y  |
| 228      | SF-AMPPPICA               | D-DOFC; (+)-5-F-Dioxolane-C; (+)-FDOC     | C26H34F4N3O; N-[Adamantan-1-yl]-1-(5-fluorophenyl)-4-methyl-5-phenyl-1H-pyrazole-3-carboxamide | .  | .  | Y  |
| 229      | SF-APP-PICA              | PX-1; SRF-30                              | C23H26F6N3O2; N-[(2S)-1-Amino-1-oxo-3-phenylpropan-2-yl]-1-(5-fluorophenyl)-1H-indole-3-carboxamide | Y  | Y  | Y  |
| 230      | SF-APP-PINACA             | PPA(N)-2201; FU-PX; PX-2                  | C22H25F5N4O2; N-[(2S)-1-Amino-1-oxo-3-phenylpropan-2-yl]-1-(5-fluorophenyl)-1H-indazole-3-carboxamide | Y  | Y  | Y  |
| 231      | SF-CHP-PINACA             | SGT-74                                    | C20H28F3N3O; N-Cycloheptyl-1-(5-fluorophenyl)-1H-indazole-3-carboxamide | .  | .  | Y  |
| 232      | SF-CPM-PINACA             | N/A                                        | C19H26F2N3O; N-[Cyclopentylmethyl]-1-(5-fluorophenyl)-1H-indole-3-carboxamide | .  | .  | Y  |
| 233      | SF-CUMYL-PEGACLONE        | N/A                                        | C25H27F7N2O; 5-(5-Fluorophenyl)-2-(2-phenylpropan-2-yl)-2,5-dihydro-1H-pyrid(4,3-b)indol-1-one | Y  | Y  | Y  |
| 234      | SF-CYP-PINACA             | N/A                                        | C17H22F3N3O; N-[Cyclopropylmethyl]-1-(5-fluorophenyl)-1H-indole-3-carboxamide | .  | .  | Y  |
| 235      | SF-CYPPICA                | N/A                                        | C18H23F2N2O; N-[Cyclopropylmethyl]-1-(5-fluorophenyl)-1H-indole-3-carboxamide | .  | .  | Y  |
| 236      | SF-EDMB-PINACA            | N/A                                        | C21H30F3N3O3; ethyl (S)-2-1-(5-fluorophenyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate | Y  | Y  | Y  |
| 237 | SF-EMB-PICA | N/A | C21H29FN2O3; Ethyl (2S)-2-[[1-(5-fluoropentyl)-1H-indole-3-carbonyl]amino]-3-methylbutanoate; Ethyl N-[1-(5-fluoropentyl)-1H-indole-3-carbonyl]-L-valinate | . | . | Y |
| 238 | SF-EMB-PINACA | N/A | C20H28FN3O3; methyl 2-[[1-(5-fluoropentyl)-1H-indole-3-carbonyl]amino]-3-methylbutanoate | Y | Y | Y |
| 239 | SF-IPBN-P7AICA | N/A | C32H32FN4O2; methyl 2-[[1-(5-fluoropentyl)-1H-indole-3-carbonyl]amino]-3-methylbutanoate | . | . | Y |
| 240 | SF-MDA-19-AD | N/A | C24H30FN3O2; N-[(5-fluoropentyl)-2-oxo-1,2-dihydro-3H-indol-3-ylidene]adamantane-1-carboxhydrazide | . | . | Y |
| 241 | SF-MDA-19-TMCP | N/A | C21H28FN3O; N-[(5-fluoropentyl)-2-oxo-1,2-dihydro-3H-indol-3-ylidene]-2,2,3,3-tetramethylcyclopropane-1-carboxyhydrazide | . | . | Y |
| 242 | SF-MDMB-2201 | N/A | C22H29FN4O2; methyl 2-[[1-(5-fluoropentyl)-1H-indole-3-carbonyl]amino]-3-methylbutanoate | . | . | Y |
| 243 | SF-MDMB-P4AICA | N/A | C20H28FN3O3; methyl 2-[[1-(5-fluoropentyl)-1H-indole-3-carbonyl]amino]-3-methylbutanoate | Y | Y | Y |
| 244 | SF-MDMB-P7AICA | N/A | C20H28FN3O3; methyl (S)-2-[[1-(5-fluoropentyl)-1H-indole-3-carbonyl]amino]-3-methylbutanoate | Y | Y | Y |
| 245 | SF-MDMB-PICA | N/A | C21H29FN2O3; N-[(5-fluoropentyl)-1H-indole-3-yl]carboxylic acid 3-methyl-L-valine, methyl ester | Y | Y | Y |
| 246 | SF-MDMB-PINACA | 5F-ADB; DIMENSION; JOINT - PRERROLLED TAB | C20H28FN3O3; methyl-2-[[1-(5-fluoropentyl)-1H-indole-3-yl]carboxylic acid 3-methylbutanoate | Y | Y | Y |
| 247 | SF-MMB-PICA | I-AMB; SF-AMB-PICA; MMW-2201 | C20H27FN2O3; Methyl (2S)-2-[[1-(5-fluoropentyl)-1H-indole-3-carbonyl]amino]-3-methylbutanoate | Y | Y | Y |
| 248 | SF-MMB-PINACA | 5F-AMB-PINACA; SF-AMB | C19H26FN3O3; Methyl (2S)-2-[[1-(5-fluoropentyl)-1H-indole-3-carbonyl]amino]-3-methylbutanoate | Y | Y | Y |
| 249 | SF-MN-18 | N/A | C32H32FN4O2; N-1-naphthalen-1-yl-[1-(5-fluoropentyl)-1H-indole-3-carbonyl]amino] | Y | Y | Y |
| 250 | SF-MPP-PICA | MPPH-2201 | C24H27FN2O3; Methyl (2S)-2-[[1-(5-fluoropentyl)-1H-indole-3-carbonyl]amino]-3-methylbutanoate; Methyl N-[1-(5-fluoropentyl)-1H-indole-3-carbonyl]-L-phenylalaninate | Y | Y | Y |
| 251 | SF-MPP-PINACA | N/A | C23H26FN3O3; Methyl (2S)-2-[[1-(5-fluoropentyl)-1H-indole-3-carbonyl]amino]-3-methylbutanoate | . | . | Y |
| 252 | SF-MSB-PINACA | N/A | C20H28FN3O3; Methyl (2S)-2-[[1-(5-fluoropentyl)-1H-indole-3-carbonyl]amino]-3-methylpentanoate | . | . | Y |
| 253 | SF-NNE1 | SF-MN-24; SF-NNE1 | C24H23FN2O2; 1-(5-Fluoropentyl)-N-(naphthalen-1-yl)-1H-indole-3-carbonyl]amino] | Y | . | Y |
| 254 | SF-NNE1-2 | SF-NNE1-2; AM-6527 (N-5-FLUOROPENTYL) | C24H23FN2O2; 1-(5-Fluoropentyl)-N-(naphthalen-2-yl)-1H-indole-3-carbonyl]amino] | Y | Y | Y |
| 255 | SF-NPB-22-7N | 7N-SF-PB-22 | C22H20FN3O2; Quinolin-8-yl-1-(5-fluoropentyl)-1H-pyrrrole[2,3-b]pyridine-3-carboxylate | . | . | Y |
| 256 | SF-PB-22 | 5-INPB-22 | C23H21FN2O2; 1-pentyfluoro-1H-indole-3-carboxylic acid 8-quinoaliny1ester | Y | Y | Y |
| 257 | SF-PB-22 AMIDE | N/A | C23H22FN3O3; 1-(5-Fluoropentyl)-N-[quinolin-8-yl]-1H-indole-3-carbonyl]amino] | . | . | Y |
| 258 | SF-PB-22 INDAZOLE ANALOGUE | QCBL(N)2201; 5F-NPB-22; SF-inpb-22 | C22H20FN3O2; Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carbonyl]amino] | Y | Y | Y |
| 259 | SF-PB-22-3Q | N/A | C23H21FN2O2; Quinolin-3-yl 1-(5-fluoropentyl)-1H-indole-3-carbonyl]amino] | . | . | Y |
| Entry | Name | Cmpd | Notes |
|-------|------|------|-------|
| 260   | SF-PB-22-4IQ | N/A | C23H21FN2O2; Isoquinolin-4-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate |
| 261   | SF-PB-22-4Q | N/A | C23H21FN2O2; Quinolin-4-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate |
| 262   | SF-PB-22-5IQ | N/A | C23H21FN2O2; Isoquinolin-5-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate |
| 263   | SF-PB-22-5Q | N/A | C23H21FN2O2; Quinolin-5-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate |
| 264   | SF-PB-22-6IQ | N/A | C23H21FN2O2; Isoquinolin-6-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate |
| 265   | SF-PB-22-6Q | N/A | C23H21FN2O2; Quinolin-6-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate |
| 266   | SF-PB-22-7IQ | N/A | C23H21FN2O2; Isoquinolin-7-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate |
| 267   | SF-PB-22-7Q | N/A | C23H21FN2O2; Quinolin-7-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate |
| 268   | SF-PB-22-8IQ | N/A | C23H21FN2O2; Isoquinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate |
| 269   | SF-P6N | N/A | C23H22FN3O; 1-(5-Fluoropentyl)-N-(naphthalen-1-yl)-1H-pyrrolo[2,3-c]pyridine-3-carboxamide |
| 270   | SF-PCN | 5-F-MN-21; | C23H22FN3O; 1-(5-Fluoropentyl)-N-(naphthalen-1-yl)-1H-pyrrolo[2,3-c]pyridine-3-carboxamide |
| 271   | SF-PNI-D | N/A | C20H18Ci2FNO; [2,3-Dichlorophenyl][1-(5-Fluoropentyl)-1H-indol-3-yl]methanone |
| 272   | SF-PY-PICA | 5-fluoro PY-PICA | C18H23FN2O; [1-(5-Fluoropentyl)-1H-indol-3-yl][pyrrolidin-1-yl]methanone |
| 273   | SF-PY-PINACA | N/A | C17H22FN3O; [1-(5-Fluoropentyl)-1H-indol-3-yl][pyrrolidin-1-yl]methanone |
| 274   | SF-SDB-005 | CBL(N)2201; | C23H21FN2O2; naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate |
| 275   | SF-SDB-006 | N/A | C23H23FN2O; N-benzyl-[1-(5-fluoropentyl)-1H-indole-3-carboxamide |
| 276   | SF-THFM-PINACA | N/A | C18H24FN3O2; 1-(5-Fluoropentyl)-N-[oxolan-2-yl]methyl-1H-indole-3-carboxamide |
| 277   | SF-THJ | N/A | C22H21FN4O; 1-(5-Fluoropentyl)-N-(quinolin-8-yl)-1H-indole-3-carboxamide |
| 278   | Si-JWH-122 | N/A | C25H24NO; [1-(5-Iodopentyl)-1H-indol-3-yl][4-methylnaphthalen-1-yl]methanone |
| 279   | SOH-UR-144 | (5-Hydroxypentyl) UR-144; UR-144 N-(5-Hydroxypentyl) | C21H29NO2; [1-(5-Hydroxypentyl)-1H-indol-3-yl][2,2,3,3-tetramethylcyclopropyl]methanone |
| 280   | 6-(1-[3-HYDROXY-4-[[2S]-4,6,6-TRIMETHYLBICYCLO[3.1.1]HEPT-3-EN-2-YL]PHENYL]CYCLOPENTYL]HEXANENITRILE | N/A | C27H37NO; 6-[[1-(3-Hydroxy-4-[[2S]-4,6,6-trimethylbicyclo[3.1.1]hept-3-2-yl]phenyl]cyclopentyl]hexanenitrile |
| 281   | 6-[[Oxan-4-yl]METHYL]CARBAMOYL]-5-[[4-[[1H-1,2,3-TRIAZOL-1-YL]METHYL]NAPHTHALENE-1-CARBONYL]AMINO]PYRIDIN-2-YL 3,3,3-TRIFLUOROPROPANE-1-SULFONATE | N/A | C29H29F7N6O5S; 6-[[[[Oxan-4-yl]methyl]carbamoyl]-5-[[4-[[1H-1,2,3-triazol-1-yl]methyl]naphthalene-1-carbonyl]amino]pyridin-2-yl 3,3,3-trifluoropropane-1-sulfonate |
| 282   | 6-BROMO-4-Oxo-1-PENTYL-N-[[1S,2S,4R]-1,3,3-TRIMETHYLBICYCLO[2.2.1]HEPTAN-2-YL]-1,4-DIHYDROQUINOLINE-3-CARBOXAMIDE | N/A | C25H33BrN2O2; 6-Bromo-4-oxo-1-pentyl-N-[[1S,2S,4R]-1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl]-1,4-dihydroquinoline-3-carboxamide |
| Molecule                                                                 | CAS Registry Number | SMILES  | PubChem CID | PubChem Substance Description |
|--------------------------------------------------------------------------|---------------------|---------|-------------|------------------------------|
| 6-IODOPRAVADOLINE                                                       | AM-630              | C23H2SIN2O3; 6-Iodo-2-methyl-1-[2-[(morpholin-4-yl)ethyl]-1H-indol-3-yl][4-methoxyphenyl]methaneone | Y |
| 6-ME-JWH-200                                                            | N/A                 | C26H26N2O2; 6-Methyl-1-[2-[(morpholin-4-yl)ethyl]-1H-indol-3-yl][naphthalen-1-yl]methaneone | Y |
| 6-MEO-JWH-018                                                           | N/A                 | C25H25N2O2; 6-Methoxy-1-pentyl-1H-indol-3-yl][naphthalen-1-yl]methaneone | Y |
| 6-METHOXY-5-[2-(MORPHOLIN-4-YL)ETHYL]-2-[[15,25,4R)-1,3,3-TRIMETHYLBICYCLO[2.2.1]HEPTAN-2-YL]2,5-DIHYDRO-1H-PYRIDO[4,3-B]INDOL-1-ONE | N/A                 | C28H37N3O3; 6-Methoxy-5-[2-(morpholin-4-yl)ethyl]-2-[[15,25,4R)-1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl]2,5-dihydro-1H-pyridol[4,3-b]indol-1-one | Y |
| 6,6,9-TRIMETHYL-3-PENTYL-7,8,9,10-TETRAHYDRO-6H-DIBENZO[ B,D]PYRAN (HYDROXYMETHYL) METHOXY | N/A                 | C21H31NO; 6,6,9-Trimethyl-3-pentyl-7,8,9,10-tetrahydro-6H-dibenzo[b,d]pyran-1-amine | Y |
| 6F-AB-HINACA                                                             | N/A                 | C19H27FN4O2; N-[[2S]-1-Amino-3-methyl-1-oxobutan-2-yl]-1-(6-fluoroxyethyl)-1H-indazole-3-carboxamide | Y |
| 6F-JWH-019                                                              | N/A                 | C25H24FN4O; [1-[6-Fluorohexyl]-1H-indol-3-yl][naphthalen-1-yl]methaneone | Y |
| 7-FLUORO-4-OXO-1-PENTYL-N-[15,25,4R)-1,3,3-TRIMETHYLBICYCLO[2.2.1]HEPTAN-2-YL]-1,4-DIHYDROQUINOLINE-3-CARBOXAMIDE | N/A                 | C25H33FN2O2; 7-Fluoro-4-oxo-1-pentyl-N-[15,25,4R)-1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl]-1,4-dihydroquinoline-3-carboxamide | Y |
| 7-METHOXY-1-[2-(MORPHOLIN-4-YL)ETHYL]-N-[2,2,6,6-TETRAMETHYLCYCLOHEXYL]-1H-INDOLE-3-CARBOXAMIDE | N/A                 | C26H39N3O3; 7-Methoxy-1-[2-(morpholin-4-yl)ethyl]-N-[2,2,6,6-tetramethylcyclohexyl]-1H-indole-3-carboxamide | Y |
| 7-METHOXY-1-[2-(MORPHOLIN-4-YL)ETHYL]-N-[2(R)-1-PHENYLPROPAN-2-YL]-1H-INDOLE-3-CARBOXAMIDE | N/A                 | C25H31N3O; 7-Methoxy-1-[2-(morpholin-4-yl)ethyl]-N-[2(R)-1-phenylpropyl-2-yl]-1H-indole-3-carboxamide | Y |
| 7-METHOXY-2-METHYL-1-[2-(MORPHOLIN-4-YL)ETHYL]-N-[2,2,6,6-TETRAMETHYLCYCLOHEXYL]-1H-INDOLE-3-CARBOXAMIDE | N/A                 | C27H41N3O3; 7-Methoxy-2-methyl-1-[2-(morpholin-4-yl)ethyl]-N-[2,2,6,6-tetramethylcyclohexyl]-1H-indole-3-carboxamide | Y |
| 7'-MEO-NABUTIE                                                          | 7'-methoxy NABUTIE  | C25H25NO2; 1-[1-Butyl-7-methoxy-1H-indol-3-yl]-2-(naphthalen-1-yl)ethan-1-one | Y |
| 7N-AB-FUBINACA                                                          | N/A                 | C20H21FN4O2; N-[[2S]-1-Amino-3-methyl-1-oxobutan-2-yl]-1-[4-fluorophenyl][methyl]-1H-pyrorol[2,3-b]pyridine-3-carboxamide | Y |
| 7N-THU-2201                                                             | N/A                 | C25H32FN2O; [1-[5-Fluoropentyl]-1H-pyrrol[2,3-b]pyridine-3-yl][naphthalen-1-yl]methaneone | Y |
| 9-(HYDROXYMETHYL)-6,6-DIMETHYL-3-[2-METHYLOCTAN-2-YL]-6H-DIBENZO[B,D]PYRAN-1-OL | N/A                 | C25H34O3; 9-(Hydroxymethyl)-6,6-dimethyl-3-[2-methyloctan-2-yl]-6H-dibenzo[b,d]pyran-1-ol | Y |
| 9-METHYL-3-[3-METHYLOCTAN-2-YL]-7,8,9,10-TETRAHYDRO-6H-DIBENZO[B,D]PYRAN-1-OL | N/A                 | C23H34O2; 9-Methyl-3-[3-methyloctan-2-yl]-7,8,9,10-tetrahydro-6H-dibenzo[b,d]pyran-1-ol | Y |
| 9B-OH-9-NHHC                                                           | 9-Nor-9β-hydroxyhexahydrocannabinol | C20H30O3; 6αα,Rβ,9αRα,10αRα,6-Dimethyl-3-pentyl-6α,7,8,9,10α-hexahydro-6H-dibenzo[b,d]pyran-1,9-diol | Y |
| A-40174                                                                 | N/A                 | C26H37N2O; 5,5-Dimethyl-8-[3-methyloctan-2-yl]-2-[prop-2-yn-1-yl]-1,3,4,5-tetrahydro-2H-[1]benzopyrono[4,3-c]pyridin-10-ol | Y |
| A-41988                                                                 | BW29Y               | C26H33FN2O; 8-[5-[4-Fluorophenyl]pentan-2-yl]-5,5-dimethyl-2-[prop-2-yn-1-yl]-1,3,4,5-tetrahydro-2H-[1]benzopyrono[4,3-c]pyridin-10-ol | Y |
| A-796,260                                                               | N/A                 | C22H30N2O2; [1-[2-(morpholin-4-yl)ethyl]-1H-indol-3-yl]-[2,2,3,3-tetramethylcyclopropyl]methaneone | Y |
| A-796,260 OPEN CHAIN ISOMER                                            | A-796,260 isomer    | C22H30N2O2; [E]-3,4,4-trimethyl-1-[1-(2-morpholinomethyl)-1H-indol-3-yl]pent-2-en-1-one | Y |
| A-834,735                                                               | N/A                 | C22H29NO2; [1-(Oxan-4-yl)methyl]-1H-indol-3-yl][2,2,3,3-tetramethylcyclopropyl]methaneone | Y |
| A-836,339                                                               | N/A                 | C16H26N2O2S; N-[3-(2-Methoxyethyl)-4,5-dimethyl-1,3-thiazol-2(3H)-ylidene]-2,2,3,3-tetramethylcyclopropane-1-carboxamide | Y |
| AB-002                                                                  | N/A                 | C25H33N3O; 2-(Adamantan-1-yl)-1-[1-pentyl-1H-indol-3-yl]ethan-1-one | Y |
| A-836,339                                                               | N/A                 | C16H26N2O2S; N-[3-(2-Methoxyethyl)-4,5-dimethyl-1,3-thiazol-2(3H)-ylidene]-2,2,3,3-tetramethylcyclopropane-1-carboxamide | Y |
| A-836,339                                                               | N/A                 | C16H26N2O2S; N-[3-(2-Methoxyethyl)-4,5-dimethyl-1,3-thiazol-2(3H)-ylidene]-2,2,3,3-tetramethylcyclopropane-1-carboxamide | Y |
| Compound | Reference | Formula | Functional Groups | Yields |
|----------|-----------|---------|-------------------|--------|
| AB-005   | N/A       | C23H32N2O; [1-[(1-Methylpiperidin-2-yl)methyl]-1H-indol-3-yl]([2,2,2,3,3-tetramethylcyclopropyl)methanone | Y Y Y |
| AB-034   | N/A       | C23H32N2O; [1-[(1-Methylpiperidin-2-yl)methyl]-1H-indole-3-yl]-[2,2,3,3-tetramethylcyclopropyl)methanone | . . Y |
| AB-2CHMINACA | ZINC299817316 | C20H28N4O2; N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-2-(cyclohexylmethyl)-2H-indazole-3-carboxamide | Y . Y |
| AB-2FUBINACA | (2H-indazole) AB-FUBINACA; AB-2FUBINACA | C20H21FN4O2; N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-2-[[4-fluorophenyl]methyl]-2H-indazole-3-carboxamide | . . Y |
| AB-2PINACA | N/A | C18H26N4O2; N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-2-pentyl-2H-indazole-3-carboxamide | . . Y |
| AB-BICA  | N/A       | C21H23N3O2; N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-benzyl-1H-indole-3-carboxamide | . . Y |
| AB-CHMICA | N/A | C21H29N3O2; N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-(cyclohexylmethyl)-1H-indole-3-carboxamide | Y . Y |
| AB-CHMINACA | N/A | C20H28N4O2; N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-(cyclohexylmethyl)-1H-indole-3-carboxamide | Y Y Y |
| AB-FUBICA | N/A | C21H22FN3O2; N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-[4-fluorophenyl]methyl]-1H-indole-3-carboxamide | . . Y |
| AB-FUBINACA | Ab-fubi; Ab-fubi; AB-FUBINACA | C20H21FN4O2; N-[(1S)-1-Aminocarbonyl]-2-methylpropyl]-1-[4-fluorophenyl]methyl]-1H-indole-3-carboxamide | Y Y Y |
| AB-FUBINACA 2-FLUOROBENZYL ISOMER | N/A | C20H21FN4O2; N-[(1S)-1-Aminocarbonyl]-2-methylpropyl]-1-[2-fluorophenyl]methyl]-1H-indole-3-carboxamide | Y Y Y |
| AB-FUBINACA 3-FLUOROBENZYL ISOMER | N/A | C20H20FN3O2; [5S]-N-[(1-amino-3-methyl-1-oxobutan-2-yl]-1-(3-fluorobenzyl)-1H-indazole-3-carboxamide | Y . . |
| AB-HINACA-COOH | N/A | C20H22FN3O2; [2S]-2-[[1-[(4-Fluorophenyl)methyl]-1H-indazole-3-carboxyl]-l-aminocarbonyl]-3-methylbutanoic acid | . . Y |
| AB-HINACA HEXENYL | N/A | C19H20N4O2; N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-(hex-5-en-1-yl)-1H-indazole-3-carboxamide | . . Y |
| AB-PICA | N/A | C19H20FN3O2; [1-(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-pentyl-1H-indole-3-carboxamide | Y . Y |
| AB-PINACA | N/A | C18H25N4O2; N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indole-3-carboxamide | Y Y Y |
| AB-PINACA PENTENYL | N/A | C18H24N4O2; N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-(pent-4-en-1-yl)-1H-indazole-3-carboxamide | . . Y |
| AB-PINACA-COOH | N-(1-Pentyl-1H-indazole-3-carbonyl)-L-va | C18H25N3O3; [2S]-3-Methyl-2-[[1-pentyl-1H-indazole-3-carbonyl]-laminocarbonyl]-butanoic acid | . . Y |
| ACPA | Arachidonylcyclopropylamide | C23H37NO; (5Z,8Z,11Z,14Z)-N-Cyclopropylcyclopropano-5,8,11,14-tetraenamide | . . Y |
| AD-CHM | N/A | C26H33N0; [Adamantan-1-yl]-[1-(cyclohexylmethyl)-1H-indol-3-yl]methanone | . . Y |
| AD-ME | N/A | C25H32N2O2; [Adamantan-1-yl]-[1-[(2-morpholin-4-yl)methyl]-1H-indol-3-yl]methanone | . . Y |
| AD-THPM | N/A | C25H31N02; [Adamantan-1-yl]-[1-[(oxan-4-yl)methyl]-1H-indol-3-yl]methanone | . . Y |
| ADB-BICA | N/A | C22H25N3O2; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-benzyl-1H-indole-3-carboxamide | . . Y |
| ADB-BINACA | N/A | C21H24N4O2; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-benzyl-1H-indazole-3-carboxamide | . . Y |
| ADB-CHMICA | N/A | C22H31N3O2; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-(cyclohexylmethyl)-1H-indole-3-carboxamide | Y Y Y |
|    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |...
| AM   | N/A  | C26H36O3; (4-FLUOROPENTYL) azepane isomer; GSXZMBIYSUZVEW-UH |
|------|------|-------------------------------------------------------------|
| 357 | AM-1253 | N/A  | C26H36O3; (4-FLUOROPENTYL) azepane isomer; GSXZMBIYSUZVEW-UH | . | . | Y |
| 358 | AM-1256 | N/A  | C27H30N2O; [1-[(Methyl)piperidin-2-yl]methyl]-1H-indol-3-ylpyren-1-yl]methanone | . | . | Y |
| 359 | AM-1288 | N/A  | C23H20N0; [1-[(4-Iodobutyl)-1H-indol-3-yl](naphthalen-1-yl)methanone | . | . | Y |
| 360 | AM-1292 | N/A  | C22H18N0; [1-[(4-Iodobutyl)-1H-indol-3-yl](naphthalen-1-yl)methanone | . | . | Y |
| 361 | AM-1295 | N/A  | C23H20N0; [1-[(4-Fluorobutyl)-1H-indol-3-yl](naphthalen-1-yl)methanone | . | . | Y |
| 362 | AM-1299 | N/A  | C26H25N3O3; [1-[(1-Methyl)piperidin-2-yl]methyl]-1H-indol-3-yl][4-nitronaphthalen-1-yl]methanone | . | . | Y |
| 363 | AM-1714 | N/A  | C22H26O4; 1,9-Dihydroxy-3-(2-methyloctan-2-yl)-6H-dibenzo[b,d]pyran-6-one | . | . | Y |
| 364 | AM-2201 | N/A  | C24H22FNO; [1-[(5-Fluoropentyl)-1H-indol-3-yl]-[naphthalen-1yl)methanone | Y | Y | Y |
| 365 | AM-2201 N-(4-FLUOROPENTYL) | N/A  | C24H22FNO; [1-[(4-Fluorobutyl)-1H-indol-3-yl](naphthalen-1yl)methanone | Y | . | . |
| 366 | AM-2202 | N/A  | JWH-018 N-(5-hydroxypentyl) ; JWH-018 (S-HO) | C24H23N02; [1-[(5-Hydroxypentyl)-1H-indol-3-yl][naphthalen-1yl)methanone | Y | . | Y |
| 367 | AM-2203 | N/A  | C24H22N0; [1-[(5-Iodopentyl)-1H-indol-3-yl](naphthalen-1yl)methanone | . | . | Y |
| 368 | AM-2210 | N/A  | C23H19N2O3; [1-[(4-Iodobutyl)-1H-indol-3-yl][4-nitronaphthalen-1yl)methanone | . | . | Y |
| 369 | AM-2225 | N/A  | C21H21FNO; [1-[(5-Fluoropentyl)-2-methyl-1H-indol-3-yl][2iodophenyl)methanone | . | . | Y |
| 370 | AM-2231 | N/A  | C24H19N3O3; 5-[3-(Naphthalene-1-carbonyl)-6-nitro-1H-indol-1yl]pentanenitrile | . | . | Y |
| 371 | AM-2232 | N/A  | C24H20N0Z; 5-[3-(Naphthalene-1-carbonyl)-1H-indol-1yl]pentanenitrile | Y | Y | Y |
| 372 | AM-2233 | N/A  | C22H23N02; (2-iodophenyl)[1-[(1-methyl-2-piperidinyl)methyl]-1H-indol-3-yl]methanone | Y | Y | Y |
| 373 | AM-2233 AZEPANE ISOMER | AM2233 azepane isomer; GSXZMBIYSUZVEW-UH | C22H23N02 [2-iodophenyl][1-[(1-methylazepan-3-yl)-1H-indol-3-yl]methanone | . | . | Y |
| 374 | AM-2389 | N/A  | C25H38O3; (6aR,9R,10aR)-3-(1-Hexylcyclobutyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydro-6H-dibenzo[b,d]pyran-1,9-diol | . | . | Y |
| 375 | AM-251 | N/A  | C22H21Cl2IN40; 1-[2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-[1-piperidinyl]pyrazole-3-carboxamide | . | . | Y |
| 376 | AM-281 | N/A  | C21H19Cl2IN40; 1-[2,4-Dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-[morpholin-4-yl]-1H-pyrazole-3-carboxamide | . | . | Y |
| 377 | AM-4030 | N/A  | C27H42O4; (65,6aR,9R,10aR)-9-(Hydroxymethyl)-6-[(1E)-3-hydroxyprop-1-en-1-yl]-6-methyl-3-(2-methyloctan-2-yl]-6a,7,8,9,10,10a-hexahydro-6H-dibenzo[b,d]pyran-1-ol | . | . | Y |
| 378 | AM-404 | N/A  | N-Arachidonoylanminophenol | C26H37N02; 5Z,8Z,11Z,14Z- N-(4-Hydroxyphenyl)nicosan-5,8,11,14-tetraenamide | . | . | Y |
| 379 | AM-4054 | N/A  | C26H36O3; (6aR,9R,10aR)-3-(Adamantan-1-yl)-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydro-6H-dibenzo[b,d]pyran-1-ol | . | . | Y |
| 380 | AM-4056 | N/A  | C25H40O3; (6aR,9R,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl]-6a,7,8,9,10,10a-hexahydro-6H-dibenzo[b,d]pyran-1-ol | . | . | Y |
|   |   |   |   |
|---|---|---|---|
| 381 | AM-407 | N/A | C26H38O2; (6aR,10aR)-6,6,9-Trimethyl-3-[(1S,4R)-1-methyl-4-propylcyclohexyl]-6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-1-ol |   |
| 382 | AM-411 | N/A | C26H34O2; (6aR,10aR)-3-[(Adamantan-1-yl)-6,6,9-trimethyl-6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-1-ol |   |
| 383 | AM-6527 | NNE1; NNEI; MN-24; JWH-018 carboxamide derivative | C24H24N2O; N-1-naphthalenyl-1-pentyl-1H-indole-3-carboxamide | Y Y Y |
| 384 | AM-6545 | N/A | C26H23C12N5O3S; 5-[4-(4-Cyanobut-1-yn-1-yl)[phenyl]-1-(2,4-dichlorophenyl)]-N-1,1-dioxo-1A6-thiomorpholin-4-yl]-4-methyl-1H-pyrazole-3-carboxamide |   |
| 385 | AM-664 | N/A | C23H24IN3O3; [2-Iodophenyl][2-methyl-1-[1-methylpiperidin-2-yl]methyl]-6-nitro-1H-indol-3-yl]methanone |   |
| 386 | AM-669 | N/A | C21H21N2O; [2-Iodophenyl][2-methyl-1-pentyl-1H-indol-3-yl]methanone |   |
| 387 | AM-679 | AM XIAO; AM-694-F | C20H19INO; [2-Iodophenyl][1-pentyl-1H-indol-3-yl]methanone |   |
| 388 | AM-682 | N/A | C22H24INO; [1-Hexyl-2-methyl-1H-indol-3-yl][2-iodophenyl]methanone |   |
| 389 | AM-683 | N/A | C20H20INO; [1-Butyl-2-methyl-1H-indol-3-yl][2-iodophenyl]methanone |   |
| 390 | AM-694 | N/A | C20H19FINO; 1-[5-Fluoropentyl]-1H-indol-3-yl][2-iodophenyl]methanone | Y Y Y |
| 391 | AM-694 INDAZOLE ANALOGUE | N/A | C19H18FINO; [1-[5-Fluoropentyl]-1H-indazol-3-yl][2-iodophenyl]methanone |   |
| 392 | AM-729 | N/A | C27H36O2; (6aR,10aR)-3-[(Adamantan-1-yl)methyl]-6,6,9-trimethyl-6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-1-ol |   |
| 393 | AM-732 | N/A | C26H36O2; (6aR,10aR)-6,6,9-Trimethyl-3-[(1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl]-6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-1-ol |   |
| 394 | AM-852 | N/A | C26H37N2O; [5Z,8Z,11Z,14Z]-N-(2-Hydroxyphenyl)icos-5,8,11,14-tetraenamide |   |
| 395 | AM-855 | N/A | C26H38O2; (4aR,12bR)-8-Hexyl-2,5,5-trimethyl-1,4a,5,8,9,10,11,12b-octahydro-4H-benzo[d]naphtho[2,3-b]pyran-1-ol |   |
| 396 | AM-881 | ACEA | C22H36CINO; [5Z,8Z,11Z,14Z]-N-[2-Chloroethyl]icos-5,8,11,14-tetraenamide |   |
| 397 | AM-883 | N/A | C23H37N2O; [5Z,8Z,11Z,14Z]-N-[Prop-2-en-1-yl]icos-5,8,11,14-tetraenamide |   |
| 398 | AM-905 | N/A | C23H34O3; (6aR,9R,10aR)-3-[(1E)-Hept-1-en-1-yl]-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydro-6H-dibenzo[b,d]pyran-1-ol |   |
| 399 | AM-906 | N/A | C23H34O3; (6aR,9R,10aR)-3-[(1Z)-Hept-1-en-1-yl]-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydro-6H-dibenzo[b,d]pyran-1-ol |   |
| 400 | AM-919 | N/A | C27H44O4; (6S,6aR,9R,10aR)-9-(Hydroxymethyl)-6-(3-hydroxypropyl)-6-methyl-3-[2-methyloctan-2-yl]-6a,7,8,9,10,10a-hexahydro-6H-dibenzo[b,d]pyran-1-ol |   |
| 401 | AM-938 | N/A | C27H44O4; (6R,6aR,9R,10aR)-9-(Hydroxymethyl)-6-(3-hydroxypropyl-1yn-1-yl)-6-methyl-3-[2-methyloctan-2-yl]-6a,7,8,9,10,10a-hexahydro-6H-dibenzo[b,d]pyran-1-ol |   |
| 402 | AM-9405 | GAT379 | C24H32N2O2·BrH; [2-(2,6-dihydroxy-4-[2-methyloctan-2-yl]phenyl)-1,3-dimethyl-1H-benzo[d]imidazol-3-ium bromide |   |
| 403 | AMB | N/A | C19H27N3O3; methyl [1-pentyl-1H-indazole-3-carbonyl]-L-valinate |   |
| 404 | AMB-CHMINACA | MA-CHMINACA; MMB-CHMINACA | C21H29N3O3; (2S)-methyl-2-[1-(cyclohexylmethyl)-1H-indol-3-ylcarbonylamino]-3,3-dimethylbutanoate | Y Y Y |
| 405 | AMB-FUBICA | N/A | C2H25FNN2O3; N-[(1-[4-fluorophenyl)methyl]-1H-indol-3-yl]carbonyl]-L-valine, methyl ester | Y | Y | Y |
| 406 | AMB-FUBINACA | FUB-AMB; MMA-FUBINACA | C2H122F3N3O3; Methyl 2-[(1-[4-fluorophenyl)methyl]-1H-indazole-3-carbonylamino]-3-methylbutanone | Y | Y | Y |
| 407 | AMG-1 | N/A | C2H30O2; (6aR,10aR)-3-(Hept-1-yn-1-yl)-6,6,9-trimethyl-6a,7,10a-tetrahydro-6H-dibenzo[b,d]pyran-1-ol | . | . | Y |
| 408 | AMG-14 | N/A | C2H53H6O4; (6aR,10aR)-3-[2-Hexyl-1,3-dioxolan-2-yl]-6,6,9-trimethyl-6a,7,10a-tetrahydro-6H-dibenzo[b,d]pyran-1-ol | . | . | Y |
| 409 | AMG-3 | N/A | C2H53H6O2S2; (6aR,10aR)-3-[2-Hexyl-1,3-dithiolan-2-yl]-6,6,9-trimethyl-6a,7,10a-tetrahydro-6H-dibenzo[b,d]pyran-1-ol | . | . | Y |
| 410 | AMG-36 | N/A | C2H74O02; (6aR,10aR)-3-(1-Hexylcyclopentyl)-6,6,9-trimethyl-6a,7,10a-tetrahydro-6H-dibenzo[b,d]pyran-1-ol | . | . | Y |
| 411 | AMG-38 | N/A | C2H63H02; (6aR,10aR)-3-(1-Hexylcyclobutyl)-6,6,9-trimethyl-6a,7,10a-tetrahydro-6H-dibenzo[b,d]pyran-1-ol | . | . | Y |
| 412 | AMG-41 | N/A | C2H53H6O2; (6aR,10aR)-3-(1-Hexylcyclopentyl)-6,6,9-trimethyl-6a,7,10a-tetrahydro-6H-dibenzo[b,d]pyran-1-ol | . | . | Y |
| 413 | AMG-9 | N/A | C2H63H02S2; (6aR,10aR)-3-{2-Hexyl-1,3-dithian-2-yl}-6,6,9-trimethyl-6a,7,10a-tetrahydro-6H-dibenzo[b,d]pyran-1-ol | . | . | Y |
| 414 | AMPPPCA | N/A | C2H63H5N3O; N-(1-Adamantan-1-yl)-4-methyl-1-pentyl-5-phenyl-1H-pyrazole-3-carboxamide | . | . | Y |
| 415 | APICA | SDB-001; 2NE1; JWH-018 ADAMANTYL CARBOXA | C2H43H2N20; N-(1-Adamantan-1-yl)-1-pentyl-1H-indole-3-carboxamide | Y | Y | Y |
| 416 | APINACA | N/A | C2H33H1N3O; N-(1-Adamantan-1-yl)-1-pentyl-1H-indazole-3-carboxamide | Y | Y | Y |
| 417 | APP-BINACA | APP-BUTINACA | C2H122H4N4O2; N-[(1-amino-1-oxo-3-phenylpropan-2-yl)-1-butyl-1H-indazole-3-carboxamide | Y | Y | . |
| 418 | APP-CHMICA | N/A | C2H3H22N9N3O2; N-[1-amino-1-oxo-3-phenylpropyl-2-yl]-1-(cyclohexylmethyl)-1H-indole-3-carboxamide | Y | . | Y |
| 419 | APP-CHMINACA | W0 2009/106980 #14; PX-3 | C2H42H8N4O2; N-[(2S)-1-Amino-1-oxo-3-phenylpropan-2-yl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide | Y | Y | Y |
| 420 | APP-FUBICA | N/A | C2H52H22F3N3O2; N-[(2S)-1-Amino-1-oxo-3-phenylpropan-2-yl]-1-[(4-fluorophenyl)methyl]-1H-indole-3-carboxamide | . | . | Y |
| 421 | APP-FUBINACA | N/A | C2H42H21F4N4O2; N-[(2S)-1-Amino-1-oxo-3-phenylpropan-2-yl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide | Y | Y | Y |
| 422 | APP-PICA | N/A | C2H42H27N3O2; N-(2S)-1-Amino-1-oxo-3-phenylpropan-2-yl]-1-pentyl-1H-indole-3-carboxamide; Na-(1-Pentyl-1H-indole-3-carboxyl)-L-phenylalaninamid | . | . | Y |
| 423 | APP-PINACA | N/A | C2H42H26N4O2; N-[(2S)-1-Amino-1-oxo-3-phenylpropan-2-yl]-1-pentyl-1H-indole-3-carboxamide | . | . | Y |
| 424 | ATHPINACA ISOMER 1 | AD-THPINACA; Adamantyl-THPINACA | C2H42H13N3O2; 1-[(tetrahydro-2H-pyran-4-yl)methyl]-N-tricyclo[3.3.1.1.7]dec-1-yl-1H-indazole-3-carboxamide | Y | Y | Y |
| 425 | AZ-11713908 | N/A | C2H73H2N4O3S2; N-[(3-Cyclohexylmethy)-2-[(5-ethoxyxyridin-2-yl)methyl]-1H-benzimidazol-5-yl]-N-methylthiophene-2-sulfonate | . | . | Y |
| 426 | BAY 38-7271 | KN 38-7271 | C2H21H23F2O5S5; 3-[[2R]-2-(Hydroxymethyl)-2,3-dihydro-1H-inden-4-yl]oxy]phenyl 4,4,4-trifluorobutane-1-sulfonate | . | . | Y |
| 427 | BAY 59-3074 | WO 2002/026702 #1 | C18H13F6N4O5S; 3-[(2-Cyano-3-trifluoromethyl)phenoxy]phenyl 4,4,4-trifluorobutane-1-sulfonate | . | . | Y |
| 428 | BB-22 | QUCHIC | C2H24N2O2; 1-(cyclohexylmethyl)-1H-indole-3-carboxylic acid 8-quinolinyl ester | Y | Y | Y |
| 429 | BE 854655 #4 | N/A | C2H23H3N3O3; 6S,6aR,9R,10aR-3-[[2R]-Heptan-2-yl]oxy]-6-methyl-5,6,6a,7,8,9,10,10a-octahydropyrimidin-1,9-diol | . | . | Y |
| 430 | BICYCLIC ANALOG XI | METHYL ANALOGUE CP-55,940 | C22H36O2; 2-[[1R,2R,5R]-5-Hydroxy-2-methylcyclohexyl]-5-[2-methyloctan-2-yl]phenol | . | . | Y |
| 431 | BIM-018 | N/A | C23H22N2O; [Naphthalen-1-yl][1-pentyl-1H-benzimidazol-2-yl]methanone | Y | . | Y |
| 432 | BLKB-2 | N/A | C16H23N3O2; N-[[2R]-1-Hydroxypropan-2-yl]-1-pentyl-1H-indazole-3-carboxamide | . | . | Y |
| 433 | BLKS-2 | CPE; Cannabipiperidinethane | C24H28N2O2; 2-[2-Methoxyphenyl]-1-[1-[1-methylpiperidin-2-yl]methyl]-1H-indol-3-yl]ethan-1-one | Y | . | Y |
| 434 | BLKS-4 | N/A | C22H22F2N2O; N-[[2,4-Difluorophenyl]methyl]-1-[oxan-4-yl]methyl]-1H-indole-3-carboxamide | . | . | Y |
| 435 | BLKS-6 | N/A | C25H32F3N4O; Cyclopropyl (2S)-2-[[5-(2-fluorophenyl)-1-[oxan-4-yl]methyl]-1H-pyrazole-3-carbonyl]methyl]-3,3-dimethylbutanoate | . | . | Y |
| 436 | BLKS-9 | N/A | C25H35F4N4O3; 5-[[2-Fluorophenyl]-1-[oxan-4-yl]methyl]-1H-pyrazol-3-yl][3R,5S]-4-[[2-methoxyethyl]-3,5-dimethylpiperazine-1-yl]methanone | . | . | Y |
| 437 | BML-190 | Indomethacin morpholinylamide | C23H23CN2O4; 2-[1-(4-Chlorobenzyl)-5-methoxy-2-methyl-1H-indol-3-yl]-1-morpholin-4-yl]ethan-1-one | . | . | Y |
| 438 | BUTYL (2S)-2-[[6AR,10AR]-1-HYDROXY-6,6,9-TRIMETHYL-6A,7,10A-TETRAHYDRO-6H-DIBENZO[b,d]PYRAN-3-YL]PROPANOATE | N/A | C23H32O4; Butyl (2S)-2-[[6AR,10AR]-1-hydroxy-6,6,9-trimethyl-6a,7,10a-tetrahydro-6H-dibenzo[b,d]pyran-3-yl]propanoate | . | . | Y |
| 439 | BUTYL 1-[[6AR,10AR]-1-HYDROXY-6,6,9-TRIMETHYL-6A,7,10A-TETRAHYDRO-6H-DIBENZO[b,d]PYRAN-3-YL]CYCLOBUTANE-1-CARBOXYLATE | N/A | C25H35O4; Butyl 1-[[6AR,10AR]-1-hydroxy-6,6,9-trimethyl-6a,7,10a-tetrahydro-6H-dibenzo[b,d]pyran-3-yl]cyclobutane-1-carboxylate | . | . | Y |
| 440 | BUTYL 2-[[6AR,10AR]-1-HYDROXY-6,6,9-TRIMETHYL-6A,7,10A-TETRAHYDRO-6H-DIBENZO[b,d]PYRAN-3-YL]2-METHYLPROPANOATE | N/A | C24H34O4; Butyl 2-[[6AR,10AR]-1-hydroxy-6,6,9-trimethyl-6a,7,10a-tetrahydro-6H-dibenzo[b,d]pyran-3-yl]2-methylpropanoate | . | . | Y |
| 441 | BZDZ2-EPYR | N/A | C23H24N4O; 3-[[3-Benzy1-1,2,4-oxadiazol-5-yl]-1-[2-([pyrrolidin-1-yl]methyl)-1H-indol | . | . | Y |
| 442 | C3-UR-144 | N/A | C19H25NO; [1-Propyl-1H-indol-3-yl][2,2,3,3-tetramethylcyclopropyl]methanone | . | . | Y |
| 443 | C4-CBD | N/A | C20H28O2; [1'R,2'R]-4-Butyl-5′-methyl-2′-[[prop-1-en-2-yl]-1′,2′,3′,4′-tetrahydro[1′,1′-biphenyl]-2,6-diol | . | . | Y |
| 444 | C4-RCS-4 | N/A | C20H21NO2; [1-Butyl-1H-indol-3-yl][4-methoxyphenyl]methanone | Y | Y | Y |
| 445 | C6-UR-144 | N/A | C22H31NO; [1-Hexyl-1H-indol-3-yl][2,2,3,3-tetramethylcyclopropyl]methanone | . | . | Y |
| 446 | C7-UR-144 | KM-X1; TMCP-020; Heptyl-UR-144 | C23H33NO; [1-pentyl-1H-indol-3-yl][2,2,3,3-tetramethylcyclopropyl]methanone | Y | Y | Y |
| 447 | CANNABICYCLOHEXANOL | CCH; CP 47,497 dimethyloctyl homologue | C22H36O2; 2-[[1S,3R]-3-Hydroxycyclohexyl]-5-[2-methylnonan-2-yl]phenol | Y | . | Y |
| 448 | CB-13 | CRA13; SAB-378 | C26H24O2; [Naphthalen-1-yl][4-(pentyloxy)naphthalen-1-yl]methanone | Y | Y | Y |
| 449 | CBL-018 | NNE1 | C24H23N2O2; Naphthalen-1-yl 1-pentyl-1H-indole-3-carboxylate | Y | Y | Y |
| 450 | CBS-0550 | N/A | C20H23F4N2O; N-[[5-tert-Butyl-2-(cyclopropylmethyl)-1-methyl-1,2-dihydro-3H-pyrazol-3-yliden]-2-fluoro-3-trifluoromethyl]benzamide | . | . | Y |
| 451 | CHE-CP-47,497 | N/A | C20H30O2; 5-[[2-Cyclohexylethyl]-2-[[1S,3R]-3-hydroxycyclohexyl]phenol | . | . | Y |
| 452 | CHM-018 | NE-CHMIMO; (CHM)-JWH-018; JWH-018 CYCLOHEXYLMETHYL | C26H25NO; [1-Cyclohexylmethyl]-1H-indol-3-yl]naphthalen-1-yl)methanone | Y | Y | Y |
|   |   |   |   |   |
|---|---|---|---|---|
| 453 | CHM-CP-47,497 | N/A | C19H28O2; 5-(Cyclohexylmethyl)-2-[[15,3R]-3-hydroxy-3-cyclohexy1-phenol | Y | Y | Y |
| 454 | CP 47,497 | (C7)-CP 47,497 | C21H34O2; 2-[[15,3R]-3-hydroxy-3-cyclohexy1]-5-(2-methyloctan-2-yl)phenol | Y | Y | Y |
| 455 | CP 47,497 (C8 + C2) | N/A | C24H40O2; 5-{1,1-Dimethyloctyl}-2-[[15,3S]-3-hydroxy-cyclohexy1]-phenol | . | . | Y |
| 456 | PP 55,244 | N/A | C26H42O3; [2R,4R,4aR,6S,8aS]-6-(Hydroxymethyl)-4-[2-hydroxy-4-[2-methyloctan-2-yl]pheny1]decahyronaphthalen-2-ol | Y | . | Y |
| 457 | PP 55,940 | N/A | C24H40O3; 2-[[1R,2R,5R]-5-hydroxy-2-(3-hydroxypropyl) cyclohexy1]-5-(2-methyloctan-2-yl)phenol | Y | . | Y |
| 458 | CP-55,243 | N/A | C26H42O3; [2S,4S,4aS,6R,8aR]-6-(Hydroxymethyl)-4-[2-hydroxy-4-[2-methyloctan-2-yl]pheny1]decahyronaphthalen-2-ol | . | . | Y |
| 459 | CP-56,667 | N/A | C24H40O3; 2-[[1S,2S,5S]-5-hydroxy-2-(3-hydroxypropyl) cyclohexy1]-5-(2-methyloctan-2-yl)phenol | . | . | Y |
| 460 | CUMYL-4-CN-B7AICA | N/A | C22H24N4O; 1-{(4-cyanobuty1)-N-(2-phenylpropane-2-yl)-7-aza-indole-3-carboxamide | Y | Y | Y |
| 461 | CUMYL-CH-MEGAclone | N/A | C27H30N2O; 5-(Cyclohexylmethyl)-2-[[2-phenylpropan-2-yl]-2,5-dihydro-1H-pyrido[4,3-b]indol-1-one | Y | Y | Y |
| 462 | CUMYL-FUBICA | N/A | C25H23FN2O; 1-{[(4-fluorophenyl)methyl]-N-(2-phenylpropan-2-yl)-1H-indole-3-carboxamide | . | . | Y |
| 463 | CUMYL-PEGAclone | N/A | C25H28N2O; 5-Pentyl-2-(2-phenylpropan-2-yl)-2,5-dihydro-1H-pyrido[4,3-b]indol-1-one | Y | Y | Y |
| 464 | CUMYL-PINACA | SGT-24 | C22H27N3O; 1-pentyl-N-[2-phenylpropan-2-yl]1H-indazole-3-carboxamide | Y | Y | Y |
| 465 | CUMYL-TFBICA | SGT-262 | C22H23F3N2O; N-[2-Phenyl]-propan-2-yl-1-{(4,4,4-trifluorobutyl)-1H-indole-3-carboxamide | . | . | Y |
| 466 | CYCLOHEPTYL-[1-2-(MORPHIN-4-YL)ETHYL]-1H-INDOL-3-YLMETHANONE | N/A | C22H30N2O2; Cycloheptyl-[1-2-(morpholin-4-yl)ethyl]-1H-indol-3-ylmthcnne | . | . | Y |
| 467 | CYCLOPENTYL-[1-(OXAN-4-YL)METHYL]-1H-INDOL-3-YLMETHANONE | N/A | C20H25N02; Cyclopentyl-[1-(oxan-4-yl)methyl]-1H-indol-3-ylmethancne | . | . | Y |
| 468 | DESACETYL-LEVONANTRADOL | N/A | C25H25N03; [65,6aR,9R,10aR]-6-methyl-3-[(2R)-5-phenylpentan-2-yl]oxy, 5,6,6a,7,8,9,10,10a-octahydrophenanthridine-1,9-diol | . | . | Y |
| 469 | DESPENTYL-UR-144 | DP-UR-144 | C16H19N0; (1H-indol-3-yl)[2,2,3,3-tetramethylcyclopropyl]methanone | Y | . | . |
| 470 | DIMETHYL-CP-47,497-C8 | SGT-262 | C21H34O2; rel-2-([15,3S]-3-hydroxy-3,3-dimethylcyclohexy1)-5-[2-methylpropan-2-yl] phenol | Y | . | Y |
| 471 | DIMETHYHEPTYL-PYRAN | EA-2233; DMHP; 1,2-dimethyheptyl-Δ3THC | C25H38O2; 6,6,9-Trime-thyl-3-(3-methyloctan-2-yl)-7,8,9,10-tetrahydro-6H-dibenz[b,d]pyran-1-ol | Y | . | Y |
| 472 | DMBA-CHMINACA | N/A | C21H29N03; 2-[(cyclohexylmethyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoic acid | Y | Y | . |
| 473 | DMP-PICA | N/A | C22H26N02; N-[2,6-Dimethylphenyl]-1-pentyl-1H-indole-3-carboxamide | Y | . | Y |
| 474 | EA-1465 | N/A | C25H38O2; 6,6,9-Trime-thyl-3-(nonan-2-yl)-7,8,9,10-tetrahydro-6H-dibenz[b,d]pyran-1-ol | . | . | Y |
| 475 | EA-1543 | N/A | C25H39O4P; Propan-2-yl 6,6,9-trimethyl-3-pentyl-7,8,9,10-tetrahydro-6H-dibenz[b,d]pyran-1-yl methylphosphonate | . | . | Y |
| 476 | EA-2233-2 | N/A | C27H40O3; [9R]-6,6,9-Trime-thyl-3-[[25,3R]-3-methyloctan-2-yl]-7,8,9,10-tetrahydro-6H-dibenz[b,d]pyran-1-yl acetate | . | . | Y |
| 477 | EAM-2201 | JWH 210 N-[5-fluoropentyl] analog | C26H26FN0; (4-ethyl-1-naphthalenyl)[1-(5-fluoropentyl)-1H-indol-3-yl]-methanone | Y | Y | Y |
| Entry | Short Running Title of the Article | N/A | C28H52NO; naphthalen-1-yl[9-pentyl-9H-carbazol-3-yl]methanone | Y | Y | Y |
|-------|-----------------------------------|-----|-------------------------------------------------------------|---|---|---|
| 491   | EG-2201                           | N/A | C28H54FNO; [9-(5-fluoropentyl)-9H-carbazol-3-yl][naphthalen-1-yl]methanone | Y | Y | Y |
| 492   | AEB-FUBINACA                      | AEB-FUBINACA; FU-AEB; FUB-AEB | C22H24FN3O3; ethyl (1-[4-fluorobenzyl]-1H-indazole-3-carbonyl)-L-valinate | Y | Y | Y |
| 493   | EPI-CP 55,940                     | N/A | C24H40O3; [2-[[1R,2R,5S]-5-Hydroxy-2-[3-hydroxypropyl]cyclohexyl]-5-[2-methyloctan-2-yl]phenol | . | . | Y |
| 494   | ETHYL 5-[2,6-DIHYDROXY-4-(2-METHYL-2-OCTANYL)PHENYL]NICOTINATE | US 2004/0087590 #5 | C23H31NO4; Ethyl 5-[2,6-dihydroxy-4-(2-methyl-2-yl)phenyl]pyridine-3-carboxylate | . | . | Y |
| 495   | FAB-144                           | (Indazole) XLR-11; SF-UR-144 indazole | C20H27FN2O2; [1-[5-fluoropyridinyl]-1H-indazol-3-yl][2,2,2,3,3-tetramethylcyclopropyl]methanone | Y | . | Y |
| 496   | FDU-MN24; FDU-NNE1                | N/A | C26H19FN2O2; Naphthalen-1-yl-(4-fluorobenzyl)-1H-indole-3-carboxamide | Y | Y | Y |
| 497   | FDU-PB-22                         | N/A | C26H18FN2O2; Naphthalen-1-yl-(4-fluorobenzyl)-1H-indole-3-carboxamide | Y | Y | Y |
| 498   | FENCHYL-PINACCA                    | N/A | C23H33N3O; 1-Pentyl-N-[(15,25,4R)-1,3,3-trimethylcyclopropyl][2,2,1]heptan-2-yl-1H-indazole-3-carboxamide | Y | Y | Y |
| 499   | FUB-144                           | FUB-UR-144 | C23H24FNO; C23H24FNO; (1-[4-fluorobenzyl]-1H-indol-3-yl)[2,2,3,3-tetramethylcyclopropyl]methanone | Y | Y | Y |
| 500   | FUB-144                           | N/A | C23H26FN3O2 | . | . | Y |
| 501   | FUB-JWH-018                       | N/A | C26H18FN2O; [1-[4-fluoropyridinyl]methyl]-1H-indol-3-yl][naphthalen-1-yl]methanone | Y | Y | Y |
| 502   | FUB-NPB-22                        | (Indazole) FUB-PB-22 | C24H16FN3O2; Quinolin-8-yl 1-[(4-fluoropyridinyl)methyl]-1H-indazole-3-carboxamide | Y | Y | Y |
| 503   | FUB-PB-22                         | QCBL-8z-F; MN-27 | C25H17FN2O2; quinolin-8-yl 1-[(4-fluoropyridinyl)methyl]-1H-indole-3-carboxamide | Y | Y | Y |
| 504   | FUBIMINA                          | (Benzimidazole) AM-2201; FTHI; BZ-2201 | C23H21FN2O2; [1-[5-Fluoropyridinyl]-1H-benzimidazol-2-yl][naphthalen-1-yl]methanone | Y | Y | Y |
| 505   | GSK-554418A                       | N/A | C19H19CIN4O2; [4-[3-Chloroanilino]-1-methyl-1H-pyrrolo[3,2-c]pyridin-7-yl][morpholin-4-yl]methanone | . | . | Y |
| 506   | GW-405,833                        | L-768,242 | C23H24C12N2O3; [2,3-Dichlorophenyl][5-methoxy-2-methyl-3-[2-[morpholin-4-yl]ethyl]-1H-indol-1-yl]methanone | . | . | Y |
| 507   | GW-842,166X                       | N/A | C18H17CIF3N4O2; 2-[2-(4,4-Dichloroanilino)-N-[(oxan-4-yl)methyl]-4-[(trifluoromethyl)pyrimidine-5-carboxamide | . | . | Y |
| 508   | HHC                               | N/A | C21H32Z2O; (6aR,10aR)-6,6,9-Trimethyl-3-pentyl-6a,7,8,9,10a-hexahydro-6H-dibenzo[b,d]pyran-1-ol | . | . | Y |
| 509   | HU-210                            | N/A | C25H38O3; 9-(HYDROXYMETHYL)-6,6-DIMETHYL-3-[2-METHYLCYCLO-2-YL]-6a,7,10,10A-TETRACYCLOBENZO[C]CHROMEN-1-OL | Y | Y | Y |
| 510   | HU-211                            | N/A | C25H38O3; (6aS,10aS)-9-(Hydroxymethyl)-6,6-dimethyl-3-[2-methylocyclan-2-yl]-6a,7,10,10A-tetrahydro-6H-dibenzo[b,d]pyran-1-ol | Y | . | Y |
| 511   | HU-239                            | N/A | C25H36O4; (6aR,10aR)-1-Hydroxy-6,6-dimethyl-3-[2-methylocyclan-2-yl]-6a,7,10,10A-tetrahydro-6H-dibenzo[b,d]pyran-9-carboxylic acid | . | . | Y |
| 512   | HU-308                            | N/A | C27H42O3; [(4S)-4-[2,6-Dimethoxy-4-[2-methylocyclan-2-yl]phenyl]-6,6-dimethylcyclopropyl][3,1.1]hept-2-en-2-yl)methanol | Y | . | Y |
| 513   | HU-320                            | N/A | C25H36O4; (15,6S)-2′,6′-Dihydroxy-4′-(2-methylocyclan-2-yl)-6-(prop-1-en-2-yl)-1,4,5,6-tetrahydro[1,1′-biphenyl]-3-carboxylic acid | . | . | Y |
| 514   | HU-331                            | N/A | C21H28O3; 3-Hydroxy-2-[[1R]-6-isoprophenyl-3-methyl-cyclohex-2-en-1-yl]-5-pentyl-1,4-benzoquinone | Y | Y | Y |
| 504 | HU-336 | N/A | C21H28O3; (6αR,10αR)-6,6,9-Trimethyl-3-pentyl-6a,7,10a-tetrahydro-1H-dibenzo[b,d]pyran-1,4(6H)-dione | . | . | Y |
| 505 | HU-345 | N/A | C21H24O3; 6,6,9-Trimethyl-3-pentyl-1H-dibenzo[b,d]pyran-1,4(6H)-dione | . | . | Y |
| 506 | HU-433 | N/A | C21H42O3; [4R]-4-[2,6-Dimethoxy-4-[2-methyloctan-2-yl]phenyl]-6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl)methanol | . | . | Y |
| 507 | HUF-101 | 4′-F-CBD; 4′-Fluorocannabinol | C21H29F2O2; [1′R,2′R]-3-Fluoro-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro[1′,1′,biphenyl]-2,6-diol | . | . | Y |
| 508 | INVERSE-JWH-018 | N/A | C24H23NO; (Naphthalen-1-yl)[3-pentyl-1H-indol-1-yl]methanone | . | . | Y |
| 509 | IPO-33 | N/A | C20H22N2O; 1-(1-Pentyl-1H-indazol-3-yl)-2-phenylethan-1-one | . | . | Y |
| 510 | JNI-42165279 | N/A | C18H17ClF2N4O3; N-[4-Chloropyridin-3-yl]-4-[2,2-difluoro-2H-1,3-benzodioxol-5-yl]methylpiperazine-1-carboxamide | . | . | Y |
| 511 | JTE 7-31 | N/A | C22H28N2O3; 2-[2-(4-Hydroxyphenyl)ethyl]-5-methoxy-4-(pentyloxy)-2,3-dihydro-1H-indol-1-one | . | . | Y |
| 512 | JTE-907 | N/A | C24H26N2O6; N-[(2H-1,3-Benzodioxol-5-yl)methyl]-7-methoxy-2-oxo-8-[pentyloxy]-1,2-dihydroquinoline-3-carboxamide | Y | Y | Y |
| 513 | JWH-001 | N/A | C17H22N2O2; 1-[2-Methyl-1-[2-(morpholin-4-yl)ethyl]-1H-indol-3-yl]ethan-1-one | . | . | Y |
| 514 | JWH-002 | N/A | C20H26N2O2; 3-Methyl-1-[2-methyl-1-[2-(morpholin-4-yl)ethyl]-1H-indol-3-yl]but-2-en-1-one | . | . | Y |
| 515 | JWH-007 | N/A | C25H25N0; 2-[2-(4-Hydroxyphenyl)ethyl]-5-methoxy-4-(pentyloxy)-2,3-dihydro-1H-indol-1-one | Y | Y | Y |
| 516 | JWH-015 | N/A | C23H21NO; [2-Methyl-1-propyl-1H-indol-3-yl]-1-naphthalenylmethanone | Y | Y | Y |
| 517 | JWH-018 | AM-678; JWH-018 | C24H23NO; Naphthalen-1-yl-[1-pentylindol-3-yl)methanone | Y | Y | Y |
| 518 | JWH-018 ADAMANTOYL DERIVATIVE | AB-001 | C24H31NO; 1-Pentyl-3-(adamant-1-yl)indole | Y | Y | Y |
| 519 | JWH-018 AZAINDOLE ANALOGUE | N/A | C23H22N2O; Naphthalen-1-yl-[1-pentyl-1H-7-azaindol-3-yl)methanone | Y | . | . |
| 520 | JWH-018 N-PENTANOIC ACID | JWH-018 N-Pentyl-5-carboxylic Acid | C24H21NO3; 5-[3-(Naphthalene-1-carboxyl)]-1H-indol-1-yl)pentanoic acid | . | . | Y |
| 521 | JWH-018 SULFONIUM BROMIDE | N/A | C24H23OS; [1-Bromo-1-pentyl-1H-1-benzo thiophen-3-yl]naphthalen-1-yl)methanone | . | . | Y |
| 522 | JWH-018 THIOKETONE | N/A | C24H23NS (Naphthalen-1-yl)[1-pentyl-1H-indol-3-yl)methanethione | . | . | Y |
| 523 | JWH-019 | 1-Hexyl-3-(1-naphthoyl)indole | C25H25NO; 1-Hexyl-3-[1-naphthoyl]indole | Y | Y | Y |
| 524 | JWH-020 | N/A | C26H27NO; (1-Heptyl-1H-indol-3-yl)naphthalen-1-yl)methanone | Y | . | . |
| 525 | JWH-022 | 1-([4-Pentene-yl]-3-[1-naphthoyl]indole | C24H21NO; 1-[(4-Pentene-yl)-3-[1-naphthoyl]indole | Y | Y | Y |
| 526 | JWH-030 | N/A | C20H21NO; [Naphthalen-1-yl][1-pentyl-1H-pyrrol-3-yl)methanone | Y | Y | Y |
| 527 | JWH-051 | N/A | C25H35O2; [6αR,10αR]-6,6-Dimethyl-3-[2-methyloctan-2-yl]-6a,7,10a-tetrahydro-6H-dibenzo[b,d]pyran-9-yl)methanol | . | . | Y |
| 528 | JWH-071 | N/A | C21H17NO; [1-ethyl-1H-indol-3-yl]-1-naphthalenylmethanone | Y | Y | Y |
| 529 | JWH-072 | N/A | C22H19NO; [Naphthalen-1-yl][1-propyl-1H-indol-3-yl)methanone | . | . | Y |
| 530 | JWH-073 | N/A | C23H21NO; [1-Butyl-1H-indol-3-yl][1-naphthyl)methanone | Y | Y | Y |
| JWH-073 METHYL DERIVATIVE | JWH-073 methyl derivative | C24H23NO; 4-methyl-naphthalen-1-yl-(1-butylindol-3-yl)methanone; 1-Butyl-3-(1-[4-methyl]naphthoyl)indol; (1-Butyl-1H-indol-3-yl)-1-[4-methyl]naphthalenylmethanone; (1-Butyl-1H-indol-3-yl)[4-methyl]naphthalen-1-yl)methanone; JWH-073 methyl derivative | Y | Y | Y |
| JWH-080 | N/A | C24H23NO2; [1-Butyl-1H-indol-3-yl][4-methoxynaphthalen-1-yl)methanone | . | . | Y |
| JWH-081 | N/A | C25H25NO2; 4-methoxynaphthalen-1-yl-[1-pentylindol-3-yl)methanone | Y | Y | Y |
| JWH-082 | N/A | C26H27NO2; [1-Hexyl-1H-indol-3-yl][4-methoxynaphthalen-1-yl)methanone | . | . | Y |
| JWH-098 | N/A | C26H27NO2; [4-Methoxynaphthalen-1-yl][2-methyl-1-pentyl-1H-indol-3-yl)methanone | . | . | Y |
| JWH-116 | N/A | C26H27NO; [2-Ethyl-1-pentyl-1H-indol-3-yl][naphthalen-1-yl)methanone | . | . | Y |
| JWH-121 | N/A | C24H23NO; [1-Butyl-1H-indol-3-yl][4-methoxynaphthalen-1-yl)methanone | . | . | Y |
| JWH-122 | N/A | C25H25NO; (4-methyl-1-naphthyl)-[1-pentylindol-3-yl)methanone | Y | Y | Y |
| JWH-122 (5-METHYL-NAPHTYL ISOMER) | N/A | C25H25NO; (5-methynaphthalen-1-yl)[1-pentyl-1H-indol-3-yl)methanone | Y | . | . |
| JWH-122 PENTENYL DERIVATIVE | JWH-122 N-(4-pentenyl) analog; MAM-2201 | C25H23NO; (4-methynaphthalen-1-yl)[1-(pent-4-en-1-yl)-1H-indol-3-yl)methanone | Y | Y | Y |
| JWH-133 | N/A | C22H32O; (6aR,10aR)-6,6,9-Trimethyl-3-(2-methylpentan-2-yl)-6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran | . | . | Y |
| JWH-145 | N/A | C26H25NO; [Naphthalen-1-yl][1-pentyl-5-phenyl-1H-pyrrol-3-vl)methanone | Y | Y | Y |
| JWH-147 | N/A | C27H27NO; [1-Hexyl-5-phenyl-1H-pyrrol-3-yl][naphthalen-1-yl)methanone | . | . | Y |
| JWH-149 | N/A | C26H27NO; [4-Methynaphthalen-1-yl][2-methyl-1-pentyl-1H-indol-3-yl)methanone | . | . | Y |
| JWH-166 | N/A | C25H25NO2; [6-Methoxynaphthalen-1-yl][1-pentyl-1H-indol-3-yl)methanone | . | . | Y |
| JWH-167 | N/A | C21H23NO; 1-(1-Pentyl-1H-indol-3-yl)-2-phénylethyl-1-one | . | . | Y |
| JWH-175 | N/A | C24H25N; 3-[Naphthalen-1-yl)methy]-1-pentyl-1H-indole | Y | . | Y |
| JWH-176 | N/A | C25H24; 1-[(E)-(3-Pentyl-1H-inden-1-ylidene)methyl]naphthalene | . | . | Y |
| JWH-181 | N/A | C28H31NO; [2-Methyl-1-pentyl-1H-indol-3-yl][4-propynaphthalen-1-yl)methanone | . | . | Y |
| JWH-182 | 1-pentyl-3-(4-propyl-1-naphthoyl)indole | C27H29NO; [1-pentylindol-3-yl]-[4-propynaphthalen-1-yl)methanone | Y | Y | Y |
| JWH-184 | N/A | C25H27N; 3-[4-Methynaphthalen-1-yl)methyl]-1-pentyl-1H-indole | . | . | Y |
| JWH-185 | N/A | C25H27NO; 3-[4-Methoxynaphthalen-1-yl)methyl]-1-pentyl-1H-indole | . | . | Y |
| JWH-193 | N/A | C26H26N2O2; [4-Methynaphthalen-1-yl][1-[2-(morpholin-4-yl)ethyl]-1H-indol-3-yl)methanone | . | . | Y |
| JWH-198 | N/A | C26H26N2O3; [4-Methoxynaphthalen-1-yl][1-[2-(morpholin-4-yl)ethyl]-1H-indol-3-yl)methanone | . | . | Y |
| JWH-200 | N/A | C25H24N2O2; 1-[2-Morpholin-4-ylthyl]-3-[1naphthoyl]indole | Y | Y | Y |
| JWH-201 | N/A | C22H25NO2; 2-[4-Methoxyphenyl]-1-(1-pentyl-1H-indol-3-yl)ethan-1-one | Y | . | Y |
| No. | Compound | Formula | Description |
|-----|----------|---------|-------------|
| 583 | JWH-316 | N/A     | C2H24FNO; 2-(4-Fluorophenyl)-1-(2-methyl-1-pentyl-1H-indol-3-yl)ethan-1-one |
| 584 | JWH-317 | N/A     | C2H23N03; 2-(2H-1,3-Benzodioxol-5-yl)-1-(1-pentyl-1H-indol-3-yl)ethan-1-one |
| 585 | JWH-337 | N/A     | C2H40O2; (1R,3R,4R)-4-(3-Hydroxypropyl)-3-[4-(2-methyloctan-2-yl)phenyl)cyclohexan-1-ol |
| 586 | JWH-344 | N/A     | C2H38O2; (1R,3R,4R)-4-(3-Hydroxypropyl)-3-[4-(2-methyloctan-2-yl)phenyl)cyclohexan-1-ol |
| 587 | JWH-346 | N/A     | C2H27N0; [5-(3-Methylphenoxy)-1-pentyl-1H-pyrrol-3-yl](napthalen-1-yl)methanone |
| 588 | JWH-365 | N/A     | C2H29N0; [5-(2-Ethylphenyl)-1-pentyl-1H-pyrrol-3-yl](napthalen-1-yl)methanone |
| 589 | JWH-366 | N/A     | C2H24N2O; (Naphthalen-1-yl)[1-pentyl-5-(pyridin-3-yl)-1H-pyrrol-3-yl]methanone |
| 590 | JWH-367 | N/A     | C2H27N02; [5-(3-Methoxyphenoxy)-1-pentyl-1H-pyrrol-3-yl](napthalen-1-yl)methanone |
| 591 | JWH-368 | N/A     | C2H24FNO; [5-(3-Fluorophenyl)-1-pentyl-1H-pyrrol-3-yl](napthalen-1-yl)methanone |
| 592 | JWH-370 | N/A     | C2H27N0; [5-(2-Methylphenoxy)-1-pentyl-1H-pyrrol-3-yl](napthalen-1-yl)methanone |
| 593 | JWH-372 | N/A     | C2H24F3NO; (Naphthalen-1-yl)[1-pentyl-5-[2-(trifluoromethyl)phenyl]-1H-pyrrol-3-yl]methanone |
| 594 | JWH-377 | JWH-018 2'-naphthyl isomer | C2H23N0; (Naphthalen-2-yl)[1-pentyl-1H-indol-3-yl]methanone |
| 595 | JWH-387 | N/A     | C2H24BrNO; [4-Bromonaphthalen-1-yl][1-pentyl-1H-indol-3-yl]methanone |
| 596 | JWH-398 | 1-PENTYL-3-(4-CHLORO-1-NAPHTHOYL)INDOLE | C2H22CINO; 4-chloro-1-naphthalenyl-[1-pentyl-1H-indol-3-yl]methanone |
| 597 | JWH-408 | N/A     | C2H25N02; [6-Methoxynaphthalen-2-yl][1-pentyl-1H-indol-3-yl]methanone |
| 598 | JWH-409 | N/A     | C2H27N02; [6-Methoxynaphthalen-2-yl][2-methyl-1-pentyl-1H-indol-3-yl]methanone |
| 599 | JWH-410 | N/A     | C2H25N02; [1-Butyl-2-methyl-1H-indol-3-yl][6-methoxynaphthalen-2-yl]methanone |
| 600 | JWH-412 | N/A     | C2H22FNO; [4-Fluoronaphthalen-1-yl][1-pentyl-1H-indol-3-yl]methanone |
| 601 | JWH-421 | N/A     | C2H22BrNO; [4-Iodonaphthalen-1-yl][1-pentyl-1H-indol-3-yl]methanone |
| 602 | JWH-424 | N/A     | C2H22BrNO; [8-Iodonaphthalen-1-yl][1-pentyl-1H-indol-3-yl]methanone |
| 603 | JWH-444 | N/A     | C2H22BrNO; [5-Bromo-1-pentyl-1H-indol-3-yl](napthalen-1-yl)methanone |
| 604 | JWH-452 | N/A     | C2H22BrNO; [5-Iodo-1-pentyl-1H-indol-3-yl](napthalen-1-yl)methanone |
| 605 | JZL-184 | N/A     | C2H24N2O9; 4-Nitrophenyl 4-[bis(2H-1,3-benzodioxol-5-yl)(hydroxy)methyl]piperidine-1-carboxylate |
| 606 | JZL-195 | N/A     | C2H23N3O5; 4-Nitrophenyl 4-[[3-phenoxyphenyl]methyl]piperazine-1-carboxylate |
| 607 | KM-233 | N/A     | C2H30O2; (6aR,10aR)-6,6,9-Trimethyl-3-(2-phenylpropan-2-yl)-6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-1-ol |
| Page | Compound | N/A | CAS Number |
|------|----------|----|------------|
| 608  | L-759,633| N/A| C26H40O2; (6aR,10aR)-1-Methoxy-6,6,9-trimethyl-3-{2-methyloctan-2-yl} | Y |
| 609  | L-759,656| N/A| C26H40O2; (6aR,10aR)-1-Methoxy-6,6-dimethyl-3-{2-methyloctan-2-yl} | Y |
| 610  | LA580IO-881| N/A| C23H27N3O6; N′-{[(E)-3,5-O-tetrahydro-4-hydroxyphenyl]methylidene}-6-nitro-2H-1,3-benzozidoxole | Y |
| 611  | LBP-1    | N/A| C23H29CN6O3; 2-[4-[[7-Chloro-1-[[oxan-4-yl]methyl-1H-indol-3-yl]-1,2,4-oxadiazol-5-yl]methyl] | Y |
| 612  | LEVONANTRADOL| CP 50,556-1; L-Nantradol| C27H35NO4; {6S,6aR,9R,10aR}-9-Hydroxy-6-methyl-3-[(2R)-5-phenylpent-2-yl]oxy]-5,6,6a,7,8,9,10a-octahydrophenanthridin-1-yl | Y |
| 613  | LH-21    | N/A| C20H20C3N3; 5-[[4-Chlorophenyl]-1-[[2,4-dichlorophenyl]-3-hexyl-1H-1,2,4-triazole | Y |
| 614  | LTI-701  | N/A| C20H21N2O2; 1-(5-fluoropentyl)-N-phenyl-1H-indole-3-carboxamide | Y |
| 615  | LY2183240| N/A| C17H17NSO; 5-[[1,1′-Biphenyl]-4-yl]methyl-N,N-dimethyl-1H-tetrazole-1-carboxamide | Y |
| 616  | M-CHMIC  | N/A| C17H20N2O; methyl-1-cyclohexylmethyl)-1H-indole-3-carboxylate | Y |
| 617  | MSFPIC   | N/A| C15H18FNO2; Methyl 1-(5-fluoropentyl)-1H-indole-3-carboxylate | Y |
| 618  | MAM-1220 | N/A| C27H28N2O; [4-Methylnapthalen-1-yl]-[1-[1-methylpiperidin-2-yl]methyl]-1H-indol-3-yl]methylone | Y |
| 619  | MAM-2201 | N/A| C26H24FNO; 1-[5-fluoropentyl]-1H-indol-3-yl]-[4-methyl-naphthalen-1-yl]methylone | Y |
| 620  | MAM-2201 INDAZOLE ANALOGUE | N/A| C24H23FN2O; [1-[5-Fluoropentyl]-1H-indazol-3-yl][4-methylnaphthalen-1-yl]methylone | Y |
| 621  | MAM-2201 N-(2-FLUOROPENTYL) | N/A| C25H24FNO; 1-[2-Fluoropentyl]-1H-indol-3-yl]-[4-methylnaphthalen-1-yl]methylone | Y |
| 622  | MAM-2201 N-(3-FLUOROPENTYL) | N/A| C25H24FNO; 1-[3-Fluoropentyl]-1H-indol-3-yl]-[4-methylnaphthalen-1-yl]methylone | Y |
| 623  | MAM-2201 N-(4-FLUOROPENTYL) | N/A| C25H24FNO; 1-[4-Fluoropentyl]-1H-indol-3-yl]-[4-methylnaphthalen-1-yl]methylone | Y |
| 624  | MAM-2201 N-(4-HYDROXYPENTYL) | N/A| C25H25N2O; 1-[4-Hydroxypentyl]-1H-indol-3-yl]-[4-methylnaphthalen-1-yl]methylone | Y |
| 625  | MAM-2232 | N/A| C25H22N2O; 5-[3-[4-Methylnaphthalene-1-carbonyl]-1H-indol-1-yl]pentanenitrile | Y |
| 626  | MBA-CHMINACA | N/A| (1-[cyclohexylmethyl]-1H-indazole-3-carbonyl)valine | Y |
| 627  | MCHB-1   | N/A| C28H37N3O2; 1-(cyclohexylmethyl)-2-[[4-ethoxyphenyl]methyl]-N,N-dimethyl-1H-benzimidazole-5-carboxamide | Y |
| 628  | MDA 19   | N/A| C21H23N3O2; (3Z)-N′-[[1-hexyl-2-oxindol-3-ylidene]benzoylhydrazide | Y |
| 629  | MDA-77   | N/A| C21H23N3O3; N′-[[6-Methoxy-2-oxo-1-pentyl-1,2-dihydro-3H-indol-3-ylidene]benzoylhydrazide | Y |
| 630  | MDMB-4EN-PINACA | N/A| C20H27N3O3; methyl-3,3-dimethyl-2-[1-(pent-4-en-1-yl)]-1H-indazole-3-carbonyl]butanoate | Y |
| 631  | MDMB-CHMCZCA | N/A| C20H27N3O3; methyl-(6)-2,9-(cyclohexylmethyl)-9H-carbazole-3-carboxamido)-3,3-dimethylbutanoate | Y |
| 632  | MDMB-CHMICA | N/A| C23H32N2O3; Methyl-2-[[1-(cyclohexylmethyl)indole-3-carbonyl]amino]-3,3-dimethylbutanoate]MM8-CHMINACA | Y |
| 633  | MDMB-CHMINACA | MDMB(N)-CHM | C22H31N3O3; Methyl (2S)-2-[[1-(cyclohexylmethyl)-1H-indazole-3-carbonyl]amino]-3,3-dimethylbutanoate | Y | . | Y |
| 634  | MDMB-FUBICA | N/A | C23H25FN2O3; methyl (2S)-2-[[1-(4-fluorophenyl)methyl]-1H-indol-3-yl(formamido)-3,3-dimethylbutanoate | Y | Y | Y |
| 635  | MDMB-FUBINACA | MDMB(N)-Bz-F; FUB-MDMB; MDMB(N)-B2-FMeth | C22H24FN3O3; Methyl (2S)-2-[[1-[[4-fluorophenyl)methyl]indazole-3-carbonyl]amino]-3,3-dimethylbutanoate | Y | Y | Y |
| 636  | MDMB-PCZCA | Methyl 3-methyl-N-(9-pentyl-9H-carbazole) | C25H32N2O3 Methyl (2S)-3,3-dimethyl-2-[[9-pentyl-9H-carbazole-3-carbonyl]amino]butanoate | Y | Y | Y |
| 637  | ME-CP 47,497 | N/A | C18H7NO3; 2-[[1S,3R]-3-Hydroxycyclohexyl]-5-[[2-(methylaminomethyl)phenol] | . | . | Y |
| 638  | MENABITAN | SP-204; menabitan hydrochloride | C37H56N2O3; 5,5-Dimethyl-8-(3-methyloctan-2-yl)-2-(prop-2-yn-1-yl)-1,3,4,5-tetrahydro-2H-[1]benzopyran-4,3-c)pyrind-10-yl-2-methyl-4-[2-methylpiperidin-1-yl]butanoate | . | . | Y |
| 639  | MEP-CHMICA | N/A | C22H30N2O3; methyl 2-[1-(cyclohexylmethyl)-1H-indole-3-carboxamido]pentanoate | Y | . | . |
| 640  | MEP-FUBICA | N/A | C22H23FN2O3; Methyl 2-[[1-[[4-fluorophenyl)methyl]-1H-indole-3-carbonyl]amino]pentanoate | Y | . | Y |
| 641  | MEPIRAPIM | N/A | C19H7NO3; 1-[[1-pentylindol-3-carbonyl]-4-methyl-piperazine3-[4-methylpiperazin-1-yl]carbonyl]-1-pentyl-1H-indole(4-methylpiperazin-1-yl)[1-pentyl-1H-indol-3-yl)methanone | Y | Y | Y |
| 642  | META-RCS-4 | RCS-3 | C21H23N2O2; [3-Methoxyphenyl]-1-pentyl-1H-indol-3-ylmethanone | Y | . | Y |
| 643  | METHANANDAMIDE. | AM-356 | C23H39NO2; [5Z,8Z,11Z,14]-N-[[2R]-1-Hydroxypropan-2-ylicosa-5,8,11,14-tetraenamide | Y | Y | Y |
| 644  | METHYL (2S)-2-[[[7-METHOXY-2-METHYL-1-[[MORPHOLIN-4-YL]ETHYL]1H-INDOLE-3-CARBONYL]AMINO]-3-PHENYLPROPANOATE | Methyl N-[[7-methoxy-2-methyl-1-[[methylaminomethyl]1H-indole-3-carbonyl]yl]phenylalaninate | C22H23N3O5; Methyl (2S)-2-[[7-methoxy-2-methyl-1-[[2-(methylaminomethyl)1H-indole-3-carbonyl]amino]-3-phenylpropanoate | . | . | Y |
| 645  | METHYL (2S)-3-[4-HYDROXYPHENYL]-2-[[[2E]-3-[4-METHOXY-3-(PENTOXY)PHENYL]PROP-2-ENYL]AMINO]PROPANOATE | Methyl N-[[2E]-3-[4-methoxy-3-(pentilloxy)phenyl]prop-2-enyl]L-tyrosinate | C25H31N6O6; Methyl (2S)-3-[[4-hydroxyphynol]-2-[[[2E]-3-[4-methoxy-3-(pentilloxy)phenyl]prop-2-enyl]amino]propanoate | . | . | Y |
| 646  | METHYL (3Z)-3-[[2-METHOXYPHENYL]AMINO]-2-THIA-4-AZASPIRO[5.5]UNDECANE-4-CARBODITHIOATE | N/A | C18H24N2O3S3; Methyl (3Z)-3-[[2-methoxyphenyl]amino]-2-thia-4-azaspiro[5.5]undecane-4-carbodithioate | . | . | Y |
| 647  | METHYL (3Z)-3-[[3-TERT-BUTYL-1,2-OXAZOL-5-YL]IMINO]-2-OXA-4-AZASPIRO[5.5]UNDECANE-4-CARBODITHIOATE | N/A | C18H27N3O2S2; Methyl (3Z)-3-[[3-tert-butyl-1,2-oxazol-5-yl]imino]-2-oxa-4-azaspiro[5.5]undecane-4-carbodithioate | . | . | Y |
| 648  | METHYL (3Z)-3-[[4-TERT-BUTYL-1,3-THIAZOL-2-YL]IMINO]-2-OXA-4-AZASPIRO[5.5]UNDECANE-4-CARBODITHIOATE | N/A | C18H27N3O2S3; Methyl (3Z)-3-[[4-tert-butyl-1,3-thiazol-2-yl]imino]-2-oxa-4-azaspiro[5.5]undecane-4-carbodithioate | . | . | Y |
| 649  | METHYL (3Z)-3-[[NAPHTHALEN-1-YL]IMINO]-2-OXA-4-AZASPIRO[5.5]UNDECANE-4-CARBODITHIOATE | N/A | C21H24N2O2S2; Methyl (3Z)-3-[[naphthalen-1-yl]imino]-2-oxa-4-azaspiro[5.5]undecane-4-carbodithioate | . | . | Y |
| 650  | METHYL (3Z)-3-[[NAPHTHALEN-1-YL]IMINO]-2-THIA-4-AZASPIRO[5.5]UNDECANE-4-CARBODITHIOATE | N/A | C21H24N2S3; Methyl (3Z)-3-[[naphthalen-1-yl]imino]-2-thia-4-azaspiro[5.5]undecane-4-carbodithioate | . | . | Y |
| 651  | METHYL 1-[[OXAN-4-YL]METHYL]-3-[[2,2,3,3-TETRAMETHYLCYCLOPROPANE-1-CARBONYL]-1H-INDOLE-6-CARBOXYLATE | N/A | C24H31N4O4; Methyl 1-[[oxan-4-yl]methyl]-3-[2,2,3,3-tetramethylcyclopropane-1-carbonyl]-1H-indole-6-carboxylate | . | . | Y |
| 652  | METHYL 6-[[2-HYDROXY-3',5'-DIMETHYL[1,1'-BIPHENYL]-4-YL]-6-METHYLPENTANOATE | N/A | C23H30O3; METHYL 6-[[2-HYDROXY-3',5'-DIMETHYL[1,1'-BIPHENYL]-4-YL]-6-METHYLHEPTANOATE | . | . | Y |
| 653  | MFUBINAC | methyl 1-[[4-fluorobenzyl]-1H-indazole-3-carboxylate, Methyl 1-[[4-fluorophenyl]methyl]indazole-3-carboxylate | C16H13FN2O2; methyl 1-[[4-fluorobenzyl]-1H-indazole-3-carboxylate | Y | . | . |
| 654  | MK-4409 | N/A | C23H18CIF2N2O2S; 2-[[4-[5-[5-Chloropyridin-2-yl]-sulfanyl]-2-[4-fluorophenyl]-1,3-oxazol-4-yl]phenyl]propan-2-ol | . | . | Y |
| 655 | MK-9470 | N/A | C2H9N3O3; N-[[25,35)-3-(3-Cyanophenyl)-4-(4-ethoxyphenyl)butan-2-yl]-2-methyl-2-[[5-methyl(pyridin-2-yl)oxy]propanamide | . | . | Y |
| 656 | MMB-022 | AMB-4en-PICA | C2OH26N2O3; methyl (1-[pent-4-en-1-yl]-1H-indole-3-carboxyl)-L-valinate; | . | Y | Y |
| 657 | MMB-CHMICA | AMB-CHMICA | C2H30N2O2 Methyl (2S)-2-[[1-(cyclohexylmethyl)-1H-indole-3-carboxyl]amino]-3-methylbutanoate | Y | Y | Y |
| 658 | MMB-PICA | Methyl-3-methyl-2-[[1-pentyl-1H-indole-3-carboxamido]butanoate; MMB-018 | C2OH28N2O3; Methyl-3-methyl-2-[[1-pentyl-1H-indole-3-carboxamido]butanoate | Y | . | . |
| 659 | MMB-PINACA | N/A | C19H27N3O3; Methyl-3-methyl-2-[[1-pentyl-1H-indole-3-carboxamido]butanoate | Y | . | . |
| 660 | MN-18 | N/A | C2H23N3O; N-(napthalen-1-yl)-1-pentyl-1H-indazole-3-carboxamide | Y | Y | Y |
| 661 | MN-25 | UR-12 | C2H63N7O3; 7-Methoxy-1-[2-(morpholin-4-yl)ethyl]-N-((1S,2R,4R)-1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl)-1H-indole-3-carboxamide | . | . | Y |
| 662 | MO-CHMINACA | MO-AMB | C2H23N2O4; 1-methoxy-3,3-dimethyl-1-oxobutan-2-yl-1-(cyclohexylmethyl)-1H-indazole-3-carboxylate | Y | Y | Y |
| 663 | MPM-CP 47,497 | N/A | C19H29N2O2; 2-[[1,3,5]-3-Hydroxycyclohexyl-5-[[1-methylpiperidin-2-yl]methyl]phenol | . | . | Y |
| 664 | MPP-CHMICA | N/A | C2H63N2O3; Methyl (25)-2-[[1-(cyclohexylmethyl)-1H-indole-3-carboxy]amino]-3-phenylpropanoate | . | . | Y |
| 665 | MPP-CHMINACA | N/A | C25H29N3O3; Methyl (25)-2-[[1-(cyclohexylmethyl)-1H-indole-3-carboxy]amino]-3-phenylpropanoate | . | . | Y |
| 666 | MPP-FUBICA | N/A | C2H62N3O2; Methyl (25)-2-[[1-(4-fluorophenyl)ethyl]-1H-indole-3-carboxy]amino]-3-phenylpropanoate | . | . | Y |
| 667 | MPP-FUBINACA | N/A | C25H22N3O3; Methyl (25)-2-[[1-[4-(fluorophenyl)methyl]-1H-indole-3-carboxy]amino]-3-phenylpropanoate | . | . | Y |
| 668 | N-[(1-AMINO-3-METHYL-1-OXOBUTAN-2-YL)-1-(PHENYL METHYL)-1H-INDAZOLE-3-CARBOXAMIDE, N-[(1-CARBAMOYL-2-METHYLPROPYL)-1-(PHENYL METHYL)1H-INDAZOLE-3-CARBOXAMIDE | N/A | C2OH22N2O2; N-[(1-Amino-3-methyl-1-oxobutan-2-yl)]-1-(phenylmethyl)-1H-indazole-3-carboxamide, N-[(1-Carbamoyl-2-methylpropyl)-1-(phenylmethyl)-1H-indazole-3-carboxamide | Y | . | . |
| 669 | N-[(1-AMINO-3-METHYL-1OXOBUTAN-2-YL)-1-(PHENYL METHYL)-1H-INDOLE-3-CARBOXAMIDE, N-[(1-CARBAMOYL-2-METHYLPROPYL)-1-(PHENYL METHYL)-1H-INDOLE-3-CARBOXAMIDE | N/A | C2H12N3O2; N-[(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(phenylmethyl)-1H-indole-3-carboxamide, N-[(1-Carbamoyl-2-methylpropyl)-1-(phenylmethyl)-1H-indole-3-carboxamide | Y | . | . |
| 670 | N-[2-METHOXYETHYL]-N-[1-METHYLETHYL]-2-{1-PENTYL-1H-INDOL-3-YL}-4-THIAZOL-METHANAMINE | N/A | C2H33N3O; N-[2-METHOXYETHYL]-N-[1-METHYLETHYL]-2-{1-PENTYL-1H-INDOL-3-YL]-4-THIAZOL-METHANAMINE | Y | Y | Y |
| 671 | N-[5-HYDROXYPENTYL]-JWH-122 | 5-HO-JWH-122; MAM2201 N-[5-hydroxypentyl] | C25H25N2O2; [5-(Hydroxypentyl)-1H-indol-3-yl] [4-methylnapthalen-1-yl]methane | Y | . | . |
| 672 | N-[6-QUINOLINYL]-1-PENTYL-1H-INDAZOLE-3-CARBOXAMIDE | N/A | C2H22N2O4; 1-pentyl-N-(quinolin-6-yl)-1H-indazole-3-carboxamide | Y | . | . |
| 673 | N-[ADAMANTAN-1-YL]-2-OXO-1-PENTYL-1,2-DIHYDROQUINOLINE-3-CARBOXAMIDE | N/A | C2H52N2O2; N-(Adamantan-1-yl)-2-oxo-1-pentyl-1,2-dihydroquinoline-3-carboxamide | . | . | Y |
| 674 | N-[ADAMANTAN-1-YL]-4-OXO-1-PENTYL-7-PHENYLSULFANYL-1,4-DIHYDROQUINOLINE-3-CARBOXAMIDE | N/A | C3H13N6O2N2S; N-(Adamantan-1-yl)-4-oxo-1-pentyl-7-(phenylsulfanyl)-1,4-dihydroquinoline-3-carboxamide | . | . | Y |
| 675 | N-[ADAMANTAN-1-YL]-4-OXO-8-PENTOXY)-1,4-DIHYDROQUINOLINE-3-CARBOXAMIDE | N/A | C2H52N2O3; N-(Adamantan-1-yl)-4-oxo-8-pentoxy)-1,4-dihydroquinoline-3-carboxamide | . | . | Y |
| 676 | N-[ADAMANTAN-1-YL]-7-FLUORO-4-OXO-1-PENTYL-1,4-DIHYDROQUINOLINE-3-CARBOXAMIDE | N/A | C2H53N1F2O2; N-(Adamantan-1-yl)-7-fluoro-4-oxo-1-pentyl-1,4-dihydroquinoline-3-carboxamide | . | . | Y |
| 677 | N-[CYCLOBUTYL]METHYL)-3-(4-[1H]-1,2,3-TRIAZOL-1-YLMETHYL]NAPHTHALEN-1-CARBONYL]AMINO]PYRIDIINE-2-CARBOXAMIDE | N/A | C2H24N6O2; N-(Cyclobutylmethyl)-3-(4-[1H]-1,2,3-triazol-1-yl)methyl]napthalene-1-carbonyl]amino]pyridine-2-carboxamide | . | . | Y |
| Citation | Formula | Molecular Weight | Properties |
|----------|---------|------------------|------------|
| 685 | N-(15)-1-Cyclohexylethyl-4-methyl-3-[piperidine-1-sulfonil]benzamide | C21H22N2O3S | Y | Y |
| 686 | N-[3-[7-Chloro-1-[[oxan-4-yl]methyl]-1H-indol-3-yl]-1,2,4-oxadiazol-5-yl]methyl-N,N'-trimethylsulphuric diamide | C20H26ClN2O4S | Y | Y |
| 687 | N-[3,4-Dichlorophenyl]methyl-4-oxo-1-pentyl-7-phenyl-1,4-dihydroquinoline-3-carboxamide | C28H26ClN2O4S | Y | Y |
| 688 | N-[3-(2-Methoxyethyl)-1,3-benzothiazol-2-yliden]-2,2,3,3-tetramethylcyclopropane-1-carboxamide | US 2008/058335 #62 | Y | Y |
| 689 | N-[3-(2-Methoxyethyl)-1,3-thiazol-2-yliden]-naphthalene-1-carboxamide | US 2008/058335 #16 | Y | Y |
| 690 | N-[3-Butyl-5-[2-hydroxyprop-2-yl]-4-methyl-1,3-thiazol-2-yliden]-5-chloro-2-methoxybenzamide | US 2008/058335 #313 | Y | Y |
| 691 | N-[2-(Cyclobutylmethyl)carbamoyl]pyrindin-3-ylquinoline-4-carboxamide | C21H20N2O3S | Y | Y |
| 692 | N-[4-Chloro-2-[[cyclohexylmethyl]carbamoyl]phenyl]naphthalene-1-carboxamide | N/A | Y | Y |
| 693 | N-Benzyl-6-methoxy-3-[2-[morpholin-4-yl]ethoxy]-1-benzofuran-2-carboxamide | N/A | Y | Y |
| 694 | N-Cycloheptyl-1-[[4-fluorophenyl]methyl]-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide | N/A | Y | Y |
| 695 | N-Cycloheptyl-1-[[4-fluorophenyl]methyl]-7-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide | N/A | Y | Y |
| 696 | N-Cycloheptyl-1-[2-(morpholin-4-yl)ethyl]-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide | N/A | Y | Y |
| 697 | N-Cycloheptyl-1-[2-(morpholin-4-yl)ethyl]-4-oxo-1,4-dihydroquinoline-3-carboxamide | N/A | Y | Y |
| 698 | N-Cyclohexyl-1-[[4-fluorophenyl]methyl]-7-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide | N/A | Y | Y |
| 699 | N-Methyl-levonantradol | N/A | Y | Y |
| 700 | N,N-Dimethyl-5-[[4-biphenyl]methy]tetrazole-2-carboxamide | LY2183240-2'-isomer | Y | Y |
| Compound Description                                                                 | CAS Number | Synonyms                                                                 |
|-------------------------------------------------------------------------------------|------------|--------------------------------------------------------------------------|
| N’-[2-OXO-1-PENTYL-1,2-DIHYDRO-3H-INDOL-3-YLIDENE]BENZOHYDRAZIDE                    | C20H21N3O2 | N’-[2-Oxo-1-pentyl-1,2-dihydro-3H-indol-3-ylidene]benzohydrazide         |
| N’-[1-(CYCLOHEXYLMETHYL)-2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE]BENZOHYDRAZIDE       | C22H23N3O2 | N’-[1-(Cyclohexylmethyl)-2-oxo-1,2-dihydro-3H-indol-3-ylidene]benzohydrazide |
| N’-[1-(CYCLOHEXYLMETHYL)-6-[2-(MORPHOLIN-4-YL)ETHOXY]-2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE]-2-PHENYLACETOHYDRAZIDE | C29H36N6O4 | N’-[1-(Cyclohexylmethyl)-6-[2-(morpholin-4-yl)ethoxy]-2-oxo-1,2-dihydro-3H-indol-3-ylidene]-2-phenylacetoxydrazide |
| NABAZENIL                                                                          | SP-175; Nabazelinum | C35H55N3O3; 6,6,9-Trimethyl-3-[3-methyloctan-2-yl]-7,8,9,10-tetrahydro-6H-dibenzo[b,d]pyran-1-yl 4-(azepan-1-yl)butanoate |
| NABILONE                                                                           | N/A        | C24H36O3; rac-(6aR,10aR)-1-Hydroxy-6,6-dimethyl-3-[2-(methyloctan-2-yl)-6,6a,7,10,10a-hexahydro-9H-dibenzo[b,d]pyran-9-one |
| NABITAN                                                                            | SP-106; Abbott 40656; Benzozyranoperidine | C35H55N3O3; 5,5-Dimethyl-8-(3-methyloctan-2-yl)-2-[(prop-2-yn-1-yl)-1,3,4,5-tetrahydro-2H-[1]benzopyran-4,3-c]pyridin-10-yl 4-(pip eridine-1-yl)butanoate |
| NABIXIMOLS                                                                         | Sativex; combination of Tetrahydrocannabinol and Cannabinoid | . . Y |
| NABOCTATE                                                                          | SP-325     | C33H53N3O3; [6,6,9-trimethyl-3-nonan-2-yl-7,8,9,10-tetrahydrobenzo[c]chromen-1-yl] 4-(diethylaminobutanoate |
| NAPHTALEN-1-YL-BENZYL-1H-INDOLE-3-CARBOXILATE                                       | N/A        | C26H19N2O; Naphthalen-1-yl-1-benzyl-1H-indole-3-carboxylate Y . . |
| NAPHTALEN-1-YL[1-(PENT-4-ENYL)-1H-PYRROLO[2,3-B]PYRIDIN-3-YL]METHANONE               | N/A        | C23H20N2O; Naphthalen-1-yl[1-(pent-4-enyl)-1H-pyrrole[2,3-b]pyridin-3-yl]m ethanone Y . . |
| NAPI                                                                                | N/A        | C25H25N5O; 2-[Naphthalen-1-yl-1-(1-pentyl-1H-indol-3-yl)ethan-1-one Y . . Y |
| NBB-22                                                                              | N/A        | C24H23N3O2; Quinolin-8-yl 1-(cyclohexylmethyl)-1H-indazole-3-carboxylate . . Y |
| NESS-040CS                                                                         | N/A        | C27H33N3O5; 1-[[4-Methylphenyl]methyl]-N-[5-methyl-2-[propan-2-yl]cyclohexyl]-1,4-dihydrithienn[3',2',4',5,cyclopenta[1,2,c]pyrazole-3-carboxamide |
| NM-2201                                                                            | CBL-2201   | C24H22F2NO2; Naphthalen-1-yl-1-(5-fluoropentyl)-1H-indole-3-carboxylate Y Y Y |
| NM-CHM                                                                             | N/A        | C26H25NO2; Naphthalen-1-yl-1-(cyclohexylmethyl)-1H-indole-3-carboxylate . . Y |
| NMP-7                                                                              | N/A        | C23H28N2O; [9-Pentyl-9H-carbazol-3-yl]pip eridine-1-yl)methanone . . Y |
| NNEI 2-INDOAZOLE ISOMER                                                             | N-(naphthalen-1-yl)-2-pentyl-2H-indazole-3-carboxamide; NNEI 2'-indazole isomer | C23H23N3O; N-(napthalen-1-yl)-2-pentyl-2H-indazole-3-carboxamide Y . . |
| NNL-1                                                                              | N/A        | C17H23F3N4O2; N-[{(2S)-1-Amino-1-oxobutan-2-yl}-1-(5-fluoropentyl)-1H-pyrrolo[2,3-b]pyridine-3-carboxamide |
| NNL-2                                                                              | BZP-2201; 5F-BEPIRAPIM | C25H30F3N3O; [4-Benzylpip erizin-1-yl][1-(5-fluoropentyl)-1H-indol-3-yl]methanone |
| NNL-3                                                                              | N/A        | C19H18F5N5O2; 1-[1-(5-fluoropentyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl(oxy)-1H-benzotriazole |
| NONABINE                                                                           | BRL-4664   | C25H33N3O2; 2,2-Dimethyl-7-[4-(methyloctan-2-yl)-4-(pyridin-4-yl)-2H-1-benzopyran-5-ol |
| O-1057                                                                             | N/A        | C32H46N2O4; (6aR,10aR)-3-(6-Cyano-2-methylhexan-2-yl)-6,6,9-trimethyl-6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-1-yl 4-(morpholin-4-yl)butanoate |
| O-1064                                                                             | N/A        | C26H44F4NO; [5Z,8Z,11Z,14Z]-N-(2-Fluoroethyl)-2,16,16-trimethylhenicosa-5,8,11,14-tetraenamide |

*Note: The table entries include CAS numbers and synonyms for various chemical compounds.*
|          |     |   |                                                                  |
|----------|-----|---|------------------------------------------------------------------|
| 724      | O-1125 | N/A | C26H39NO3; 6-[(6aR,10aR)-1-Hydroxy-6,6,9-trimethyl-6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-3-yl]-N,N,6-trimethylheptanamide | . | . | Y |
| 725      | O-1238 | N/A | C22H29N3O2; (6aR,10aR)-3-[(2Z)-6-Azidohex-2-en-1-yl]-6,6,9-trimethyl-6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-1-ol | . | . | Y |
| 726      | O-1248 | N/A | C19H17C3N4O; 7-Chloro-1-[(2,4-dichlorophenyl)-N-(piperidin-1-yl)-1H-indazole-3-carboxamide | . | . | Y |
| 727      | O-1269 | N/A | C22H22C3N3O; 5-[(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-pentyl-1H-pyrazole-3-carboxamide | . | . | Y |
| 728      | O-1376 | N/A | C25H36O; 5’-Methyl-4-[(2-methylan-2-yl)-2’-[(propan-2-yl][1,1’-biphenyl]-2-ol | . | . | Y |
| 729      | O-1422 | N/A | C21H34O2; 2-Cyclohexyl-5-[(2-methylan-2-yl)benzene-1,3-diol | . | . | Y |
| 730      | O-1424 | N/A | C20H32O2; 2-Cyclopropyl-5-[(2-methylan-2-yl)benzene-1,3-diol | . | . | Y |
| 731      | O-1425 | N/A | C20H32O2S; 5-[(2-Methylan-2-yl)-2-(thian-4-yl)benzene-1,3-diol | . | . | Y |
| 732      | O-1601 | N/A | C25H36O2; 5’-Hydroxymethyl]-4-[(2-methylan-2-yl)-2’-[(propan-2-yl][1,1’-biphenyl]-2-ol | . | . | Y |
| 733      | O-1602 | N/A | C17H22O2; (1’R,2’R)-5,6-Dimethyl-2’-[(prop-1-en-2-yl]-1’2’,3’,4’-tetrahydro[1,1’-biphenyl]-2,4-diol | . | . | Y |
| 734      | O-1656 | N/A | C22H36O2; 2-Cyclohexyl-5-[(2-methylan-2-yl)benzene-1,3-diol | . | . | Y |
| 735      | O-1658 | N/A | C22H36O2; 2-(2-Methylcyclohexyl)-3-[(2-methylan-2-yl)benzene-1,3-diol | . | . | Y |
| 736      | O-1660 | N/A | C25H38O2; 2-[(Adamantan-2-yl]-5-[(2-methylan-2-yl)benzene-1,3-diol | . | . | Y |
| 737      | O-1663 | N/A | C27H38O2; 14-[(2-Methylan-2-yl)-21,22,23,24,25,26-hexahydro[11,11,21,24,31-terphenyl]-12,16-diol | . | . | Y |
| 738      | O-1812 | N/A | C26H42N2O2; (5Z,8Z,11Z,14Z)-20-Cyano-N-[(2R)-1-hydroxypropan-2-yl]-16,16-dimethylcycosa-5,8,11,14-tetraenamide | . | . | Y |
| 739      | O-1826 | N/A | C22H36O2; 2-[(3S)-3-Methylcyclohexyl]-5-[(2-methylan-2-yl)benzene-1,3-diol | . | . | Y |
| 740      | O-1871 | N/A | C23H38O2; 2-[(3,3-Dimethylcyclohexyl)-5-[(2-methylan-2-yl)benzene-1,3-diol | . | . | Y |
| 741      | O-1918 | N/A | C19H26O2; (1R,2R)-2’-[(2,4-Dimethoxy-4’,5-dimethyl-2-[(prop-1-en-2-yl]-1,2,3,4-tetrahydro-1’-biphenyl | . | . | Y |
| 742      | O-1966 | N/A | C24H40O3; 1-[(2,6-Dimethoxy-4-[(2-methylan-2-yl)phenyl]-3-methylcyclohexan-1-ol | . | . | Y |
| 743      | O-2050 | N/A | C23H31NO4S; 6-[(6aR,10aR)-1-Hydroxy-6,6,9-trimethyl-6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-3-yl]-hex-4-yn-1-yl)methanesulfonamide | . | . | Y |
| 744      | O-2113 | N/A | C25H39NO4S; 5-[(6aR,10aR)-1-Hydroxy-6,6,9-trimethyl-6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-3-yl]-5-methyloxylmethanesulfonamide | . | . | Y |
| 745      | O-2372 | N/A | C28H41NO4; 6-[(6aR,10aR)-1-Hydroxy-6,6,9-trimethyl-6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-3-yl]-6-methyl-1-(morpholin-4-yl)heptan-1-one | . | . | Y |
| 746      | O-2373 | N/A | C29H43NO3; 6-[(6aR,10aR)-1-Hydroxy-6,6,9-trimethyl-6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-3-yl]-6-methyl-1-(piperidin-1-yl)heptan-1-one | . | . | Y |
| 747      | O-2545 | N/A | C26H36N2O2; (6aR,10aR)-3-[(6-1H-Imidazol-1-yl)-2-methylhexan-2-yl]-6,6,9-trimethyl-6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-1-ol | . | . | Y |
|   |   |   |   |
|---|---|---|---|
| O-2694 | N/A | C3H60N2O5; (6aR,10aR)-6,6,9-Trimethyl-3-[2-methyl-7-(morpholin-4-yl)-7-oxoheptan-2-yl]-6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-1-yl 4-[di(propan-2-yl)amino]butanoate | . | . | Y |
| O-774 | N/A | C25H35NO2; 7-[(6aR,10aR)-1-Hydroxy-6,6,9-trimethyl-6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-3-yl]-7-methylcyclooctenitrile | . | . | Y |
| O-806 | N/A | C22H27BrO2; (6aR,10aR)-3-(6-Bromohex-2-yn-1-yl)-6,9-trimethyl-6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-1-ol | . | . | Y |
| O-823 | N/A | C23H27NO2; 7-[(6aR,10aR)-1-Hydroxy-6,6,9-trimethyl-6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-3-yl]hept-5-ynenitrile | . | . | Y |
| ORG 27569 | N/A | C24H28ClN3O; 5-chloro-3-ethyl-1H-indole-2-carboxylic acid [2-[4-piperidin-1-yl-phenyl]ethyl]amide | Y | Y | Y |
| ORG 27759 | N/A | C21H24F3N3O; N-[2-[4-(dimethylamino)phenyl]ethyl]-3-ethyl-5-fluoro-1H-indole-2-carboxamide | Y | Y | Y |
| ORG 28312 | N/A | C24H35N3O2; [1-(Cyclohexylmethyl)-7-methoxy-1H-indol-3-yl][[[3R,5S]-3,4,5-trimethylpiperazin-1-yl]methanone | . | . | Y |
| ORG 28611 | SCH-900,111; | C23H33N3O2; [1-(Cyclohexylmethyl)-7-methoxy-1H-indol-3-yl][[(3S)-3,4,5-dimethylpiperazin-1-yl]methyl] | . | . | Y |
| ORG 29647 | N/A | C22H24ClN3O; (R)-N-(1-Benzylpyrrolidin-3-yl)-5-chloro-3-ethyl-1H-indole-2-carboxamide fumarate | Y | Y | Y |
| ORTHO-RCS-4 | RCS-2 | C21H23NO2; [2-Methoxyphenyl][1-pentyl-1H-indol-3-yl]methanone | Y | Y | Y |
| P-F-CUMYL-THPICA | N/A | C24H27FN2O2; N-[2-[4-Fluorophenyl]propan-2-yl]-1-[(oxan-4-yl)methyl]-1H-indole-3-carboxamide | . | . | Y |
| PARAHEXYL | Synhexyl; n-hexyl-Δ3THC; n-Hexyl-D3-THC | C22H23O2; 3-Hexyl-6,6,9-trimethyl-7,8,9,10-tetrahydro-6H-dibenzo[b,d]pyran-1-ol | . | . | Y |
| PB-22 | QUPIC; 1-Pentyl-8-quinoliny1 ester-1H-in | C23H27N2O2; 1-Pentyl-1H-indole-3-carboxylic acid 8-quinoliny1 ester | Y | Y | Y |
| PB-22 N-[2-FLUOROPENTYL] | N/A | C23H21F2N2O2; quinolin-8-yl 1-(2-fluoropentyl)-1H-indole-3-carboxylate | Y | . | . |
| PB-22 N-[4-FLUOROPENTYL] | N/A | C22H20FN3O2; Quinolin-8-yl 1-(4-fluoropentyl)-1H-indazol-3-carboxylate | Y | . | . |
| PENTENYL-CP 47,497 | N/A | C17H24O2; 2-[[1S,3R]-3-Hydroxy cyclohexyl]-5-(pent-4-en-1-yl)phenol | . | . | Y |
| PENTYL NAPHTHOYL BENZIMIDAZOLONE | N/A | C3H22N2O2; 1-(Naphthalene-1-carbonyl)-3-pentyl-1,3-dihydro-2H-benzimidazol-2-one | . | . | Y |
| PENTYL NAPHTHOYL BENZOTHIAZOLE | N/A | C3H23NOS; (Naphthalen-1-yl)[3-pentyl-2,3-dihydro-1,3-benzothiazol-2-yl]methanone | . | . | Y |
| PENTYL NAPHTHOYL PYRAZOLOPYRIDINE 6N | N/A | C22H21N3O; [Naphthalen-1-yl]pyrazol[3,4-c]pyridin-3-yl)methanone | . | . | Y |
| PENTYL NAPHTHOYL PYRAZOLOPYRIDINE 7N | N/A | C22H21N3O; [Naphthalen-1-yl]pyrazol[3,4-b]pyridin-3-yl)methanone | . | . | Y |
| PENTYL NAPHTHOYLIMIDAZOLE | N/A | C15H20N2O; [Naphthalen-1-yl][1-pentyl-1H-imidazol-4-yl]methanone | . | . | Y |
| PENTYL NAPHTHOYLNIDANE | N/A | C25H26O; (Naphthalen-1-yl)[3-pentyl-2,3-dihydro-1H-inden-1-yl]methanone | . | . | Y |
| PENTYL-CP 47,497 | N/A | C17H26O2; 2-[[1S,3R]-3-Hydroxy cyclohexyl]-5-pentylphenol | . | . | Y |
| PERROTTETINENE | cis-PET | C24H28O2; (6aS,10aR)-6,6,9-Trimethyl-3-(2-phenylethyl)-6a,7,8,10a-tetrahydro-6H-dibenzo[b,d]pyran-1-ol | . | . | Y |
| PF-04457845 | PF-04457845; 1020315-31-4; UNII-H4C81MBY | C23H20F3N5O2; N-(Pyridazin-3-yl)-4-[[3-[[5-(trifluoromethyl)pyridin-2-yl]oxy]phenyl]methylidene]piperidine-1-carboxamide | . | . | Y |
|    | Short Running Title of the Article | Journal Name, 2014, Vol. 0, No. 0 | 43 |
|----|-----------------------------------|-----------------------------------|----|
| 773 | PF-3845                           | PF-3845; 1196109-52-0; PF3845; PF 3845 | C24H23F3N4O2; N-(Pyridin-3-yl)-4-[[3-[(5-trifluoromethyl)pyridin-2-yl]oxoy]phenyl]methyl]piperidine-1-carboxamide | . | . | Y |
| 774 | PF-S14273                         | PF-S14273; 851728-60-4; PF S14273; FjMQ | C21H17Cl2F2N3O2; 2-(2-Chloroophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2H-pyrazolo[3,4-f][1,4]oxazepin-8(5H)-one | . | . | Y |
| 775 | PIPISB                           | [11C]PipISB | C27H26FN3O3S; N-[[4-(Fluorophenyl)methyl]-4-[[3-(piperidin-1-yl)1H-indole-1-sulfanyl]benzamid | . | . | Y |
| 776 | PSB-SB-1202                      | N/A | C23H26O4; S-Methoxy-3-[(2-methoxyphenyl)methyl]-7-pentyl-2H-1-benzopyran-2-one | . | . | Y |
| 777 | PSB-SB-487                       | N/A | C26H32O4; S-Hydroxy-3-[[2-(hydroxyphenyl)methyl]-7-(2-methylnonan-2-yl)-2H-1-benzopyran-2-one | . | . | Y |
| 778 | QMPSB                           | N/A | C22H22N2O4S; Quinolin-8-yl-3-{(piperidine-1-sulfanyl)benzate} | . | . | Y |
| 779 | QUINOLIN-8-YL 3-{AZEPANE-1-SULFONYL}BENZOATE | N/A | C22H22N2O4S; Quinolin-8-yl-3-{azepane-1-sulfonyl}benzate | . | . | Y |
| 780 | QUINOLIN-8-YL 3-{PIPERIDINE-1-SULFONYL}BENZOATE | N/A | C21H19N2O4S; Quinolin-8-yl-3-(piperidine-1-sulfanyl)benzate | . | . | Y |
| 781 | QUINOLIN-8-YL 4-METHYL-3-{MORPHOLINE-4-SULFONYL}BENZOATE | N/A | C21H20N2OSS; Quinolin-8-yl-4-methyl-3-(morpholine-4-sulfanyl)benzate | . | . | Y |
| 782 | QUINOLIN-8-YL-1-BENZYL-1H-INDAZOLE-3-CARBOXYLATE | N/A | C24H17N3O2; Quinolin-8-yl-1-benzyl-1H-indazole-3-carboxylate | Y | . | . |
| 783 | QUINOLINYL FLUOROPENTYL FLUOROPHENYL PYRAZOLE CARBOXYLATE | N/A | C24H21F2N3O2; Quinolin-8-yl-1-{(fluorophenyl)-5-[(2-fluorophenyl)-1H-pyrazole-3-carboxylate} | . | . | Y |
| 784 | RCS-4                             | 3-[4-Methoxybenzoyl]-1-pentylindole | C21H23N2O2; [4-methoxyphenyl]-1-pentylindol-3-yl)methane | Y | Y | Y |
| 785 | RIMONABANT                        | Acomplia; SR141,716 | C22H21C13N4O; 5-[(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide | Y | . | Y |
| 786 | S-444,823                        | N/A | C25H33N3O4S; 3-[[1-{[(Cyclohexylmethyl)-2-oxo-1,2,5,6,7,8,9,10-octahydrocycloocta[b]pyridine-3-carboxylamin}]-1,3-thiazol-4-yl)propanoic acid | . | . | Y |
| 787 | SDB-002                          | APICA; SDB-001; UNII-HKU510FH74 | C25H34N2O; N-[(Adamanlan-1-yl)methyl]-1-pentyl-1H-indole-3-carboxamide | . | . | Y |
| 788 | SDB-004                          | CHM-PICA | C21H13N3O2; N-(Cyclohexylmethyl)-1-pentyl-1H-Indole-3-carboxamide | . | . | Y |
| 789 | SDB-005                          | N/A | C23H21N2O2; 1-pentyl-1H-indazole-3-carboxylic acid-naphthalen-1-yl ester | Y | Y | Y |
| 790 | SDB-006                          | N/A | C21H24N2O2; N-benzyl-1-pentyl-1H-indole-3-carboxamide | Y | Y | Y |
| 791 | SER-601                          | COR-167 | C28H38N2O2; N-{(Adamantan-1-yl)-4-oxo-1-pentyl-6-(propan-2-yl)-1,4-dihydroquinoline-3-carboxamide | . | . | Y |
| 792 | SGT-10                           | N/A | C25H28N2O2; 1-{(Cyclohexylmethyl)-N-[[15,2R]-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-1H-indole-3-carboxamide | . | . | Y |
| 793 | SGT-100                          | N/A | C24H31F2N2O; N-{(Adamantan-2-yl)-1-{(5-fluorophenyl)-1H-indole-3-carboxamide} | . | . | Y |
| 794 | SGT-101                          | N/A | C21H22F2N2O; 1-{(5-Fluorophenyl)-N-[[4-(fluorophenyl)methyl]-1H-indole-3-carboxamide} | . | . | Y |
| 795 | SGT-108                          | N/A | C20H19Cl2F2N2O; N-[[2,3-Dichlorophenyl]-1-{(5-fluorophenyl)-1H-indole-3-carboxamide} | . | . | Y |
| 796 | SGT-12                          | (CHM)p-CN-JWH-018 | C27H24N2O; 4-[[Cyclohexylmethyl]-1H-indole-3-carboxyl]naphthalene-1-carbonitrile | . | . | Y |
| 797 | SGT-138                          | 2AD-2NE1 | C24H32N2O; N-{(Adamantan-2-yl)-1-pentyl-1H-indole-3-carboxamide | . | . | Y |
| 798 | SGT-139                          | P-F-SDB-006 | C21H23F3N2O; N-[[4-(fluorophenyl)methyl]-1-pentyl-1H-indole-3-carboxamide | . | . | Y |
| 799 | SGT-142 | cis-MYRTanyl-PINACA | C23H33N3O; N-{[(2S)-6,6-Dimethylbicyclo[3.1.1]heptan-2-yl]methyl}-1-pentyl-1H-indazole-3-carboxamide | . | . | Y |
| 800 | SGT-147 | N/A | C24H27FN2O2; 1-(5-Fluoropentyl)-4-oxo-N-{(2-phenylpropan-2-yl)-1,4-dihydroquinoline-3-carboxamide | . | . | Y |
| 801 | SGT-148 | CUMYL-DMBINACA | C23H29N3O; -3,3-Dimethylbutyl]-N-{(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide | . | . | Y |
| 802 | SGT-149 | CUMYL-FUBINACA | C24H22FN3O; 1-[(4-Fluorophenyl)ethyl]-N-{(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide | . | . | Y |
| 803 | SGT-15 | AM-2201 Methoxy naphtyl analog | C25H24F2N3O; Flurophenyl)methyl]-1-(5-fluoropentyl)-1H-indole-3-carboxamide | . | . | Y |
| 804 | SGT-150 | CUMYL-MP MINACA | C24H30N4O; 1-[(2-Isoquinolin-1-yl)ethyl]-N-{(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide | . | . | Y |
| 805 | SGT-152 | N/A | C25H29N3O; 1-{(Bicyclo[2.2.1]heptan-2-yl)ethyl]-N-{(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide | . | . | Y |
| 806 | SGT-156 | CUMYL-CHMICA | C25H30N2O; 1-(Cyclohexylmethyl)-N-{(2-phenylpropan-2-yl)-1H-indole-3-carboxamide | . | . | Y |
| 807 | SGT-157 | p-Ci-CUMYL-PINACA | C22H25ClFN3O; N-{[2-(4-Chlorophenyl)propan-2-yl]-1-pentyl-1H-indazole-3-carboxamide | . | . | Y |
| 808 | SGT-158 | N/A | C22H25CF3N3O; N-{[2-(4-Chlorophenyl)propan-2-yl]-1-(5-fluoropentyl)-1H-indazole-3-carboxamide | . | . | Y |
| 809 | SGT-16 | 5F-AB-001 | C24H30FNO; (Adamantan-1-yl)-3-[5-fluoropentyl]-1H-indol-3-yl]methanone | Y | . | Y |
| 810 | SGT-162 | N/A | C22H24FN3O; 1-(5-Fluoropentyl)-N-{(1-phenyclopropyl)-1H-indazole-3-carboxamide | . | . | Y |
| 811 | SGT-177 | 2AD-2NE1-6F | C24H31FN2O; N-(Adamantan-2-yl)-6-flurono-1-pentyl-1H-indole-3-carboxamide | . | . | Y |
| 812 | SGT-18 | EAM-2232 | C26H24N2O; 5-[3-(4-ethylcarboxaldehyde),1-carbonyl]-1H-indol-1-ylpentanenitrile | . | . | Y |
| 813 | SGT-184 | CUMYL-MEINACA | C23H28N4O2; 1-[(2-Morpholin-4-yl)ethyl]-N-{(2-phenylpropan-2-yl)-1H-indole-3-carboxamide | . | . | Y |
| 814 | SGT-185 | N/A | C20H23N3O; N-{(2-Phenylpropan-2-yl)-1-propyl-1H-indazole-3-carboxamide | . | . | Y |
| 815 | SGT-186 | N/A | C23H29N3O; 1-Hexyl-N-{(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide | . | . | Y |
| 816 | SGT-187 | N/A | C24H31N3O; 1-Heptyl-N-{(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide | . | . | Y |
| 817 | SGT-188 | CUMYL-THPICA | C24H28N2O2; 1-{(Oxan-4-yl)methyl}-N-{(2-phenylpropan-2-yl)-1H-indole-3-carboxamide | . | . | Y |
| 818 | SGT-19 | F-2201; 4'-F-AM-2201; JWH-412; N-[5-fluoropentyl] | C24H21F2N2O; (4-Fluorophenylthalam-1-yl)-[1-(5-fluoropentyl)-1H-indol-3-yl]methanone | Y | Y | Y |
| 819 | SGT-194 | 2AD-ATHPINACA; 2-Adamantyl-TPINACA | C24H31N3O2; N-[Adamantan-2-yl]-1-{(oxan-4-yl)methyl}-1H-indole-3-carboxamide | Y | . | Y |
| 820 | SGT-197 | N/A | C22H23FN2O2; N-[4-Fluorophenyl]ethyl]-1-{(oxan-4-yl)methyl}-1H-indole-3-carboxamide | . | . | Y |
| 821 | SGT-1A | PNI-E | C22H25NO; [3,4-Dimethylphenyl]-penta-1H-indole-3-carboxylic acid | . | . | Y |
| 822 | SGT-20 | 4'-CI-AM-2201; CI-2201 | C24H21CIFNO; (4-Chloronaphthalen-1-yl)-[1-(5-fluoropentyl)-1H-indol-3-yl]methanone | Y | . | Y |
| 823 | SGT-214 | N/A | C22H25FN2O2; 2-Phenylpropan-2-yl-1-{(5-fluoropentyl)-1H-indazole-3-carboxylate | . | . | Y |
| ID  | Title          | Formula                                                                 | log P  | Log D  |
|-----|----------------|-------------------------------------------------------------------------|--------|--------|
| 824 | SGT-22         | C4-APINACA; (C4)-AKB48                                                 |        |        |
| 825 | SGT-225-R      | BLKB-1                                                                  |        |        |
| 826 | SGT-23         | CUMYL-BINACA                                                            |        |        |
| 827 | SGT-233        | N/A                                                                     |        |        |
| 828 | SGT-234        | CUMYL-PIPETINACA                                                        |        |        |
| 829 | SGT-235        | N/A                                                                     |        |        |
| 830 | SGT-237        | CUMYL-P7AICA                                                            |        |        |
| 831 | SGT-240        | N/A                                                                     |        |        |
| 832 | SGT-247        | N/A                                                                     |        |        |
| 833 | SGT-25         | CUMYL-5F-PINACA; 5F-CUMYL-PINACA; GBX                                   |        |        |
| 834 | SGT-250        | N/A                                                                     |        |        |
| 835 | SGT-255        | N/A                                                                     |        |        |
| 836 | SGT-257        | DMH-PINACA                                                              |        |        |
| 837 | SGT-259        | N/A                                                                     |        |        |
| 838 | SGT-260        | N/A                                                                     |        |        |
| 839 | SGT-263        | CUMYL-5F-P7AICA; 5F-CUMYL-P7AICA                                        |        |        |
| 840 | SGT-27         | (Indazole) JWH-122; THJ-122                                            |        |        |
| 841 | SGT-30         | (Indazole) EAM-2201                                                     |        |        |
| 842 | SGT-35         | (Indazole) JWH-081; THJ-081                                            |        |        |
| 843 | SGT-37         | ADAMANTYL-CHMINACA; AKB-CHM                                             |        |        |
| 844 | SGT-38         | (Indazole) JWH-210; THJ-210                                            |        |        |
| 845 | SGT-41         | CUMYL-CHMINACA                                                          |        |        |
| 846 | SGT-42         | CUMYL-THPINACA                                                          |        |        |
| 847 | SGT-43         | N/A                                                                     |        |        |
| 848 | SGT-46         | N/A                                                                     |        |        |
|   |   |   |   |   |   |
|---|---|---|---|---|---|
| 849 | SGT-47 | N/A | C21H29N3OS; 2-Methoxy-N-methyl-N-[(2-[1-penty1-1H-indol-3-yl]-1,3-thiazol-4-yl)methyl]ethan-1-amine | . | . | Y |
| 850 | SGT-48 | PTI-1 | C21H29N3S; N,N-Diethyl-2-[(1-penty1-1H-indol-3-yl)-4-thiazolemethanamine | Y | Y | Y |
| 951 | SGT-49 | PTI-2 | C23H33N3OS; N-[2-Methoxyethyl]-N-[(2-[1-penty1-1H-indol-3-yl]-1,3-thiazol-4-yl)methyl]propan-2-amine | . | . | Y |
| 852 | SGT-5 | N/A | C24H25N3O; 3-(3-Benzyl-1,2,4-oxadiazol-5-yl)-1-(cyclohexylmethyl)-1H-indole | . | . | Y |
| 853 | SGT-50 | (CHM) JWH-122; CHM-122 | C27H27NO; [1-(Cyclohexylmethyl)-1H-indol-3-yl][4-methylnaphthalen-1-yl]methanone | . | . | Y |
| 854 | SGT-52 | N/A | C20H28FN3O; [3S]-3,4-Dimethylpiperazin-1-yl][1-[5-fluoropentyl]-1H-indol-3-yl]methanone | . | . | Y |
| 855 | SGT-53 | N/A | C22H33N3O; [(3R,5S)-4-Ethyl-3,5-dimethylpiperazin-1-yl][1-penty1-1H-indol-3-yl]methanone | . | . | Y |
| 856 | SGT-55 | CUMYL-BICA | C22H26N2O; 1-Butyl-N-[2-phenylpropan-2-yl]-1H-indole-3-carboxamide | Y | Y | Y |
| 857 | SGT-56 | CUMYL-PICA | C23H28N2O; 1-Pentyl-N-[2-fluoropentylpropan-2-yl]-1H-indole-3-carboxamide | Y | Y | Y |
| 858 | SGT-57 | TMCP-PINACA | C20H29N3O; 1-Penty1-N-[2,2,3,3-tetramethylcyclopropyl]-1H-indazole-3-carboxamide | . | . | Y |
| 859 | SGT-58 | (THPM) PB-22; QUTHPIC | C24H22N2O3; Quinolin-8-yl 1-[(oxan-4-yl)methyl]-1H-indole-3-carboxylate | . | . | Y |
| 860 | SGT-59 | CHP-PINACA | C20H29N3O; N-Cycloheptyl-1-penty1-1H-indazole-3-carboxamide | . | . | Y |
| 861 | SGT-60 | p-F-CUMYL-PINACA | C22H26FN3O; N-[2-[4-Fluorophenyl]propan-2-yl]-1-penty1-1H-indazole-3-carboxamide | . | . | Y |
| 862 | SGT-62 | PRAM-2201; PR-2201 | C27H28FNO; [1-[5-Fluoropentyl]-1H-indol-3-yl][4-propylnaphthalen-1-yl]methanone | . | . | Y |
| 863 | SGT-63 | N/A | C23H26F2N2O; 1-(5-Fluoropentyl)-N-[2-[4-fluorophenyl]propan-2-yl]-1H-indole-3-carboxamide | . | . | Y |
| 864 | SGT-64 | N/A | C23H25F2N2O; 1-(5-Fluoropentyl)-N-[2-[4-fluorophenyl]propan-2-yl]-1H-indazole-3-carboxamide | . | . | Y |
| 865 | SGT-66 | BENZYL-PINACA | C20H23N3O; N-Benzyl-1-penty1-1H-indazole-3-carboxamide | . | . | Y |
| 866 | SGT-67 | CUMYL-5F-PICA; SF-CUMYL-PICA | C23H27FN2O; 1-(5-Fluoropentyl)-N-[2-phenylpropan-2-yl]-1H-indole-3-carboxamide | Y | Y | Y |
| 867 | SGT-68 | N/A | C22H22FN3O; [(3R,5S)-4-Ethyl-3,5-dimethylpiperazin-1-yl][1-[5-fluoropentyl]-1H-indol-3-yl]methanone | . | . | Y |
| 868 | SGT-69 | ADB-TFBICA | C19H24F3N3O2; N-[[25]-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-[4,4,4-trifluorobutyl]-1H-indole-3-carboxamide | . | . | Y |
| 869 | SGT-70 | ADB-THPICA | C21H29N3O3; N-[[25]-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-[(oxan-4-yl)methyl]-1H-indole-3-carboxamide | . | . | Y |
| 870 | SGT-78 | CUMYL-4CN-BINACA; CUMYL-CYBINACA | C22H24N4O; 1-(4-Cyanobuty1)-N-[2-phenylpropan-2-yl]-1H-indazole-3-carboxamide | Y | Y | Y |
| 871 | SGT-8 | (CHM) 7-MeO-JWH-081 | C28H29N3O3; [1-(Cyclohexylmethyl)-7-methoxy-1H-indol-3-yl][4-methoxyindophthalen-1-yl]methanone | . | . | Y |
| 872 | SGT-81 | PROPYLPINACA | C16H23N3O; 1-Pentyl-N-propyl-1H-indazole-3-carboxamide | . | . | Y |
| 873 | SGT-83 | PENTYL-PINACA | C18H27N3O; N-1-Dipentyl-1H-indazole-3-carboxamide | . | . | Y |
| 874 | SGT-85 | CHX-PINACA | C19H27N3O; N-Cyclohexyl-1-pentyl-1H-indazole-3-carboxamide | . | . | Y |
| 875 | SGT-86 | 2AD-AK848; 2AD-APINACA | C23H31N3O; N-(Adamantan-2-yl)-1-pentyl-1H-indazole-3-carboxamide | . | . | Y |
| 876 | SGT-87 | DCBN-PINACA | C20H21Cl2N3O; N-[(3,4-Dichlorophenyl)methyl]-1-pentyl-1H-indazole-3-carboxamide | . | . | Y |
| 877 | SGT-88 | THQ-PINACA | C22H25N3O; [3,4-Dihydroquinolin-1(2H)-yl]([1-pentyl-1H-indazol-3-yl)methanone | . | . | Y |
| 878 | SGT-9 | N/A | C6H30N2O; 1-(Cyclohexylmethyl)-N-[(1S)-1,2,3,4-tetrahydrotriphenyl-1-yl]-1H-indole-3-carboxamide | . | . | Y |
| 879 | SPICE | Spice products: Spice Silver; Spice Gold | C21H30O2; C25H38O3; C21H34O2; C22H23NO; C22H25NO2; ... | . | Y | Y |
| 880 | SR-144,528 | N/A | C29H34Cl3N3O; 5-(4-Chloro-3-methylphenyl)-1-[(4-methylphenyl)methyl]-N-[[1S,25,4R]-1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl]-1H-pyrazole-3-carboxamide | . | . | Y |
| 881 | STS-135 | STS-135; 5-fluoro-APICA | C24H31F1N2O; N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide | Y | Y | Y |
| 882 | TEDALINIB | GRC-10693 | C19H21F2N3O; (45,7R)-N-tert-Butyl-1-(2,4-difluorophenyl)-4,5,6,7-tetrahydro-1H-4,7-methanoindazole-3-carboxamide | . | . | Y |
| 883 | THJ-018 | N/A | C23H22N2O; 1-naphthalenyl(1-pentyl-1H-indazol-3-yl)-methanone | Y | Y | Y |
| 884 | THU-2201 | 5F-JWH-018-N; 5F-THJ-018; AM-2201 indazole | C23H21F1N2O; 1-((5-fluoropentyl)-1H-indazol-3-yl)[naphthalen-1-yl)methanone | Y | Y | Y |
| 885 | TINABINOL | SP-119; Tinabinolum | C23H34O2S; 5,5-Dimethyl-8-(3-methyloctan-2-yl)-1,2,3,5-tetrahydrothiopyranono[2,3-c][1]benzopyran-10-ol | . | . | Y |
| 886 | TRANS-1-[2-HYDROXY-4-(1,1-DIMETHYLHEPTYL)PHENYL]-2-(3-HYDROXYPROPYLCYCLOHEXANE | US 4371720 #1-23 | C24H40O2; 2-[(1R,2S)-2-(3-Hydroxypropyl)cyclohexyl]-S-(2-methyloctan-2-yl)phenol | . | . | Y |
| 887 | TRANS-CP 47,497-C8 | trans CP 47,497-C8 homologue | C22H36N2O; 2-((15,3S)-3-hydroxycyclohexyl)S-(2-methylnonan-2-yl)phenol | Y | Y | Y |
| 888 | UR-144 (-2H) | XLR11 N-(4-pentenyl); UR-144 N-(4-pentenyl) | C21H27NO; (1-(pent-4-en-1-yl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone | Y | Y | Y |
| 889 | UR-144 | TMCP-018; KM-X1; MN-001; YX-17 | C21H20NO; (1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone | Y | Y | Y |
| 890 | UR-144 N-(3-CHLOROPENTYL) | N/A | C21H28ClNO; [1-3-chloroindol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone | Y | . | . |
| 891 | URB-447 | N/A | C25H21ClN2O; 2-[(1R,25,5R)-5-Hydroxy-2-(2-hydroxypropyl)cyclohexyl]-5-(2-methyloctan-2-yl)phenol | Y | . | Y |
| 892 | URB-532 | FAAH Inhibitor I; URB532; CHEMBL76745 | C18H21NO3; 4-(Benzoxyl)phenyl butylcarbamate | . | . | Y |
| 893 | URB-597 | KDS-4103 | C20H22NO2; [3-(3-Carbamoylphenyl)phenyl]N-cyclohexylcarbamate | Y | Y | Y |
| 894 | URB-602 | N/A | C19H21NO2; Cyclohexyl [1,1′-bifhenyl]-3-ylcarbamate | Y | . | Y |
| 895 | URB-754 | 86672-58-4 | C16H14N2O2; 6-Methyl-2-(p-tolylamino)-4H-benzo[d][1,3]oxazin-4-one | Y | Y | Y |
| 896 | URB-937 | N/A | C20H22N2O4; 3′-Carbamoyl-6-hydroxy[1,1′-bifhenyl]-3-yl cyclohexylcarbamate | . | . | Y |
| 897 | US 4371720 #1-20 | N/A | C24H40O3; 2-[(1R,25,5R)-5-Hydroxy-2-(2-hydroxypropyl)cyclohexyl]-5- (2-methyloctan-2-yl)phenol | . | . | Y |
| 898 | US 4371720 #1-24 | N/A | C25H42O3; (1R,4S)-3-[(2-Hydroxy-4-(2-methyloctan-2-yl)phenyl]-4-(3-hydroxypropyl)cycloheptan-1-ol | . | . | Y |
| 899 | US 4371720 #1-26 | N/A | C27H45NO3; [1-(1R,4S)-3-[(2-Hydroxy-4-(2-methyloctan-2-yl)phenyl]-4-(3-hydroxypropyl)cycloheptyl]acetamide | . | . | Y |
| 900 | US 4371720 #1-28 | N/A | C24H38O3; [3R,4R]-3-[(2-Hydroxy-4-(2-methyloctan-2-yl)phenyl]-4-(3-hydroxypropyl)cyclohexan-1-one | . | . | Y |
| US Patent | # | Chemical Formula |
|-----------|---|-----------------|
| 4371270 | #1-29 | C2H38O4; 2-[(1R,2R,5R)-5-Hydroxy-2-[3-hydroxypropyl]cyclohexyl]-5-[(2S)-octan-2-yl]oxy]phenol |
| 4371270 | #1-33 | C2H38O4; (1R,4S)-3-[[25]-5-phenylpentan-2-yl]oxy]phenyl]-4-(3-hydroxypropyl)cycloheptan-1-ol |
| 4371270 | #1-6 | C2SH42O3; 2-[[1R,2R,5R]-5-Hydroxy-2-[4-hydroxybutyl]cyclohexyl]-5-[2-methyloctan-2-yl]phenol |
| 4371270 | #1-7 | C2SH44O3; 2-[[1R,2R,5R]-5-Hydroxy-2-[5-hydroxypentyl]cyclohexyl]-5-[2-methyloctan-2-yl]phenol |
| 4371270 | #1-8 | C2SH42O3; 2-[[1R,2R,5R]-5-Hydroxy-2-[3-methoxypropyl]cyclohexyl]-5-[2-methyloctan-2-yl]phenol |
| 4371270 | #2-5 | C2H36O3; 2-[[1S,35,5R]-3-Hydroxy-5-(hydroxymethyl)cyclohexyl]-5-[2-methyloctan-2-yl]phenol |
| 4393138 | #2E | C2H35BrN2O3; (3R)-5-Methyl-2-[[methyl[4]-methyl-2,3-dihydro[1,4]oxazino[2,3,4-hi]indol-6-yl]methanone |
| 4393138 | #2I | C2H26N2O3; 5-Methyl-2-[[methyl[4]-methyl-2,3-dihydro[1,4]oxazino[2,3,4-hi]indol-6-yl](naphthalen-1-yl)methanone |
| 5068234 | #2J | C2H36N2O3; 6-[[1-1H-indol-3-yl]methanone |
| 5068234 | #2M | C2H21F2N2O; 2-Fluorophenyl]1-[[1-methylpyrrolidin-2-yl]methyl]-1H-indol-3-yl)methanone |
| 5292736 | #10 | C2H72N7O; 4-2-[(1E)-2-Methyl-1-[[naphthalen-1-yl]methylidene]-1H-inden-3-yl]ethyl)morpholine |
| 5292736 | #13 | C2H27N3O3; 4-2-[(1E)-1-[[3,4-Dimethoxyphenyl]methylidene]-1H-inden-3-yl]ethyl)morpholine |
| 5292736 | #18 | C2H24N4O2; 4-2-[[3-[2-(Morpholin-4-yl)ethyl]-1H-inden-1-ylidene)methyl]-1H-indole |
| 5292736 | #19 | C2H25N2O; 4-2-[3-[2-(Morpholin-4-yl)ethyl]-1H-inden-1-ylidene)methyl]naphthalen-1-ol |
| 5292736 | #3 | C2H27N2O; 4-2-((1E)-1-[[3,4-Methoxyphenyl]methylidene]-2-methyl-1H-inden-3-yl)ethyl]methylidene |
| 5292736 | #8 | C2H27N2O; 4-2-((1E)-1-[[3,4-Methoxynaphthalen-1-yl]methylidene]-1H-inden-3-yl)ethyl]methylidene |
| 5292736 | #9 | C2H26N5O; 4-2-[(1E)-1-[[Naphthalen-1-yl]methylidene]-1H-inden-3-yl]ethyl)morpholine |
| 6017919 | #1-8 | C2H27N4O; (2E)-N-[[4-Hydroxyphenyl]methyl]-3-[4-methoxy-3-[pentloxy]phenyl]prop-2-enamide |
| 6017919 | #5-2 | C2H27N3O3; N-2-[2-(Hydroxyphenyl)ethyl]-4-[pentoxy]naphthalene-2-carboxamide |
| 6017919 | #7-91 | C2H26N4O5; 7-Methoxy-2,4-dioxy-8-(pentoxy)-N-[2-(pyridin-4-yl)ethyl]-1,4-dihydroquinazoline-3(2H)-carboxamide |
| 6509352 | #25 | C2H25F2N2O4; N-[4-Fluorophenyl]methyl]-7-methoxy-2-oxo-8-(pentoxy)-1,2-dihydroquinoline-3-carboxamide |
| 6930118 | #8 | C2H23N3O; 3-(3-Benzyl-1,2,4-oxadiazol-5-yl)-1-pentyl-1H-indole |
| 7297796 | #17 | C2H31BrN203S; 4-Bromo-3-[piperidine-1-sulfonf]-N-[[1S,25,4R]-1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl]benzamide |
| 7297796 | #33 | C2H30N204S; N-(Adamantan-2-yl)-4-methyl-3-(morpholine-4-sulfonyl)benzamide |
| 7297796 | #36 | C19H26N204S; N-[2R]-Bicyclo[2.2.1]heptan-2-yl]-4-methyl-3-(morpholine-4-sulfonyl)benzamide |
US 7297796 #7
N/A
C2H31BrN203S; 4-Bromo-N-[[6,6-dimethylbicyclo[3.1.1]heptan-2-yl]methyl]-3-piperidine-1-sulfonyl]benzamide

US 7297796 #76
N/A
C2H32N204S; 4-Methyl-N-{[morpholine-4-sulfonyl]-N-[3,3,5-trimethylcyclohexyl]benzamide}

US 7297796 #9
N/A
C18H19BrN204S; N-Benzyl-4-bromo-3-{morpholine-4-sulfonyl}benzamide

US 7304064 #14
N/A
C25H7N3O2; [1-(Cyclohexylmethyl)-7-methoxy-1H-indol-3-yl][[3R,5S]-4-ethyl-3,5-dimethylpiperazin-1-yl]methanone

US 7304064 #17A
N/A
C25H5N3O2; [1-(Cyclohexylmethyl)-7-methoxy-1H-indol-3-yl][9A5]-octahydro-2H-pyrido[1,2-a]pyrazin-2-yl]methanone

US 7700634 #13
N/A
C23H30N4OS; N-[(3R)-3-Cyclohexyl-2,3-dihydro[1,4]oxazino[2,3,4-h]indol-6-yl]-1,2,4-thiadiazol-5-yl]methyl-N-ethylmethylethan-1-amine

US 7700634 #15A
N/A
C22H29ClN4O2S; [1-(3-Chloro-1-{[oxan-4-yl]methyl}-1H-indol-3-yl]-1,3-thiazol-4-yl]methyl-N,4-dimethylpiperazine-2-amine

US 7700634 #20
N/A
C25H34ClN3O5S; [N-[2-{3-Chloro-1-{(cyclohexylmethyl)2-methoxy-N-methylmethylethan-1-amine}

US 7700634 #23D
N/A
C22H28ClN3O2S; N-[2-{[3-Chloro-1-{[oxan-4-yl]methyl}-1H-indol-3-yl]-1,3-thiazol-4-yl]methyl]-2-methoxy-N-methylmethylethan-1-amine

US 7700634 #38
N/A
C23H30N4OS; 1-(Cyclohexylmethyl)-7-methoxy-3-[[pyrrolidin-1-yl]methyl]-1,3,4-thiadiazol-2-yl]-1H-indole

US 7763732 #10A
N/A
C27H37N5O3S; 1-{[3-(3-Ethyl-1-{[oxan-4-yl]methyl}-1H-indol-3-yl]-1,2,4-thiadiazol-5-yl]methyl}-N-(2-hydroxyethyl)piperidine-4-carboxamide

US 7763732 #15
N/A
C20H25ClN4O4S2; N-[3-{7-Chloro-1-{[oxan-4-yl]methyl}-1H-indol-3-yl]-1,2,4-thiadiazol-5-yl]methyl-N-(2-hydroxyethyl)methanesulfonamide

US 7772227 #10
N/A
C26H37N3O5S; [3R]-3-Cyclohexyl-2,3-dihydro[1,4]oxazino[2,3,4-h]indol-6-yl][1R,5S]-4-{(2-methoxethyl)3,5-dimethylpiperazin-1-yl]methanone

US 7772227 #12B
N/A
C23H31N3O3; [[4S]-4-Cyclopentyl-5,6-dihydro-4H-pyrrolo[3,2,1-i]quinolin-1-yl][4-ethylpiperazin-1-yl]methanone

US 7772227 #2
N/A
C25H31N3O2; [3R]-3-Cyclohexyl-2,3-dihydro[1,4]oxazino[2,3,4-h]indol-6-yl][9A5]-octahydro-2H-pyrido[1,2-a]pyrazin-2-yl]methanone

US 7772227 #4
N/A
C23H31N3O2; [3R]-3-Cyclohexyl-2,3-dihydro[1,4]oxazino[2,3,4-h]indol-6-yl][3S]-3,4-dimethylpiperazin-1-yl]methanone

US 7772227 #8
N/A
C23H35N3O2; [3R]-3-Cyclohexyl-2,3-dihydro[1,4]oxazino[2,3,4-h]indol-6-yl][3R,5S]-4-ethyl-3,5-dimethylpiperazin-1-yl]methanone

US 7820144 #2-28
N/A
C21H21IN2O2; (2-Iodophenyl)[1-[(4-methylmorpholin-3-yl)methyl]-1H-indol-3-yl]methanone

US 7820144 #2-31
N/A
C25H24N4O2; [1-[(4-Methylmorpholin-3-yl)methyl]-1H-indol-3-yl][naphthalen-1-yl]methanone

US 8106218 #3.4
N/A
C25H33ClN3O3S; 7-Chloro-1-[[5-Chloropyrrolo[3,1.1]heptan-2-yl]methyl]-4,5-dihydro-1H-thieno[2,3-g]indazole-3-carboxamide

VDM-11
VDM 11; 313998-81-1
C27H39NO2; [52,82,112,142]-N-[4-(Hydroxy-2-methylphenyl)icos-5,8,11,14-tetraenamide

VIRODHAMINE
O-arachidonoylethanolamine; O-AEA
C22H37N2O2; 2-Aminoethyl (52,82,112,142)-icos-5,8,11,14-tetraenamide

WIN 48,098
Pravadoline; Pleconaril; 153168-05-9
C23H26N2O2; [2-Methoxyphenyl][2-methyl-1-[(2-morpholin-4-yl)ethyl]-1H-indol-3-yl]methanone

WIN 53,365
N/A
C26H26N2O2; [2-Methyl-1-[(2-morpholin-4-yl)ethyl]-1H-indol-3-yl]methanone
| Compound | Formula | Description |
|----------|---------|-------------|
| 950      | WIN 54,461 | 6-Bromopradalone C23H25BrN2O3; [6-Bromo-2-methyl-1-[2-[(morpholin-4-yl)ethyl]-1H-indol-3-yl]-[4-methoxyphenyl]-methaneone |
| 951      | WIN 55,212-3 | LSM-15495 C27H26N2O3; [3S]-5-Methyl-3-[[(morpholin-4-yl)methyl]-2,3-dihydro-1H-indol-6-yl]-[naphthalen-1-yl]methaneone |
| 952      | WIN 55,212-2 | WIN 55,212-2 C27H26N2O3; (11R)-2-methyl-11-[(morpholin-4-yl)methyl]-3-[(naphthalene-1-carbonyl)-9-oxa-1-azatricyclo[6.3.1.0^{3,6}]jodeca-2,4(12,5),7-tetraene] |
| 953      | WIN 56,098 | N/A C30H28N2O2; [Anthracen-9-yl]-[2-methyl-1-[2-[(morpholin-4-yl)ethyl]-1H-indol-3-yl]-methaneone |
| 954      | WO 1997/000860 #7 | N/A C27H27BrN2O3; [4-Bromonaphthalen-1-yl]-[7-methoxy-2-methyl-1-[2-(morpholin-4-yl)ethyl]-1H-indol-3-yl]-methaneone |
| 955      | WO 1998/037061 #183 | N/A C21H24N03P; Methyl P-butyl-N-[4-[[naphthalen-1-yl]oxy]phenyl]-phosphonamidate |
| 956      | WO 1998/037061 #216 | N/A C22H26F3N04S; 4-[[(2-Propyl-1,2,3,4-tetrahydroisquinolin-5-yl)oxy]-phenyl-4,4,4-trifluorobutane-1-sulfonate |
| 957      | WO 1998/037061 #274 | N/A C20H22F3N04S; 4,4,4-Trifluoro-N-[(3R)-2-(hydroxymethyl)-2,3-dihydro-1H-inden-4-yl]oxy]phenyl]butane-1-sulfonamide |
| 958      | WO 1998/037061 #34 | N/A C20H21NO4S; N-[3-[[Naphthalen-1-yl]oxy]phenyl]butane-1-sulfonamide |
| 959      | WO 1998/037061 #39 | N/A C18H19N3O3S; N-[6-[(Quinolin-8-yl]oxy][pyridin-3-yl]butane-1-sulfonamide |
| 960      | WO 1998/037061 #51 | N/A C23H19N03S; N-[3-[[Naphthalen-1-yl]oxy]phenyl]-1-phenylmethanesulfonamide |
| 961      | WO 1998/037061 #90 | N/A C20H21N04S2; N-[4-[[Naphthalen-1-yl-sulfanyl]phenyl]butane-1-sulfonamide |
| 962      | WO 1998/037061 #92 | N/A C21H23N04S; N-[4-[[6-(Hydroxymethyl)naphthalen-1-yl]oxy]-phenyl]butane-1-sulfonamide |
| 963      | WO 2000/010967 #1 | N/A C19H17F3O6S; 3-[[2-(Hydroxyethyl)]-1-benzofuran-7-yl]oxy]-phenyl-4,4,4-trifluorobutane-1-sulfonate |
| 964      | WO 2001/058869 #109 | N/A C22H34N4O3S; (7S)-7-[(Morpholin-4-yl)methyl]-N-[[15,25,4R]-1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl]-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-2-carboxamide |
| 965      | WO 2001/058869 #114 | N/A C26H38N2O2; 7-Methoxy-2-methyl-1-phenyl-N-[[15,25,4R]-1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl]-1H-indole-3-carboxamide |
| 966      | WO 2001/058869 #122 | N/A C29H36N2O3S; 7-Methoxy-1-[[4-methoxyphenyl]methyl]-2-methyl-N-[[15,25,4R]-1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl]-1H-indole-3-carboxamide |
| 967      | WO 2001/058869 #18 | N/A C26H32N2O5S; Methyl (2S)-2-[[6-methoxy-2-methyl-7-(pentylxylo)-1H-indole-3-carbonyl]-amino]-3-phenylpropanoate; Methyl N-[[6-methoxy-2-methyl-7-(pentylxylo)-1H-indole-3-carbonyl]-L-phenylalaninate |
| 968      | WO 2001/058869 #184 | N/A C21H25N3O3S; 5-[[2-Methoxyphenyl][methyl]-1-[2-[(morpholin-4-yl)ethyl]-1,5-dihydro-4H-pyrrolo[3,2-c]pyridin-4-one |
| 969      | WO 2001/058869 #189 | N/A C26H34N2O2; 5-Butyl-6-methoxy-2-[[15,25,4R]-1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl]-2,5-dihydro-1H-pyrido[4,3-b]indol-1-one |
| 970      | WO 2001/058869 #190 | N/A C28H31N3O2; 6-Methoxy-5-[(pyridin-4-yl)methyl]-2-[[15,25,4R]-1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl]-2,5-dihydro-1H-pyrido[4,3-b]indol-1-one |
| 971      | WO 2001/058869 #198 | N/A C28H39N3O2; 2-Methyl-1-[2-[(morpholin-4-yl)ethyl]-5-phenyl-N-[[15,25,4R]-1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl]-1H-pyrrole-3-carboxamide |
| Document Identifier | N/A | Chemical Structure |
|---------------------|-----|--------------------|
| WO 2001/058869 #200 | N/A | C29H37N3O2; 1-{[Morpholin-4-yl]ethyl}-2-phenyl-5-[[15,25,4R]-1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl]-1,5-dihydro-4H-pyrollo[3,2-c]pyridin-4-one |
| WO 2001/058869 #204 | N/A | C22H26N4O3; N-Benzyl-7-methoxy-1-{[2-{(morpholin-4-yl)ethyl}]-1H-indazole-3-carboxamide |
| WO 2001/058869 #216 | N/A | C24H28N4O3; N-{[15,2R]-2-Hydrroyy-2,3-dihydro-1H-inden-1-yl}-7-methoxy-1-{[2-(morpholin-4-yl)ethyl]1H-indazole-3-carboxamide |
| WO 2001/058869 #223 | N/A | C25H38N4O3; 7-Methoxy-1-{[2-{(morpholin-4-yl)ethyl}]-N-[2,2,6,6-tetramethylcyclohexyl]-1H-indazole-3-carboxamide |
| WO 2001/058869 #23 | N/A | C26H32N4O4; Methyl (2S)-2-[7-methoxy-2-methyl-1-[2-(morpholin-4-yl)ethyl]-1H-indole-3-carbonyl]amino)-3-phenylpropanoate; methyl (2S)-2-[7-methoxy-2-methyl-1-[2-(morpholin-4-yl)ethyl]-1H-indole-3-carbonyl]-L-phenylalaninamide |
| WO 2001/058869 #231 | N/A | C25H30N4O3; 7-Methoxy-1-{[2-{(morpholin-4-yl)ethyl}]-N-{[15]-1,2,3,4-tetrahydroanthalen-1-yl]1H-indazole-3-carboxamide |
| WO 2001/058869 #232 | N/A | C23H26N4O3; N-{[2H-1,3-Benzodioxol-5-yl]methyl}-7-methoxy-1-{[2-(morpholin-4-yl)ethyl]1H-indazole-3-carboxamide |
| WO 2001/058869 #256 | N/A | C26H36N4O3; N-[[(Adamantan-1-yl)methyl]-7-methoxy-1-{[2-(morpholin-4-yl)ethyl]-1H-indazole-3-carboxamide |
| WO 2001/058869 #261 | N/A | C25H38N4O3; 7-Methoxy-N-[(1R,2S,5R)-5-methyl-2-{(propan-2-yl)cyclohexyl}-1-[2-(morpholin-4-yl)ethyl]-1H-indazole-3-carboxamide |
| WO 2001/058869 #27 | N/A | C24H28N4O4; Methyl (2S)-2-{[1-{(morpholin-4-yl)ethyl}]-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]amino)-3-phenylpropanoate; Methyl N-{[1-{(morpholin-4-yl)ethyl}]-1H-pyrrolo[2,3-b]pyridine-3-carbonyl}-L-phenylalaninate |
| WO 2001/058869 #280 | N/A | C20H28N4O4; 7-Methoxy-1-{[2-{(morpholin-4-yl)ethyl}]-N-{[(2R)-oxolan-2-yl]methyl]-1H-indazole-3-carboxamide |
| WO 2001/058869 #293 | N/A | C24H30N4O3; 7-Methoxy-1-{[2-{(morpholin-4-yl)ethyl}]-N-[2-phenylpropan-2-yl]-1H-indazole-3-carboxamide |
| WO 2001/058869 #30 | N/A | C23H28N4O2; 2-Methyl-1-{[2-{(morpholin-4-yl)ethyl}]-N-[2-(pyridin-2-yl)ethyl]-1H-indole-3-carboxamide |
| WO 2001/058869 #33 | N/A | C27H33N3O6; Methyl (2S)-3-{[4-hydroxypyphenyl]-2-{[(7-methoxy-2-methyl-1-[2-(morpholin-4-yl)ethyl]-1H-indole-3-carbonyl]amino)propanoate; Methyl N-{(7-methoxy-2-methyl-1-[2-(morpholin-4-yl)ethyl])1H-indole-3-carbonyl]-L-tyrosinate |
| WO 2001/058869 #34 | N/A | C23H33N3O5S; Methyl (2S)-2-{[(7-methoxy-2-methyl-1-[2-(morpholin-4-yl)ethyl]-1H-indole-3-carbonyl]amino]-4-[methylsulfonyl]butanoate; Methyl N-{(7-methoxy-2-methyl-1-[2-(morpholin-4-yl)ethyl]-1H-indole-3-carbonyl]-L-methioninate |
| WO 2001/058869 #35 | N/A | C23H33N3O5; Methyl (2S)-2-{[(7-methoxy-2-methyl-1-[2-(morpholin-4-yl)ethyl]-1H-indole-3-carbonyl]amino)-3-methylbutanoate; Methyl N-{(7-methoxy-2-methyl-1-[2-(morpholin-4-yl)ethyl]-1H-indole-3-carbonyl]-L-tyrosinate |
| WO 2001/058869 #391 | N/A | C21H31N5O3; (4-Ethylpipеразин-1-yl)[7-methoxy-1-{[2-(morpholin-4-yl)ethyl]-1H-indazol-3-yl}methanone |
| WO 2001/058869 #40 | N/A | C26H31N3O4; Methyl (2S)-2-{[(2-methyl1-[2-(morpholin-4-yl)ethyl]-1H-indole-3-carbonyl]amino)-3-phenylpropanoate; Methyl N-{(2-methyl-1-[2-(morpholin-4-yl)ethyl]-1H-indole-3-carbonyl]-L-phenylalaninate |
| WO 2001/058869 #41 | N/A | C25H29N2O2; (3,4-Dihydroquinolin-1(2H)-yl)(2-methyl-1-{2-(morpholin-4-yl)ethyl}-1H-indol-3-yl)methanone |
| Patent Number | Source Document Number | CAS Number | Chemical Structure | Year |
|---------------|------------------------|------------|-------------------|------|
| WO 2001/058869 #44 | N/A | C26H33N3O3; 7-Methoxy-2-methyl-N-[1-{4-(methylphenyl)ethyl}-1-[2-[(morpholin-4-yl)ethyl]-1H-indole-3-carboxamide | 2001 |
| WO 2001/058869 #45 | N/A | C24H28N4O4; Methyl (ZS)-2-[[1-{2-[(morpholin-4-yl)ethyl]-1H-indazole-3-carbonyl}amino]-3-phenylpropanoate; Methyl N-[1-{2-[(morpholin-4-yl)ethyl]-1H-indazole-3-carbonyl}]L-phenylalaninate | 2001 |
| WO 2001/058869 #450 | N/A | C21H22Cl2N3O; (2,3-Dichlorophenyl)-7-methoxy-1-[2-[(morpholin-4-yl)ethyl]-1H-indazole-3-carboxamide | 2001 |
| WO 2001/058869 #490 | N/A | C22H22N4O3; N-(Cyclohexylmethyl)-7-methoxy-1-[2-[(morpholin-4-yl)ethyl]-1H-indazole-3-carboxamide | 2001 |
| WO 2001/058869 #50 | N/A | C25H36N4O3; 7-Methoxy-1-[2-[(morpholin-4-yl)ethyl]-N-[naphthalen-1-yl]-1H-indazole-3-carboxamide | 2001 |
| WO 2001/058869 #507 | N/A | C25H34N4O3; (3R)-3-[[Morpholin-4-yl]methyl]-N-[15,25,4R]-1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl]-2,3-dihydro[1,4]oxazino[2,3,4-h][indazole-6-carboxamide | 2001 |
| WO 2001/058869 #55 | N/A | C25H26N4O3; 7-Methoxy-1-[2-[(morpholin-4-yl)ethyl]-N-(naphthalen-1-yl)-1H-indazole-3-carboxamide | 2001 |
| WO 2001/058869 #59 | N/A | C23H21N3O4; Methyl (ZS)-2-((2,5-dimethyl-1-[2-[(morpholin-4-yl)ethyl]-1H-pyrrole-3-carbonyl]amino)-3-phenylpropanoate; Methyl N-[2,5-dimethyl-1-[2-[(morpholin-4-yl)ethyl]-1H-pyrrole-3-carbonyl}L-phenylalaninate | 2001 |
| WO 2001/058869 #66 | N/A | C19H25N3O3; Methyl (ZS)-2-[[1-pentyl-1H-imidazole-4-carbonyl]amino]-3-phenylpropanoate; Methyl N-[1-pentyl-1H-imidazole-4-carbonyl]-L-phenylalaninate | 2001 |
| WO 2001/058869 #78 | N/A | C24H33N3O3; Methyl (ZS)-3,3-dimethyl-2-[[3R]-5-methyl-3-[[1-(morpholin-4-yl)methyl]-2,3-dihydro[1,4]oxazino[2,3,4-h][indole-6-carbonyl]amino]butanoate; Methyl 3-methyl-N-[[3R]-5-methyl-3-[[1-(morpholin-4-yl)methyl]-2,3-dihydro[1,4]oxazino[2,3,4-h][indole-6-carbonyl]L-valinate | 2001 |
| WO 2001/058869 #79 | N/A | C27H7N3O3; (3R)-5-Methyl-3-[[morpholin-4-yl]methyl]-N-[15,25,4R]-1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl]-2,3-dihydro[1,4]oxazino[2,3,4-h]indole-6-carboxamide | 2001 |
| WO 2001/058869 #63 | N/A | C15H16F3N4O5; 3-(4-Ethyl-1H,3-oxazol-2-yl)phenyl 4,4,4-trifluorobutane-1-sulfonate | 2001 |
| WO 2002/042248 #109 | N/A | C27H25N3O3; [4-2-{(Morpholin-4-yl)ethoxy}naphthalen-1-yl](naphthalen-1-yl)methanone | 2002 |
| WO 2002/042248 #38 | N/A | C26H25N3O3; Quinolin-8-yl 4-{hexoxy}naphthalene-1-carboxylate | 2002 |
| WO 2002/042248 #44 | N/A | C26H26O3S; (1-Hexyloxy)-4-(naphthalene-1-sulfonlyphenyl)naphthalene | 2002 |
| WO 2002/042269 #54 | N/A | C21H21Cl2N3O5; [2,3-Dichlorophenyl]-7-ethyl-1-[3-(methylsulfanyl)propyl]-1H-indol-3-yl)methanone | 2002 |
| WO 2003/035005 #1 | N/A | C24H32N4O3; N-(Adamantan-1-yl)-1-[2-((morpholin-4-yl)ethyl]-1H-indazole-3-carboxamide | 2003 |
| WO 2003/035005 #12 | N/A | C21H21N3O3; [2-Iodo]phenyl][1-[[1-methylpiperidin-2-yl]methyl]-1H-indazol-3-yl)methanone | 2003 |
| WO 2003/035005 #2 | N/A | C25H34N4O3; N-(Adamantan-1-yl)-1-[1-methylpiperidin-2-yl]methyl]-1H-indazole-3-carboxamide | 2003 |
| WO 2003/035005 #3 | N/A | C23H28N4O3; N-(Adamantan-1-yl)-1-(4-cyanobutyl)-1H-indazole-3-carboxamide | 2003 |
| WO 2003/035005 #4 | N/A | C22H28Cl3N3O5; N-(Adamantan-1-yl)-1-(4-chlorobutyl)-1H-indazole-3-carboxamide | 2003 |
| 1012 | WO 2003/035005 #5 | N/A | C2H28IN3O; N-(Adamantan-1-yl)-1-(4-iodobutyl)-1H-indazole-3-carboxamide | . | . | Y |
| 1013 | WO 2003/066603 #13 | N/A | C2H24N2O2; Ethyl 2-ethyl-5,7-dimethyl-3-(naphthalen-1-yl)-4-oxo-3,4-dihydroquinazoline-6-carboxylate | . | . | Y |
| 1014 | WO 2003/066603 #2 | N/A | C2H28N4O8S; Ethyl 2-(((2-hydroxyethyl)carbamoyl)oxy)methyl)-5,7-dimethyl-2-(methylsulfamoyl)phenyl)-4-oxo-3,4-dihydroquinazoline-6-carboxylate | . | . | Y |
| 1015 | WO 2003/066603 #93 | N/A | C2H36N4O8S; Cyclobutylmethyl 2-(((2-hydroxy-2-methylpropyl)carbamoyl)oxy)methyl)-5,7-dimethyl-2-(methylsulfamoyl)phenyl)-4-oxo-3,4-dihydroquinazoline-6-carboxylate | . | . | Y |
| 1016 | WO 2004/108688 #8 | N/A | C2H39N3O2; [1-Cyclohexylmethyl]-2-[2-(2-methylbutan-2-yl)-1H-benzimidazol-5-yl]((2R,6S)-2,6-dimethylmorpholin-4-yl)methane | . | . | Y |
| 1017 | WO 2005/016351 #10-030 | N/A | C2H29N3O2; 2-Oxo-N-((1R)-1-phenylethyl)-1-[[pyridin-4-yl]methyl]-1,2,5,6,7,8,9,10-octahydrocyclooct[a]bpyridine-3-carboxamide | . | . | Y |
| 1018 | WO 2005/016351 #11-003 | N/A | C2H32N2O2; 1-(Cyclohexylmethyl)-5,6-dimethyl-2-oxo-N-(2-phenylpropan-2-yl)-1,2-dihydropyridine-3-carboxamide | . | . | Y |
| 1019 | WO 2005/016351 #13-023 | N/A | C2H32N2O2; 1-Butyl-2-oxo-N-(2-phenylpropan-2-yl)-1,2,5,6,7,8-hexahydro-5,8-methanoquinoline-3-carboxamide | . | . | Y |
| 1020 | WO 2005/016351 #13-030 | N/A | C2H36N2O2; 1-Butyl-5-methyl-2-oxo-6-phenyl-N-(2-phenylpropan-2-yl)-1,2-dihydropyridine-3-carboxamide | . | . | Y |
| 1021 | WO 2005/016351 #13-044 | N/A | C2H28N2O3; 1-Butyl-2-oxo-N-(2-phenylpropan-2-yl)-1,5,7,8-tetrahydro-2H-pyrano[4,3-b]pyridine-3-carboxamide | . | . | Y |
| 1022 | WO 2005/016351 #11-103 | N/A | C2H23N3S3; Prop-2-en-1-yl (82)-8-[[quinolin-5-yl]imino]-7-thia-9-azaspiro[4,5]decane-9-carboxthioate | . | . | Y |
| 1023 | WO 2005/028456 #9 | N/A | C2H35N2O2S; N-(Adamantan-1-yl)-4-pentyl-5-phenyl-1,3-thiazole-2-carboxamide | . | . | Y |
| 1024 | WO 2006/129178 #294 | N/A | C2H23F2N3O; 1-(2,4-Difluorophenyl)-N-(2-phenylpropan-2-yl)-4,5,6,7-tetrahydro-1H-4-methanoinazol-3-carboxamide | . | . | Y |
| 1025 | WO 2007/061360 #14 | N/A | C31H29N7O3; N-(Cyclobutylmethyl)-6-[[pyridin-2-yl]methoxy]-3-[[1H-1,2,3-triazol-1-yl]methyl]napthalene-1-carbonyl]amino]pyridine-2-carboxamide | . | . | Y |
| 1026 | WO 2008/032164 #13 | N/A | C2H30N4O3; N-([25]-1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-3-(3,3-dimethybutyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide | . | . | Y |
| 1027 | WO 2008/032164 #132 | N/A | C2H28N8O4N; N-([25]-1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-3-[[oxan-4-yl]methyl]-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide | . | . | Y |
| 1028 | WO 2008/032164 #14 | N/A | C2H31N5O3S; N-([25]-1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-3-[[1-methylpyrperidin-2-yl]methyl]-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide | . | . | Y |
| 1029 | WO 2008/032164 #152 | N/A | C18H26N4O3S; N-([25]-1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-4-methyl-3-[2-(methylsulfanyl)ethyl]-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide | . | . | Y |
| 1030 | WO 2008/032164 #169 | N/A | C2H29F4O4N3; N-([25]-1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-3-(cyclohexylmethyl)-5-fluoro-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide | . | . | Y |
| 1031 | WO 2008/032164 #176 | N/A | C2H31N3O3; 3-(Cyclohexylmethyl)-N-[[25]-1-hydroxy-3,3-dimethylbutan-2-yl]-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide | . | . | Y |
| 1032 | WO 2008/032164 #188 | N/A | C2H24N3O3; 3-(Cyclohexylmethyl)-N-[[15,2R]-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide | . | . | Y |
| Patent Number | Date | Priority Number | Chemical Structure | Note |
|---------------|------|----------------|--------------------|------|
| WO 2008/032164 #199 | N/A | C23H27N3O2; 2-Oxo-3-pentyl-N-[[15]-1,2,3,4-tetrahydronaphthalen-1-yl]-2,3-dihydro-1H-benzimidazole-1-carboxamide | . | Y |
| WO 2008/032164 #200 | N/A | C21H30N4O3; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-3-(cyclohexyl)methyl]-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide | . | Y |
| WO 2008/032164 #202 | N/A | C19H28N4O3; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-2-oxo-3-pentyl-2,3-dihydro-1H-benzimidazole-1-carboxamide | . | Y |
| WO 2008/032164 #21 | N/A | C19H28N6O4; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-3-[2-(morpholin-4-yl)ethyl]-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridine-1-carboxamide | . | Y |
| WO 2008/032164 #217 | N/A | C20H28N4O3; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-3-(2-cyclobutyl)ethyl]-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide | . | Y |
| WO 2008/032164 #218 | N/A | C20H28N4O3; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-3-(3-cycloproplylpropyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide | . | Y |
| WO 2008/032164 #223 | N/A | C19H25NSO3; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-3-(4-cyanobutyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide | . | Y |
| WO 2008/032164 #231 | N/A | C19H22N6O3; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-2-oxo-3-[[pyrimidin-4-yl]methyl]-2,3-dihydro-1H-benzimidazole-1-carboxamide | . | Y |
| WO 2008/032164 #233 | N/A | C18H22N6O4; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-3-[5-methyl-1,2,4-oxadiazol-3-yl]methyl]-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide | . | Y |
| WO 2008/032164 #238 | N/A | C19H23NSO3S; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-3-[[2-methyl-1,3-thiazol-5-yl]methyl]-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide | . | Y |
| WO 2008/032164 #276 | N/A | C24H27N3O3; 3-[[Oxan-4-yl]methyl]-2-oxo-N-[[15]-1,2,3,4-tetrahydronaphthalen-1-yl]-2,3-dihydro-1H-benzimidazole-1-carboxamide | . | Y |
| WO 2008/032164 #292 | N/A | C18H26N4O3; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-3-butyl-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide | . | Y |
| WO 2008/032164 #293 | N/A | C18H23F3N4O3; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-2-oxo-3-[4,4,4-trifluorobutyl]-2,3-dihydro-1H-benzimidazole-1-carboxamide | . | Y |
| WO 2008/032164 #304 | N/A | C21H27FN4O3; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-3-[[4-fluorocyclohex-3-en-1-yl]methyl]-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide | . | Y |
| WO 2008/032164 #306 | N/A | C21H28F2N4O3; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-3-[[4,4-difluorocyclohexyl]methyl]-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide | . | Y |
| WO 2008/032164 #311 | N/A | C21H25N3O4; N-[[2,5-Dimethylfur-3-yl]methyl]-3-[[oxan-4-yl]methyl]-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide | . | Y |
| WO 2008/032164 #312 | N/A | C19H22N4O4; N-[[5-Methyl-1,2-oxazol-3-yl]methyl]-3-[[oxan-4-yl]methyl]-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide | . | Y |
| WO 2008/032164 #328 | N/A | C20H24N4O3S; N-[[2-Ethyl-1,3-thiazol-4-yl]methyl]-3-[[oxan-4-yl]methyl]-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide | . | Y |
| WO 2008/032164 #348 | N/A | C21H24N4O3; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-3-benzyl-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide | . | Y |
| WO 2008/032164 #357 | N/A | C21H23F4N3O3; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-3-[[2-fluorophenyl]methyl]-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide | . | Y |
| 1053 | WO 2008/032164 #359 | N/A | C22H24N6O3; N- [(1S)-1-((5-Amino-1,3,4-oxadiazol-2-yl)-2,2- \dimethylpropyl]-3-benzyl-2-oxo-2,3-dihydro-1H-benzimidazole-1- carboxamide | . | . | Y |
| 1054 | WO 2008/032164 #363 | N/A | C21H23FN4O3; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-3- [(4- fluorophenyl)methyl]-2-oxo-2,3-dihydro-1H-benzimidazole-1- carboxamide | . | . | Y |
| 1055 | WO 2008/032164 #4 | N/A | C20H29N5O4; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-3-[(2- (morpholin-4-yl)ethyl]-2-oxo-2,3-dihydro-1H-benzimidazole-1- carboxamide | . | . | Y |
| 1056 | WO 2008/032164 #47 | N/A | C23H28N4O3; 3-[(Morpholin-4-yl)ethyl]-2-oxo-N-[(2-phenylpropan-2- yl)-2,3-dihydro-1H-benzimidazole-1-carboxamide | . | . | Y |
| 1057 | WO 2008/032164 #5 | N/A | C21H30N4O5; Methyl (2S)-3,3-dimethyl-2-[[3-[(2-(morpholin-4-yl) \ethyl)]-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxyl][methyl]butanoate | . | . | Y |
| 1058 | WO 2008/032164 #54 | N/A | C24H32N4O3; N-(Adamantan-1-yl)-3-[(2-(methylamino)propyl]-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide | . | . | Y |
| 1059 | WO 2008/032164 #73 | N/A | C24H24N6O3; 3-[(Morpholin-4-yl)ethyl]-N-(naphthalen-1-yl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide | . | . | Y |
| 1060 | WO 2008/101995 #1 | N/A | C23H29CN6O2S; 2-[[3-[(7-Chloro-1-[[oxan-4-yl]methyl]-1H-indol-3- \yl]-1,2,4-thiadiazol-5-yl][methyl]piperazin-1-yl]acetamide | . | . | Y |
| 1061 | WO 2008/101995 #24 | N/A | C25H33ClN6O4; 2-[[2S]-4-[[3-[(7-Chloro-1-[[oxan-4-yl]methyl]-1H-indol-3- \yl]-1,2,4-oxadiazol-5-yl][methyl]2-(hydroxymethyl)piperazin-1-yl]-N- \methylacetamide | . | . | Y |
| 1062 | WO 2008/152086 #1 | N/A | C25H33N3O; 3-Butyl-5,5-dimethyl-4-phenyl-N-[(2-phenylpropan-2-yl)- \4,5-dihydro-1H-pyrazole-1-carboxamide | . | . | Y |
| 1063 | WO 2009/024819 #1-29 | N/A | C28H39N3O3; N-[4-(Cyclopropylamino)-4-oxobutyl]-N-ethyl-9-methyl-2- \(oxan-4-yl)-2,2,3,4,9-tetrahydro-1H-carbazole-6-carboxamide | . | . | Y |
| 1064 | WO 2009/037244 #101 | N/A | C25H36FN3O; 5-[(2-Fluorophenyl)-1-pentyl-N-[[1R,2S,4R]-1,7,7- \trimethylbicyclo[2.2.1]heptan-2-yl]-4,5-dihydro-1H-pyrazole-3- \carboxamide | . | . | Y |
| 1065 | WO 2009/037244 #105 | N/A | C24H30FN3O; N-[(4-Fluorophenyl)propan-2-yl]-1-pentyl-5-phenyl- \4,5-dihydro-1H-pyrazole-3-carboxamide | . | . | Y |
| 1066 | WO 2009/106980 #1 | N/A | C18H23NSO2; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-[(3- \cyanopropyl)-1H-indazole-3-carboxamide | . | . | Y |
| 1067 | WO 2009/106980 #10 | N/A | C25H36N4O2; 1-[(Cyclohexylmethyl)-N-[(2S)-1-[(cyclopropylamino)-3,3- \dimethyl-1-oxobutan-2-yl]-1H-indazole-3-carboxamide | . | . | Y |
| 1068 | WO 2009/106980 #133 | N/A | C22H32N4O2; 1-[(Cyclohexylmethyl)-N-[(2S)-5,3,3-dimethyl-1- \(methylamo)-1-oxobutan-2-yl]-1H-indazole-3-carboxamide | . | . | Y |
| 1069 | WO 2009/106980 #15 | N/A | C21H30N4O2; N-[(2S)-1-Amino-4-methyl-1-oxopentan-2-yl]-1- \(cyclohexylmethyl)-1H-indazole-3-carboxamide | . | . | Y |
| 1070 | WO 2009/106980 #173 | N/A | C23H32FN5O3; N-[(2S)-1-[(2-Amino-2-oxoethyl)amino]-3,3-dimethyl-1- \oxobutan-2-yl]-1-(cyclohexylmethyl)-5-fluoro-1H-indazole-3- \carboxamide | . | . | Y |
| 1071 | WO 2009/106980 #188 | N/A | C24H35FN4O3; 1-(Cyclohexylmethyl)-7-fluoro-N-[(2S)-1-[(3- \hydroxypropyl)amino]-3,3-dimethyl-1-oxobutan-2-yl]-1H-indazole-3- \carboxamide | . | . | Y |
| 1072 | WO 2009/106980 #2 | N/A | C17H21N5O2; N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-(3- \cyanopropyl)-1H-indazole-3-carboxamide | . | . | Y |
| 1073 | WO 2009/106980 #249 | N/A | C19H23N7O2; N-[(1S)-1-(5-Amino-1,3,4-oxadiazol-2-yl)-2,2- \dimethylpropyl]-1-(3-cyanopropyl)-1H-indazole-3-carboxamide | . | . | Y |
| Document ID   | Page Number | N/A | Chemical Structure                                                                 | Yaw  | Yaw  |
|---------------|-------------|-----|-------------------------------------------------------------------------------------|-------|-------|
| WO 2009/106980 #252 | 1074        | N/A | C24H35FN4O3; 1-(Cyclohexylmethyl)-6-fluoro-N-[(2S)-1-[(3-hydroxypropyl)amino]-3,3-dimethyl-1-oxobutan-2-yl]-1H-indazole-3-carboxamide | .     | .     |
| WO 2009/106980 #305 | 1075        | N/A | C26H34N6O6; Ethyl 5-[[((2S)-3,3-dimethyl-2-[(1-[(oxan-4-yl)methyl]-1H-indazole-3-carbonyl)amino]butanoyl)amino)methyl]-1,3,4-oxadiazole-2-carboxylate | .     | .     |
| WO 2009/106980 #307 | 1076        | N/A | C25H33N7O4; N-[(2S)-1-[(5-Carboxamoyl-1,3,4-oxadiazol-2-yl)methyl]amino]-3,3-dimethyl-1-oxobutan-2-yl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide | .     | .     |
| WO 2009/106980 #333 | 1077        | N/A | C25H26F3N5O5; N-[(2S)-1-[(2-Amino-2-oxoethyl)amino]-3,3-dimethyl-1-oxobutan-2-yl]-1-(2-oxo-2-[4-(trifluoromethoxy)phenyl]ethyl)-1H-indazole-3-carboxamide | .     | .     |
| WO 2009/106980 #342 | 1078        | N/A | C25H37N5O4; 1-[(2-Cyclohexyl[methyl]amino)-2-oxoethyl]-N-[(2S)-1-[(2-hydroxyethyl)amino]-3,3-dimethyl-1-oxobutan-2-yl]-1H-indazole-3-carboxamide | .     | .     |
| WO 2009/106980 #387 | 1079        | N/A | C24H31N7O5; N-[(2S)-1-[(5-Carboxamoyl-1,2,4-oxadiazol-3-yl)methyl]amino]-3,3-dimethyl-1-oxobutan-2-yl]-1-[(oxan-4-y)methyl]-1H-indazole-3-carboxamide | .     | .     |
| WO 2009/106980 #4   | 1080        | N/A | C21H21N5O2; N-[(2S)-1-Amino-1-oxo-3-phenylpropan-2-yl]-1-(3-cyanopropyl)-1H-indazole-3-carboxamide | .     | .     |
| WO 2009/106980 #433 | 1081        | N/A | C24H36N4O3; 1-(Cycloheptylmethyl)-N-[(2S)-1-[(2-hydroxyethyl)amino]-3,3-dimethyl-1-oxobutan-2-yl]-1H-indazole-3-carboxamide | .     | .     |
| WO 2009/106980 #435 | 1082        | N/A | C21H27CF2N4O2; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-7-chloro-1-[(4,4-difluorocyclohexyl)methyl]-1H-indazole-3-carboxamide | .     | .     |
| WO 2009/106980 #442 | 1083        | N/A | C25H35N5O4; 1-(4-Cyanobutyl)-N-[(2S)-1-[(4-hydroxyoxan-4-yl)methyl]amino]-3,3-dimethyl-1-oxobutan-2-yl]-1H-indazole-3-carboxamide | .     | .     |
| WO 2009/106980 #444 | 1084        | N/A | C19H25F3N4O2; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-[5,5,5-trifluoropropyl]-1H-indazole-3-carboxamide | .     | .     |
| WO 2009/106980 #457 | 1085        | N/A | C20H28N4O2S; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-[thian-4-yl]methyl]-1H-indazole-3-carboxamide | .     | .     |
| WO 2009/106980 #508 | 1086        | N/A | C18H22F4N4O3; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-[7-fluoro-1-[(2,2,2-trifluoroethoxy)ethyl]-1H-indazole-3-carboxamide | .     | .     |
| WO 2009/106980 #528 | 1087        | N/A | C22H30N4O2; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-7-fluoro-1-[(2,2,2-trifluorocyclobutyl)methyl]-1H-indazole-3-carboxamide | .     | .     |
| WO 2009/106980 #545 | 1088        | N/A | C19H23F3N4O2; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-[(3,3-difluorocyclobutyl)methyl]-7-fluoro-1H-indazole-3-carboxamide | .     | .     |
| WO 2009/106980 #575 | 1089        | N/A | C18H22F4N4O2; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-7-fluoro-1-[(4,4,4-trifluorobuty)-1H-indazole-3-carboxamide | .     | .     |
| WO 2009/106980 #586 | 1090        | N/A | C21H25F4N5O2; 1-[(4-Cyanobutyl)-N-[(2S)-3,3-dimethyl-1-oxo-1-[(2,2,2-trifluoroethoxy)amino]butan-2-yl]-7-fluoro-1H-indazole-3-carboxamide | .     | .     |
| WO 2009/106980 #6   | 1091        | N/A | C19H28N4O3; N-[(2S)-1-Hydroxy-3,3-dimethylbutan-2-yl]-1-[(oxan-4-yl)methyl]-1H-pyrazolo[3,4-b]pyridine-3-carboxamide | .     | .     |
| WO 2009/106980 #604 | 1092        | N/A | C19H24F4N4O2; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-7-fluoro-1-[(5,5,5-trifluoropropyl)-1H-indazole-3-carboxamide | .     | .     |
| WO 2009/106980 #610 | 1093        | N/A | C20H29F4N4O2; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-7-fluoro-1H-indazole-3-carboxamide | .     | .     |
| WO 2009/106980 #11  | 1094        | N/A | C25H26F3N7O4; N-[(2S)-1-[(5-Carboxamoyl-1,3,4-oxadiazol-2-yl)methyl]amino]-3,3-dimethyl-1-oxobutan-2-yl]-1-[4-fluorophenyl]methyl]-1H-indazole-3-carboxamide | .     | .     |
WO 2009/106982 #12
N/A
C2OH23NSO2; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-
benzyl-1H-pyrazolo[3,4-b]pyridine-3-carboxamide
. . . Y

WO 2009/106982 #170
N/A
C21H22F2N4O2; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-5-
fluoro-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide
. . . Y

WO 2009/106982 #171
N/A
C24H26F2N4O2; N-[(2S)-1-(Cyclopropylamino)-3,3-dimethyl-
1-oxobutan-2-yl]-5-fluoro-1-[(4-fluorophenyl)methyl]-1H-indazole-
3-carboxamide
. . . Y

WO 2009/106982 #172
N/A
C23H26F2N4O3; 5-Fluoro-1-[(4-fluorophenyl)methyl]-N-[(2S)-1-
(2-hydroxyethyl)amino]-3,3-dimethyl-1-oxobutan-2-yl]-1H-indazole-
3-carboxamide
. . . Y

WO 2009/106982 #175
N/A
C21H22F2N4O2; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-7-
fluoro-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide
. . . Y

WO 2009/106982 #176
N/A
C24H26F2N4O2; N-[(2S)-1-(Cyclopropylamino)-3,3-dimethyl-
1-oxobutan-2-yl]-7-fluoro-1-[(4-fluorophenyl)methyl]-1H-indazole-
3-carboxamide
. . . Y

WO 2009/106982 #177
N/A
C23H26CFN4O3; 7-Fluoro-1-[(4-fluorophenyl)methyl]-N-[(2S)-1-
(2-hydroxyethyl)amino]-3,3-dimethyl-1-oxobutan-2-yl]-1H-indazole-
3-carboxamide
. . . Y

WO 2009/106982 #181
N/A
C21H22CFN4O2; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-7-
chloro-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide
. . . Y

WO 2009/106982 #183
N/A
C23H26CFN4O3; 7-Chloro-1-[(4-fluorophenyl)methyl]-N-[(2S)-1-
(2-hydroxyethyl)amino]-3,3-dimethyl-1-oxobutan-2-yl]-1H-indazole-
3-carboxamide
. . . Y

WO 2009/106982 #226
N/A
C21H21C2FN4O2; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-5,7-
dichloro-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide
. . . Y

WO 2009/106982 #247
N/A
C25H29FN4O4; N-[(2S)-1-[(3R,4R)-3,4-Dihydroxyprop-2-yl]-3,3-
dimethyl-1-oxobutan-2-yl]-1-[(4-fluorophenyl)methyl]-1H-indazole-
3-carboxamide
. . . Y

WO 2009/106982 #282
N/A
C21H21F3N4O2; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-6,7-
difluoro-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide
. . . Y

WO 2009/106982 #6
N/A
C23H23NSO2; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-
benzyl-6-bromo-1H-indazole-3-carboxamide
. . . Y

WO 2009/106982 #330
N/A
C24H25F3N4O2; N-[(2S)-1-(3,3-Difluoroazetidin-1-yl)-3,3-dimethyl-
1-oxobutan-2-yl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide
. . . Y

WO 2009/106982 #336
N/A
C24H26F2N4O2; N-[(2S)-1-(3-Fluoroazetidin-1-yl)-3,3-dimethyl-
1-oxobutan-2-yl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide
. . . Y

WO 2009/106982 #6
N/A
C20H23NSO2; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-
[(pyridin-2-yl)methyl]-1H-indazole-3-carboxamide
. . . Y

WO 2009/106982 #81
N/A
C23H27F4N4O3; 1-[(4-Fluorophenyl)methyl]-N-[(2S)-1-
[2-
hydroxyethyl]amino]-3,3-dimethyl-1-oxobutan-2-yl]-1H-indazole-
3-carboxamide
. . . Y

WO 2009/106982 #99
N/A
C26H23FN5O4S; N-[(2S)-1-[(2-
[Cyclopropanesulfonyl]amino)ethyl]amino]-3,3-dimethyl-1-oxobutan-
2-yl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide
. . . Y

WO 2011/025541 #455
N/A
C20H21F2N3O3; (4aS,5aS)-1-[(2,4-Difluorophenyl)-N-[(4-
hydroxyethyl)oxan-4-yl]-4a,5,5a-tetrahydro-1H-
cyclopropa[4,5]cyclopenta[1,2-c]pyrazole-3-carboxamide
. . . Y
| WO 2011/025541 #493 | N/A | C18H19F2N3O2; 4aS,5aS)-1-{(2,4-Difluorophenyl)-N-(1-hydroxy-2-methylpropan-2-yl)-4,4a,5,5a-tetrahydro-1H-cyclopropa[4,5]cyclopenta[1,2-c]pyrazole-3-carboxamide | . | Y | 1115 |
| WO 2011/025541 #634 | N/A | C21H24F2N5O; (4aS,5aS)-1-{(2,4-Difluorophenyl)-N-(1,1,1-trifluoro-2-methylpropan-2-yl)-4,4a,5,5a-tetrahydro-1H-cyclopropa[4,5]cyclopenta[1,2-c]pyrazole-3-carboxamide | . | Y | 1119 |
| WO 2011/025541 #667 | N/A | C18H23N5O3; (4aS,5aS)-1-{(4,4a,5,5a-tetrahydro-1H-indol-3-yl)-methylamino}-1-oxobutan-2-yl]-4,4a,5,5a-tetrahydro-1H-cyclopropa[4,5]cyclopenta[1,2-c]pyrazole-3-carboxamide | . | Y | 1120 |
| WO 2011/025541 #921 | N/A | C21H19F2N3O2; (4aS,5aS)-1-{(4,4a,5,5a-tetrahydro-1H-indol-3-yl)-methylamino}-1-oxobutan-2-yl]-4,4a,5,5a-tetrahydro-1H-cyclopropa[4,5]cyclopenta[1,2-c]pyrazole-3-carboxamide | . | Y | 1121 |
| WO 2012/116278 #699 | N/A | C18H23N5O3; (4aS,5aS)-1-{(4,4a,5,5a-tetrahydro-1H-indol-3-yl)-methylamino}-1-oxobutan-2-yl]-4,4a,5,5a-tetrahydro-1H-cyclopropa[4,5]cyclopenta[1,2-c]pyrazole-3-carboxamide | . | Y | 1122 |
| WO 2014/015298 #12 | N/A | C28H27NO; 4-{(1E)-1-[1,2-Dihydroacenaphthenyl-5-yl]methylidene}-1H-inden-3-yl]ethylmorpholine | . | Y | 1124 |
| WO 2014/015298 #13 | N/A | C30H27NO; 4-{(1E)-1-[1-(Phenanthren-4-yl)methylidene]-1H-inden-3-yl]ethylmorpholine | . | Y | 1125 |
| WO 2014/015298 #23 | N/A | C22H22NO; 4-(2-{(1E)-1-[1-(2-Iodophenyl)methylidene]-1H-inden-3-yl]ethyl]morpholine | . | Y | 1126 |
| WO 2014/015298 #54 | N/A | C26H27NO3; Methyl 4-{(1-pentyl-1H-indole-3-carbonyl)-4a,8a-dihydronaphthalene-1-carboxylate | . | Y | 1127 |
| WO 2014/015298 #61 | N/A | C27H27NO2; 1-{[(6aR,10aR)-1-(methylamino)-1-oxobutan-2-yl]-4,4a,5,5a-tetrahydro-1H-indol-3-yl)-methylidene]-[(2S)-1H-indol-3-yl]carbonyl)naphthalen | . | Y | 1128 |
| WO 2014/015298 #62 | N/A | C24H22FNO; (4-Fluoro-1-pentyl-1H-indol-3-yl)methanone | . | Y | 1129 |
| WO 2014/015298 #63 | N/A | C24H22FNO; (5-Fluoro-1-pentyl-1H-indol-3-yl)methanone | . | Y | 1130 |
| WO 2014/015298 #64 | N/A | C24H22FNO; (6-Fluoro-1-pentyl-1H-indol-3-yl)methanone | . | Y | 1131 |
| WO 2014/015298 #65 | N/A | C24H22FNO; (7-Fluoro-1-pentyl-1H-indol-3-yl)methanone | . | Y | 1132 |
| WO 2014/015298 #66 | N/A | C29H31NO; 4-(2-{(1E)-1-[4-(Ethylnaphthalen-1-yl)carboxamide | . | Y | 1133 |
| WO 2014/015298 #67 | N/A | C29H31NO; 4-(2-{(1E)-1-[4-(Ethylnaphthalen-1-yl)carboxamide | . | Y | 1134 |
| WO 2014/039042 #1.10 | N/A | C26H34N2O4; 3-{[(4H-1,2,3-triazol-1-yl)propyl 2-[(6aR,10aR)-1-hydroxy-6,6,9-trimethyl-6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-3-yl]-2-methylpropanoate | . | Y | 1135 |
| Document Number | Index Number | Abstract | Y/N |
|-----------------|--------------|----------|-----|
| WO 2014/039042 #1.3 | N/A | C25H33NO4; 4-Cyanobutyl 2-[(6aR,10aR)-1-hydroxy-6,6,9-trimethyl-6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-3-yl]-2-methylpropanoate | Y |
| WO 2014/039042 #1.30 | N/A | C23H32O3S; 5-Propyl 2-[(6aR,10aR)-1-hydroxy-6,6,9-trimethyl-6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-3-yl]-2-methylpropanethioate | Y |
| WO 2014/039042 #1.31 | N/A | C25H37NO3; 3-(Hydroxy-6,6,9-trimethyl-6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-3-yl)-2-methyl-N-pentylpropanamide | Y |
| WO 2014/039042 #1.33 | N/A | C25H36O4; 2-[(6aR,10aR)-1-hydroxy-6,6,9-trimethyl-6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-3-yl]-2-methylpropanoate | Y |
| WO 2014/039042 #1.8 | N/A | C24H31NO4; 3-Cyanopropyl 2-[(6aR,10aR)-1-hydroxy-6,6,9-trimethyl-6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-3-yl]-2-methylpropanoate | Y |
| WO 2014/039042 #2.2 | N/A | C24H34O5; Butyl 2-[(6aR,10aR)-1-hydroxy-9-(hydroxymethyl)-6,6-dimethyl-6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-3-yl]-2-methylpropanoate | Y |
| WO 2014/039042 #2.5 | N/A | C24H31NO5; 3-Cyanopropyl 2-[(6aR,10aR)-1-hydroxy-9-(hydroxymethyl)-6,6-dimethyl-6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-3-yl]-2-methylpropanoate | Y |
| WO 2014/039042 #2.7 | N/A | C27H39NO6; 3-(Morpholin-4-yl)propyl 2-[(6aR,10aR)-1-hydroxy-9-(hydroxymethyl)-6,6-dimethyl-6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-3-yl]-2-methylpropanoate | Y |
| WO 2014/039042 #3.4 | N/A | C23H32O5; Butyl 2-[(6aR,10aR)-1-hydroxy-6,6-dimethyl-9-oxo-6a,7,8,9,10,10a-hexahydro-6H-dibenzo[b,d]pyran-3-yl]-2-methylpropanoate | Y |
| WO 2014/039042 #3.6 | N/A | C23H34O5; Butyl 2-[(6aR,9R,10aR)-1,9-dihydroxy-6,6-dimethyl-6a,7,8,9,10,10a-hexahydro-6H-dibenzo[b,d]pyran-3-yl]-2-methylpropanoate | Y |
| WO 2014/039042 #3.9 | N/A | C24H36O5; Butyl 2-[(6aR,9R,10aR)-1-hydroxy-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydro-6H-dibenzo[b,d]pyran-3-yl]-2-methylpropanoate | Y |
| WO 2014/167530 #MJ10 | N/A | C28H33NO3; 1-[(Adamantan-2-yl)methyl]-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide | Y |
| WO 2014/167530 #MJ12 | N/A | C22H33NO3; N-[(2-Cyclohexylpropan-2-yl)-1-pentyl-1H-indazole-3-carboxamide | Y |
| WO 2014/167530 #MJ17 | N/A | C24H27F2N3O; 1-[(4,4-Difluorocyclohexyl)methyl]-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide | Y |
| WO 2014/167530 #MJ18 | N/A | C25H31NO3; 1-(5-Cycloheptylmethyl)-N-[2-phenylpropan-2-yl]-1H-indazole-3-carboxamide | Y |
| XLR-11 | 5-F-JUR-144 | C21H28FNO; [1-(5-fluoropentyl)indol-3-yl]-2,2,3,3-tetramethylcyclopentyl)methanone | Y |
| XLR-11 N-(2-FLUOROPENTYL) | 1-(2-Fluoropentyl)-1H-indol-3-yl][2,2,3,3-tetramethylcyclopentyl)methanone | Y |
| XLR-11 N-(3-FLUOROPENTYL) | 1-(3-Fluoropentyl)-1H-indol-3-yl][2,2,3,3-tetramethylcyclopentyl)methanone | Y |
| XLR-11 N-(4-FLUOROPENTYL) | 1-(4-Fluoropentyl)-1H-indol-3-yl][2,2,3,3-tetramethylcyclopentyl)methanone | Y |
| XLR-12 | UNII-8F8H9MH5WP; 8F8H9MH5WP | C20H24F3NO; [2,2,3,3-Tetramethylcyclopentyl]1-(4,4,4-trifluorobutyl)-1H-indol-3-yl)methanone | Y |
